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ABSTRACT  
   
Cells live in complex environments and must be able to adapt to environmental changes 
in order to survive. The ability of a cell to survive and thrive in a changing environment depends 
largely on its ability to receive and respond to extracellular signals. Initiating with receptors, signal 
transduction cascades begin translating extracellular signals into intracellular messages. Such 
signaling cascades are responsible for the regulation of cellular metabolism, cell growth, cell 
movement, transcription, translation, proliferation and differentiation. This dissertation seeks to 
dissect and examine critical signaling pathways involved in the regulation of proliferation in neural 
stem cells (Chapter 2) and the regulation of Glioblastoma Multiforme pathogenesis (GBM; 
Chapter 3). In Chapter 2 of this dissertation, I hypothesize that the mTOR signaling pathway 
plays a significant role in the determination of neural stem cell proliferation given its control of cell 
growth, metabolism and survival.  I describe the effect of inhibition of mTOR signaling on neural 
stem cell proliferation using animal models of aging. My results show that the molecular method 
of targeted inhibition may result in differential effects on neural stem cell proliferation as the use 
of rapamycin significantly reduced proliferation while the use of metformin did not.  Abnormal 
signaling cascades resulting in unrestricted proliferation may lead to the development of brain 
cancer, such as GBM. In Chapter 3 of this dissertation, I hypothesize that the inhibition of the 
protein kinase, aPKCι/λ results in halted GBM progression (invasion and proliferation) due to its 
central location in multiple signaling cascades. Using in-vitro and in-vivo models, I show that 
aPKCι/λ functions as a critical node in GBM signaling as both cell-autonomous and non-cell-
autonomous signaling converge on aPKCι/λ resulting in pathogenic downstream effects. This 
dissertation aims to uncover the molecular mechanisms involved in cell signaling pathways which 
are responsible for critical cellular effects such as proliferation, invasion and transcriptional 
regulation.  
 
  ii 
DEDICATION 
   
 
 
 
 
 
 
 
 
To my parents for showing me by example that anything is possible with hard work and 
persistence. It is because of your unconditional love and support that I succeed. 
For this I am eternally grateful. 
 
 
To Jon, my best friend, my world, my rock; 
I love you always and forever. 
  iii 
ACKNOWLEDGMENTS 
   
 
First and foremost I would like to thank my mentors, Dr. Sourav Ghosh, Dr. Nader Sanai, 
and Dr. Zaman Mirzadeh, for all you have done for me. Thank you for your belief in me and your 
support through both the difficult and the exciting times.  Thank you for your patience and 
guidance, and most of all, for your willingness to share your knowledge and expertise with me. 
Your unwavering support, encouragement and belief in me have provided me with a sense of 
security which allowed me to be adventurous, daring and confident in the lab. Each of you has 
shaped the scientist I have become. Without you, none of this would have been possible.  
 
I would also like to thank my committee members, Dr. Janet Neisewander, Dr. Ron 
Hammer, Dr. Joan Shapiro, Dr. Nhan Tran, and Dr. Vinodh Narayanan, for your time and 
dedication to helping me succeed. You were there with an open door and an open mind and for 
that, I am grateful.  I will always aspire to be encouraging, caring, and supportive throughout my 
career, as you have been for me.  
 
A special thanks to Dr. Sanai, Dr. Mirzadeh, and Dr. Narayanan for providing me with an 
aspirational model of my own career as a physician-scientist. There is no one who shares your 
strong commitment and passion to science and medicine.  Your diligence, hard work, and 
endless effort has inspired me to work harder and to aim higher.   
 
Finally, I would like to thank my colleagues and students I have had the pleasure of 
working with throughout the years.  Sabine Borwege, thank you for your camaraderie, your 
helpfulness, your advice, and your support. Most of all, thank you for your laughter. 
  iv 
TABLE OF CONTENTS  
          Page 
LIST OF TABLES .................................................................................................................................. vii  
LIST OF FIGURES ............................................................................................................................... viii  
LIST OF SYMBOLS / NOMENCLATURE ............................................................................................. xi  
CHAPTER  
1     INTRODUCTION ................................................................................................................. 1 
Signal Transduction .............................................................................. 1 
Enzyme-Coupled Surface Receptor Signaling: RTKs .......................... 2 
The PI3K/PTEN/AKT Pathway ............................................................. 3 
The PI3K/AKT/mTOR Pathway ............................................................ 4 
Mammalian target of rapamycin (mTOR) Function .............................. 5 
The EGFR/PI3K/PTEN/AKT Pathway in in GBM ................................. 7 
Atypical Protein Kinase C (aPKC) ........................................................ 10 
TNFα, aPKC & NF-κB signaling in GBM .............................................. 11 
Figures .................................................................................................. 14 
2      MTOR SIGNALING IN NEURAL DEVELOPMENT AND AGING .................................... 20 
Introduction to Manuscript ................................................................................. 20 
mTOR in Embryonic Neural Development & Neurodevelopmental 
Disorders .............................................................................................. 20 
mTOR in Adult Neural Stem Cell Proliferation, Differentiation & 
Neurogenesis ....................................................................................... 24 
Stabilization, Survival & Integration of Adult Newborn Neurons .......... 30 
Manuscript: Contrasting Effects of Chronic, Systemic Treatment with mTOR 
Inhibitors Rapamycin and Metformin on Adult Neural Progenitors in Mice ....... 34 
Abstract ................................................................................................ 34  
Introduction ........................................................................................... 34 
Materials and Methods ......................................................................... 37 
  v 
             Page 
Supplementary Materials and Methods ................................................ 43 
Results .................................................................................................. 45 
Discussion ............................................................................................ 49 
Figures .................................................................................................. 52 
Supplementary Figures ........................................................................ 60 
Acknowledgements .............................................................................. 62 
3  SIGNALING IN GLIOBLASTOMA ................................................................................ 63 
Introduction to Manuscript ................................................................................. 63 
Glioblastoma ......................................................................................... 63 
The Heterogeneity of GBM ................................................................... 65 
The GBM Tumor Stroma & Extracellular Signaling .............................. 67 
Primary GBM Intracellular Signaling .................................................... 69 
Manuscript: Targeting aPKC Simultaneously Disables Cell Autonomous and 
Non-cell Autonomous Oncogenic Signaling in Glioblastoma ............................ 73 
Abstract ................................................................................................ 73 
Introduction ........................................................................................... 73 
Materials and Methods ......................................................................... 74  
Results .................................................................................................. 84  
Discussion ............................................................................................ 96 
Figures .................................................................................................. 99 
Supplementary Figures ........................................................................ 114 
Acknowledgements .............................................................................. 129 
4 DISCUSSION AND IMPLICATIONS ............................................................................ 130 
mTOR Signaling in GBM ................................................................................... 130 
aPKC and mTOR Signaling in NSC Proliferation & DIfferentiation ................... 134 
SVZ Niche, Polarity in NSC Proliferation & Differentiation ................................ 136 
TNF-α and EGFR Signaling in NSC Proliferation & Differentiation ................... 140 
  vi 
              Page 
EGFR Signaling and NF-κΒ .............................................................................. 142 
The Glioma Stem Cell Hypothesis .................................................................... 145 
Inhibitors in GBM Clinical Trials ........................................................................ 148 
REFERENCES ...................................................................................................................... 151 
APPENDIX 
                    A  Curriculum Vitae ........................................................................................... 181 
 
 
 vii 
LIST OF TABLES 
Table Page 
2.1       Neither rapamycin nor metformin significantly increase food intake or body weight .......... 53   
2.2       Rapamycin, but not metformin, inhibits the proliferation of neural progenitors in vitro ....... 57    
2.3       Rapamycin, but not metformin, causes G1 phase arrest in vitro ........................................ 58  
3.S1     List of primers ....................................................................................................................... 112 
3.S2     List of siRNA and shRNA sequences .................................................................................. 113 
 
 
 
 
  
 viii 
LIST OF FIGURES 
Figure Page 
1.1        Receptor Tyrosine Kinase (RTK) Signaling ............................................................ 14 
1.2        The PI3K/AKT Signaling Pathway .......................................................................... 15 
1.3        The PI3K/AKT/mTOR Signaling Pathway .............................................................. 16 
1.4        TCGA analyses of GBM tumor mutations............................................................... 17  
1.5        atypical Protein Kinase C (aPKC) ........................................................................... 18 
1.6        TNF-α/NF-κB Signaling ........................................................................................... 19 
2.1        Chronic, systemic rapamycin & metformin administration in mice inhibits  
                mTOR activity in the brain ....................................................................................... 52 
2.2        Chronic rapamycin treatment, but not metformin, inhibits the proliferation of  
 neural progenitors in the SVZ region of the adult mammalian brain...................... 54 
2.3         Chronic rapamycin treatment, but not metformin, inhibits the proliferation of  
 neural progenitors in DG ......................................................................................... 55 
2.4.       Rapamycin, but not metformin, inhibits proliferation of neural stem cells 
 in-vitro ....................................................................................................................... 56 
2.5        Rapamycin, but not metformin, inhibits differentiation of neural stem cells  
 in-vitro ....................................................................................................................... 59 
2.S1        Chronic rapamycin, but not metformin, treatment reduces neural  
 progenitor numbers in the SVZ region of the adult mammalian brain ................... 60  
2.S2        Chronic rapamcyin treatment, but not metformin, reduces neuroblasts  
 and/or immature neuron numbers ........................................................................... 61  
3.1        Clinical association and therapeutic efficacy of targeting aPKC in mouse 
 models of GBM ........................................................................................................ 99  
3.2        aPKC is activated downstream of tumor-intrinsic oncogenic RTK signaling  
                pathways ................................................................................................................... 101  
 ix 
Figure Page 
3.3        Myeloid cells, paracrine TNFα and NF-κB signature are detected in  
 GBM and favor progression .................................................................................... 102 
3.4        Myeloid cell-derived TNFα promotes GBM proliferation, invasion and  
 EGFR kinase inhibitor resistance and correlates with aPKC activation ................ 103 
3.5        TNFα-induced NF-κB signaling in GBM is dependent on aPKC ........................... 105 
3.6        Bimodal function of aPKC in EGF and TNFα induced signaling in  
 GBM cells ................................................................................................................. 109 
3.7        Schematic illustrating aPKC-containing signaling complexes in cell  
                 autonomous RTK and non cell-autonomous TNFa/NF-kB oncogenic  
                 signaling in GBM ..................................................................................................... 111 
3.S1        aPKC expression in non-tumor brain and in histologically characteristic 
 regions of GBM ........................................................................................................ 114  
3.S2        Validation of aPKC knockdown efficiencies and PZ09 inhibitory effect ................. 115 
3.S3       EGFR isoforms expression in GBM6 and EGFR phosphorylation kinetics in 
                 GBM6 and U251/EGFR .......................................................................................... 116 
3.S4        Myeloid cells, TNFα production and NF-κB activation in mouse models 
 of GBM ..................................................................................................................... 117 
3.S5        TNFα is produced by myeloid cells when in contact with GBM cells ..................... 118  
3.S6        Human myeloid cell-derived TNFα contributes to increased GBM  
 proliferation and invasion ......................................................................................... 119  
3.S7        Murine myeloid cell-derived TNFα contributes to increased GBM proliferation  
                 and invasion ............................................................................................................. 120 
3.S8        Phosphorylation of aPKC precedes phosphorylation of p65.................................. 121  
3.S9        TNFα induced IκΒα degradation is not affected by aPKC silencing...................... 122  
 x 
Figure Page 
3.S10       Activation of aPKC and induced NF-kB gene signature in GBM cells upon 
                 co-culture with myeloid cells ................................................................................... 123 
3.S11       Myeloid cell-induction of GBM proliferation and invasion is dependent  
 on aPKC ................................................................................................................... 124  
3.S12       Erlotinib, but not aPKC inhibition, suppresses EGFR phosphorylation ................. 125 
3.S13       Induction of distinct sets of genes by EGF and TNFα signaling in GBM cells ...... 126 
3.S14       Validation of EGFR, AKT and Src inhibition in U87/EGFRVIII ............................... 127 
3.S15       PRKCI is the predominant GBM-associated isoform of aPKC .............................. 128 
  
 xi 
LIST OF SYMBOLS / NOMENCLATURE  
 
AKT protein kinase B   NSC neural stem cell  
aPKC atypical protein kinase C  OB olfactory bulb 
ATP adenosine trisphosphate  Par-3/6 partitioning defective 3/6  
BDNF brain derived neurotrophic factor PB1 phox/bem domain 
BrdU 5-bromo-2’-deoxyuridine  PDK1 3-phosphoinositide-dependent kinase1 
C1/C2 conserved region 1/2   PI3K phosphoinositide 3 kinase 
CBP creb binding protein   PIP2 phosphatidylinositol 4,5-bisphosphate 
CNS central nervous system   PIP3 phosphatidylinositol 3,4,5-triphosphate 
cPKC conventional PKC   PTEN phosphatase and tensin homolog 
DAG diacylglycerol    Rheb ras homolog enriched in brain 
DG dentate gyrus    RTK receptor tyrosine kinase 
EGF epidermal growth factor   RTS Rubinstein Taybi syndrome 
EGFR EGF receptor    SGZ subgranular zone 
FADD fass-associated death domain  SH2 src homology domain 
GBM glioblastoma multiforme   SVZ subventricular zone 
GSC glioma stem cell   TCGA The Cancer Genome Atlas 
IGF insulin growth factor   TMZ temozolomide 
IL interleukin    TNFα tumor necrosis factor alpha 
IRS insulin receptor substrate  TNFR tumor necrosis factor receptor 
MCP monocyte chemoattract protein  TRADD TNFR-associated death domain 
NF1 neurofibromatosis   TSC tuberous sclerosis complex 
NF-κΒ nuclear factor kappa b   VCAM vascular cell adhesion protein 
nPKC novel protein kinase C   VEGF vascular endothelial growth factor 
 1 
CHAPTER 1 
INTRODUCTION 
The work presented in this dissertation comprises two distinct topics which both involve 
cell signaling pathways in cells of the central nervous system (CNS). Chapter 2 describes 
mammalian target or rapamycin (mTOR) signaling and the use of mTOR inhibitors in the 
proliferation of neural stem cells in aging mice. This work is presented as a manuscript which was 
published in February 2013 in the journal Age. Chapter 3 describes an investigation of atypical 
protein kinase C (aPKC) signaling in Glioblastoma Multiforme (GBM).  Chapter 3 is currently in 
revision for publication. This introductory chapter will provide an overview for both Chapter 2 and 
Chapter 3, focusing on topics such as oncogenetic signaling, proliferation and differentiation – 
which are all processes controlled by signal transduction pathways. 
Signal Transduction 
 Cells live in a complex environment and must monitor and respond to stimuli in order to 
survive. They must be able to detect extracellular stimuli and transfer signals to the interior 
cytoplasm of the cell. Received signals are converted through a signaling pathway leading to a 
cellular response or change in cell behavior, such as gene transcription. There are multiple types 
of signaling, including endocrine signaling, paracrine signaling, and autocrine signaling. 
Endocrine signaling involves hormones which are secreted by an endocrine gland and travel to 
their effector cell where they regulate cellular changes. This type of signaling can involve 
hormones traveling over long distances to reach their effector cell which may lie anywhere in the 
body.  Paracrine signaling refers to signaling which takes place between cells in close proximity, 
affecting cells only in the local environment. Autocrine signaling occurs when a cell produces 
signals that it responds to itself. For instance, cancer cells produce their own signals, such as 
growth factors, which stimulate their proliferation and oncogenicity in an autocrine signaling 
manner. 
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 The signal transduction process initiates with a receptor on a target cell. Receptors are 
molecules that act as a gateway between the intracellular and extracellular space. Usually 
containing an extracellular and intracellular domain, receptors bind to ligands on the extracellular 
surface of the cell and transmit the signal through their intracellular domains downstream to 
effector proteins, eventually leading to an alteration in metabolism, gene expression, movement, 
or behavior. At any given point in time within the extracellular space, there are a multitude of 
extracellular signals a cell must interpret, including many proteins, peptides, amino acids, 
nucleotides, and other signal molecules. The specificity of receptors expressed by a target cell is 
the determining factor as to whether signaling occurs and/or a cellular response is initiated. 
Receptors bind with high affinity to their target protein, or ligand, which allows for specialized 
signal transduction cascades to occur.  
Enzyme-Coupled Surface Receptor Signaling: Receptor tyrosine kinases (RTKs) 
Enzyme-coupled receptors are receptor proteins containing a ligand binding domain on 
the extracellular surface of the plasma membrane and are capable of enzyme activity (either 
intrinsic or associated) in the intracellular cytosolic domain.  Receptor tyrosine kinases (RTKs) 
are the most abundant class of enzyme-coupled receptors. RTKs are able to directly 
phosphorylate tyrosine targets on their intracellular domain as well as on other intracellular 
tyrosine targets. Upon ligand binding, the receptor dimerizes, which allows for the cross-
phosphorylation (or transautophosphorylation) of the receptor chains (Figure 1.1). This increase 
in phosphorylated tyrosines creates docking sites for other signaling proteins. Signaling 
complexes can then be assembled at these docking sites in order to deliver the signal further 
downstream to other effector proteins. This signal cascade may eventually lead to the nucleus, 
causing a change in the transcriptional regulation of various genes. An example of such an RTK 
is the Epidermal Growth Factor Receptor (EGFR), which plays an important role in cell survival, 
proliferation, and cell growth. EGFR signaling is imperative for proper development and disruption 
of its signaling cascade can lead to detrimental effects, including cancer. EGFR activation, 
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initiated by epidermal growth factor (EGF) ligand binding to EGFR, leads to EGFR 
transautophosphorylation which activates downstream kinases such as phosphoinositide 3-
kinase (PI3K).   
The PI3K/PTEN/AKT Pathway 
PI3K is a kinase containing a Src homology domain region (SH2) which mediates binding 
to phosphorylated tyrosines. It is a plasma-membrane-bound enzyme which can bind to the 
intracellular RTK chains upon their transautophosphorylation.  Upon binding to intracellular 
phosphorylated RTK chains, PI3K is then responsible for phosphorylating the 3 position of the 
membrane inositol ring, which generates multiple phosphorylated lipids, or phosphoinositides, 
including the formation of active phosphatidylinositol 3,4,5-triphosphate (PIP3) from inactive 
phosphatidylinositol 4,5-biphosphate (PIP2). Phosphoinositides play an important role in signal 
transduction as they too act as a docking site and recruit other signaling molecules. PI3K is 
activated through various RTKs, including EGFR, and plays a role in the regulation of growth and 
cell survival signals. Mutations leading to activation of PI3K are common in cancer (including 
GBM; Figure 1.4) as active PI3K leads to unrestricted growth signals, proliferation, and cell 
survival (Figure 1.2). PI3K pathway inhibitors have the potential to improve clinical outcome in 
various cancers as inhibition of this oncogenic pathway could induce cell death, halt oncogenic 
proliferation, invasion and cell survival  (Wen, Lee, Reardon, Ligon, & Alfred Yung, 2012). 
Negative signal regulation also occurs in the cell.  Phosphatase and tensin homolog 
(PTEN) is a phosphatase that dephosphorylates PIP3 to the inactive PIP2. Loss of PTEN is 
oncogenic and occurs in multiple cancers including GBM, breast, endometrium and colon cancer, 
among others (Wong, Engelman, & Cantley, 2010).  Either the inactivation or the loss of PTEN 
and/or the activation of PI3K leads to uncontrolled downstream PI3K signaling resulting in 
unregulated growth signals and/or oncogenesis.  
Further downstream of PI3K and PTEN is the protein kinase AKT (also known as protein 
kinase B).  AKT is a serine/threonine protein kinase which contains a pleckstrin homology (PH) 
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domain, a protein-protein interaction domain that facilitates its binding to phosphoinositides on the 
cell membrane. In the case of EGFR signaling, EGF ligand initially binds to EGFR leading to 
transautophosphorylation which begins the signaling cascade. PI3K then binds to the intracellular 
dimerized receptor chains and catalyzes the formation of active PIP3 from inactive PIP2 at the 
membrane. Due to AKTs ability to associate with phosphoinositides, this phosphorylation of PIP2 
into PIP3 recruits AKT to the membrane where it binds to PIP3, leading to its activation (Figure 
1.2).  Upon binding, AKT is phosphorylated by 3-phosphoinositide-dependent kinase (PDK1) and 
the mammalian target of rapamycin complex 2 (mTORC2; (J. Wang et al., 2012). This 
subsequently leads to phosphorylation by Akt of numerous downstream targets involved in cell 
survival, proliferation and cell growth (J. Wang et al., 2012).  
The PI3K/AKT/mTOR Pathway 
The PI3K/AKT pathway regulates cell growth through the use of another serine/threonine 
kinase, mTOR. In the cell, mTOR can be found in 2 protein complexes which have different 
upstream activators and downstream effectors, mTOR complex 1 (mTORC1) and mTOR complex 
2 (mTORC2). mTORC1 associates with the protein raptor and is sensitive to the inhibitor 
rapamycin. mTORC2 associates with rictor and is rapamycin-insensitive. mTORC1 stimulates 
ribosome production and protein synthesis and thus encourages cell growth. Among other 
extracellular signals, various growth factors activate mTORC1 via the PI3K/AKT pathway and 
through a complex mechanism involving the GTPase Ras homolog enriched in brain (Rheb) and 
a protein heterodimer consisting of tuberous sclerosis 1 and 2 (TSC1and TSC2; (Laplante & 
Sabatini, 2012). The TSC1/TSC2 heterodimer acts as a GTPase-activating protein (GAP) for 
Rheb, a GTPase, which directly binds mTORC1 when in its active (GTP-bound) conformation 
(Figure 1.3).   When active GTP-bound Rheb binds to mTORC1, mTORC1 becomes activated 
and its kinase activity is stimulated (Laplante & Sabatini, 2012).  Negative regulation of mTORC1 
activity also occurs via the GAP TSC1/TSC2, as it converts Rheb into an inactive (GDP-bound) 
conformation causing Rheb and mTORC1 to disassociate.  Interestingly, mTORC1 participates in 
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negative feedback inhibition of its own activator, PI3K, through the downstream effector target of 
mTORC1, p70 s6 kinase (S6K1; Figure 1.3). mTORC1 activation leads to phosphorylation of 
S6K1, which then inhibits PI3K in a negative regulation feedback manner (J. Huang & Manning, 
2009; Laplante & Sabatini, 2012). 
Mammalian target of rapamycin (mTOR) Function  
mTORC is considered a signal integrator and is crucial for cell growth and homeostasis 
(Zoncu, Efeyan, & Sabatini, 2011). Cell growth depends heavily on the cells environment as 
increase in size or number of cells requires sufficient supply of nutrients and energy.  If conditions 
are favorable, the cell can synthesize new proteins, nucleic acids, and lipids for growth.  Through 
a myriad of downstream signaling processes, mTOR plays a critical role in cell growth processes, 
including, general protein synthesis, as well as lipid synthesis for proliferating cells, inhibition of 
cell degradation (autophagy), cell metabolism and ATP production.  This is due to mTORs central 
role in coordinating growth through its environment-dependent activation. For instance, mTORC1 
regulates the synthesis of ribosomal RNAs (rRNAS) by upregulating the activity of RNA PolI, the 
rRNA polymerase, allowing for the biogenesis of ribosomes. The synthesis of ribosomes is 
energetically costly to the cell, and thus occurs in times of energy and nutrient abundance. The 
mTORC1 GTPase Rheb has also been found to play a role in this process as a loss of Rheb 
inhibits mTORC1 activation during nutrient starvation (S. C. Johnson, Rabinovitch, & Kaeberlein, 
2013).  
mTORC1 also inhibits autophagy, which is an important process allowing for recycling of 
cellular components. If in an environment with low nutrient availability, the cell may participate in 
autophagy by way of recycling proteins and organelles in order to synthesize nutrients (Zoncu et 
al., 2011). During autophagy, intracellular components are isolated into autophagosomes and are 
later degraded by lysosomes. Interestingly, a strong correlation between autophagy and 
lifespan/aging has been well established in the literature (D. W. Lamming et al., 2012; Dudley W. 
Lamming, Ye, Sabatini, & Baur, 2013). As the aging process occurs, cellular physiology declines, 
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leading to the decreased function of cells and entire organs as well as a decrease in autophagy.  
The inactivation of genes necessary for autophagy results in a reduced lifespan in yeast, C. 
elegans and Drosophila while an increase in autophagy extended lifespan in Drosophila (Alvers 
et al., 2009; Hars et al., 2007; Lionaki, Markaki, & Tavernarakis, 2013), providing evidence for the 
prominent role of autophagy in aging and lifespan.  mTOR signaling has been proven to be a 
regulator of this process.  Inhibition of mTOR using rapamycin results in an increase in autophagy 
and extends lifespan in multiple organisms including mice (Cornu, Albert, & Hall, 2013).  In yeast, 
inhibition of mTOR through rapamycin treatment increased lifespan while mTOR stimulation 
decreased lifespan (Alvers et al., 2009). Furthermore, the use of another mTOR inhibitor, 
metformin, was also shown to extend life span in mice (Vladimir N. Anisimov et al., 2008; V. N. 
Anisimov et al., 2011). In addition to rapamycin and/or metformin treatment, dietary restriction, 
resulting in amino acid deprivation for cells, has been shown to extend lifespan (Levenson & 
Rich, 2007). The effect of dietary restriction on lifespan extension has been attributed to inhibition 
of mTOR (Cornu et al., 2013) due to its environment-dependent activation.  
mTOR signaling has also been shown to play a significant role in cell proliferation and 
cell cycle regulation in mouse and human cells (Fingar & Blenis, 2004; N. Gao et al., 2004; Ning 
Gao, Zhang, Jiang, & Shi, 2003; X. Gao, McDonald, Hlatky, & Enderling, 2013; Ohanna et al., 
2005; Sehgal, 1998). Although a defined mechanism has yet to be elucidated, rapamycin is 
considered a good immunosuppressant as mammalian B and T cells, when treated with 
rapamycin, undergo a G1-phase cell cycle arrest with little toxicity (Fingar & Blenis, 2004). In the 
CNS, activation of mTOR signaling is upregulated during neural stem cell differentiation in mouse 
neural stem cells (Han et al., 2008). In addition, rapamycin has been shown to reduce BrdU+ 
cells in the dentate gyrus (DG) of rats (Zeng, Rensing, & Wong, 2009) and mice treated with 
rapamycin displayed reduced hippocampal neurogenesis (Raman, Kong, Gilley, & Kernie, 2011; 
Raman, Kong, & Kernie, 2013). This data, among others, provides evidence of the role of 
mTORC1 in the regulation of cell proliferation both within and outside of the CNS.   
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Given the critical role of mTOR in the regulation of cell growth, nutrient sensing, cell 
proliferation and organism lifespan extension, we asked whether mTORC1 signaling was capable 
of impacting the age-related decline in neural progenitor proliferation. In Chapter 2, we tested the 
role of mTORC1 signaling in neural progenitor proliferation of aged-mice by using inhibitors of 
mTORC1, rapamycin and metformin. Not surprisingly, in aged mice, we found a decrease in 
proliferation compared to young mice. Unexpectedly, however, in aged mice treated with 
rapamycin, we found an even greater decrease compared to aged mice treated with vehicle alone 
or mice treated with metformin. While both rapamycin and metformin inhibit mTORC1, the two 
inhibitors mediate inhibition via different mechanisms. Rapamycin works by inhibition of mTORC1 
directly, while metformin activates adenosine monophosphate-activated protein kinase (AMPK), 
an inhibitor of mTOR. Given that rapamycin treatment extended lifespan in animal models, and 
given the prominent role of mTOR in cellular growth and proliferation, it was surprising to discover 
a rapamycin-mediated decrease in neural progenitor proliferation in aged mice.   This 
examination and its findings are presented as a published manuscript in Chapter 2. 
The EGFR/PI3K/PTEN/AKT pathway in Glioblastoma Multiforme (GBM) 
While the EGFR/PI3K/PTEN/AKT pathway activates mTOR (Figure 1.3), it also activates 
other downstream effector proteins and plays a central role in cellular signaling. The 
EGFR/PI3K/PTEN/AKT signaling pathway is an important regulator of oncogenesis. Activation of 
this pathway is oncogenic promotes various cancers including GBM (Wong et al., 2010). GBM is 
classified by the World Health Organization (WHO) as a grade IV astrocytoma, the highest grade 
of glioma.  It is the most common and most aggressive tumor of the CNS with tumor cells rapidly 
dividing and invading surrounding normal brain tissue. This devastating disease has an extremely 
poor prognosis with a 5-year survival rate of 5% (CBTRUS) despite receipt of the current 
standard of care which includes surgical resection, radiation, and chemotherapy with 
temozolomide (TMZ), an alkylating agent.  This aggressive treatment regimen fails often due to 
the tumor cells ability to evade radiation and chemotherapy as well as their stealth invasion into 
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surrounding areas.  In 2008, The Cancer Genome Atlas (TCGA) study profiled roughly 200 GBM 
tumor samples in an effort to describe the mutations leading to GBM formation (R. McLendon et 
al., 2008). The study was repeated with additional samples in 2013 by Brennan et al., (2013). The 
complementary results of these studies was the elucidation of several signal transduction 
pathways gone awry (Figure 1.4;(Brennan et al., 2013; Roger McLendon et al., 2008)).  
The most frequent genetic aberrations discovered included signaling pathways which 
lead to proliferation and survival, key aspects to the oncogenicity of GBM (Brennan et al., 2013; 
Roger McLendon et al., 2008). These are displayed in Figure 1.4.  For example, a homozygous 
deletion of CDKN2A/CDKN2B (P16/INK4A) is found in 61% of GBM samples. CDKN2A and 
CDKN2B are tumor suppressor proteins that inhibits CDK4, a cyclin dependent kinase found 
amplified in 14% of GBM samples (Brennan et al., 2013; Roger McLendon et al., 2008). CDK4 
phosphorylates retinoblastoma protein (RB), eventually allowing the cell to progress from G1 
phase to S. RB1, which controls cell cycle progression, is found to be deleted or mutated in 7.6% 
of tumors (Brennan et al., 2013; R. McLendon et al., 2008). These genetic mutations contribute to 
the highly proliferative and highly oncogenic aspect of GBM while also making it difficult to treat 
successfully.  
 Data from the TCGA study also found that EGFR amplification is seen in roughly 57% of 
GBM patients, while RTK signaling in general is mutated in 90% of patients overall (Figure 1.4; 
(Brennan et al., 2013; Roger McLendon et al., 2008).  The EGFRVIII mutation results in the 
deletion of exons 2-7 of EGFR and is frequently seen in GBM patients who already have an 
EGFR amplification mutation (Brennan et al., 2013; Roger McLendon et al., 2008). EGFRVIII 
leads to a loss of the extracellular domain of EGFR, leaving EGFR unresponsive to EGF ligand 
and resulting in constitutive activation of the EGFR signaling pathway (Brennan et al., 2013; 
Roger McLendon et al., 2008). However, the 2013 study elucidated other mutations which 
frequently occur to the EGFR gene. For instance, three different C-terminal mutations were 
discovered to alter the cytoplasmic terminals of EGFR, and these mutations have been shown to 
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be tumorigenic in mouse animal models of GBM (Brennan et al., 2013; Cho et al., 2011). In 
addition, deletions of exons 12-13 and exons 14-15 were found in 28% and 3% of GBM tumors, 
respectively (Brennan et al., 2013). Furthermore, roughly 25% of patients have a gain of function 
mutation in PIK3CA or PIK3R1, which encode for the PI3K subunits p110a and p85 respectively 
(Brennan et al., 2013; Roger McLendon et al., 2008).  In addition, approximately 40% of GBM 
cases have a deletion of PTEN, the negative regulator of PI3K, once again, leading to its 
unrestricted activation (Brennan et al., 2013; Roger McLendon et al., 2008).  The authors report 
that 89% of tumors had at least one mutation in the PI3K signaling pathway and roughly 40% had 
two or more mutations (Brennan et al., 2013).  Interestingly, these two mutations, PI3K and PTEN 
mutations were found to be mutually exclusive, as over 50% of tumors had a mutation in either 
PI3K or PTEN (Brennan et al., 2013).  Many of these genomic mutations (EGFR gain of function 
mutation, EGFRVIII, PI3K gain of function mutation, PTEN loss of function mutation) lead to an 
unrestricted downstream activation of PI3K, a master regulator of cell growth and proliferation. 
Unfortunately, many GBM patients present with multiple mutations affecting this pathway, 
allowing the tumor cells to be extremely aggressive and making the pathway difficult to control.  
 Due to the strong reliance on EGFR signaling in GBM, EGFR inhibitors have been tested 
as therapy for GBM patients (Brandes et al., 2008; Huse, Holland, & DeAngelis, 2013; Huse & 
Holland, 2010; Reardon et al., 2010; Uhm et al., 2011). However, despite the multitude of clinical 
trials studying EGFR inhibitors, they have mostly proven to be unsuccessful in improving patient 
survival (Brandes et al., 2008; Huse et al., 2013; Huse & Holland, 2010; Reardon et al., 2010; 
Uhm et al., 2011). Chapter 3 presents a manuscript submitted for publication which describes a 
novel therapeutic which we found to be more effective than EGFR therapy. This therapy involved 
the inhibition or silencing of atypical Protein Kinase C (aPKC), a kinase found to be downstream 
of both EGFR and PI3K in GBM cells (Chapter 3).  Inhibition and/or silencing of aPKC resulted in 
reduced EGFR-induced oncogenic proliferation, invasion and migration in glioma cells, as well as 
in animal models of GBM.   
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Atypical Protein Kinase C (aPKC)  
The protein kinase C (PKC) family of Ser/Thr kinases comprises ~2% of the human 
kinome and is broadly conserved.   12 isoforms exist in mammal species and are classified into 
three subgroups based on regulatory and functional characteristics (Figure 1.5a): conventional 
PKCs (cPKC), novel PKCs (nPKC) and atypical PKCs (aPKC). All subgroups maintain a 
conserved carboxy-terminal catalytic domain and an N-terminal regulatory domain, which are 
linked by a hinge region. In addition, all subgroups possess a psuedosubstrate domain, which 
acts to maintain inactivation by blocking kinase activity.  The cPKC subgroup consists of PKCα, 
PKCΒ, and PKCγ.  cPKC members have both a conserved region 1 (C1) and a conserved region 
2 (C2) domain, allowing them to be activated by diacylglycerol (DAG) and Ca2+, respectively. 
PKCδ, PKCε, PKCθ comprise the nPKC subgroup. Similar to cPKCs, nPKCs contain a C1 region 
and are DAG responsive. However, they lack a functioning C2 domain and thus are insensitive to 
Ca2+ stimulation.  Both the cPKC subgroup and the nPKC subgroup have two zinc fingers. The 
third subgroup of the PKC family, aPKCs, are atypical both in structure and function, having only 
one zinc finger and lacking a functioning C1 or C2 region.  There are two members of this 
subfamily, aPKCζ and aPKCλ/ι, and neither is activated by either DAG or Ca2+. Instead, aPKCs 
are activated by binding to other proteins through a Phox/Bem1 domain (PB1), which is not 
present in the cPKC or the nPKC subgroups. Differential PB1 domain binding may provide a 
means for downstream signaling specificity. For example, aPKC binding to partitioning defective 6 
(Par6) through its PB1 domain forms the aPKC-Par6 complex which has been shown to play 
important roles for cellular polarity, while the aPKC-p62 complex has been shown to regulate 
nuclear factor kappa b (NF- κΒ) activity (Figure 1.5b).  
Importantly, while Aplasia and Drosophila have only one aPKC gene, the aPKC subgroup 
in vertebrates is comprised of two genes, PRKCI and PRKCZ.  These genes encode for three 
distinct proteins. PRKCI encodes for aPKCλ/ι, while PRKCZ codes for aPKCζ (Figure 1.5c). 
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PKMζ arises from an alternative internal promoter of PRKCZ, which creates PKMζ, the shortened 
and constitutively active form of PKCζ which lacks the N-terminus entirely. Because aPKCζ and 
aPKCλ/ι share a 72% sequence homology, evidence regarding differences in aPKCλ/ι versus 
aPKCζ signaling cascades is lacking. This is likely due to a lack of specific reagents for 
discrimination. Nevertheless, more recent data has successfully analyzed the differential roles of 
the aPKC isoforms (Parker et al., 2013b). Interestingly, differential distribution of the isoforms in 
the CNS has been reported which revealed abundant expression of aPKCλ/ι and PKMζ with 
reduced expression of aPKCζ (Parker et al., 2013b).  
aPKC has been shown to respond to EGF ligand and participate in the EGF/PI3K/AKT 
pathway in various cell types (Akimoto et al., 1996; Herrera-Velit, Knutson, & Reiner, 1997; Hirai 
& Chida, 2003; Mary L. Standaert, Bandyopadhyay, Kanoh, Sajan, & Farese, 2001; M. L. 
Standaert et al., 1997). In rat 3Y1 cells (Akimoto et al., 1996), adipocytes (Mary L. Standaert et 
al., 2001) and monocytes (Herrera-Velit et al., 1997), aPKC was found to be activated 
downstream of PI3K.  Furthermore, aPKC has been shown to bind and phosphorylate AKT (Diaz-
Meco & Moscat, 2001) and it is phosphorylated by PDK1 at Thr-410 (Le Good et al., 1998; Mary 
L. Standaert et al., 2001). In addition, PIP3 was found to induce dose-dependent increases in 
aPKC activity (Mary L. Standaert et al., 2001), thus further implicating it as a player in the 
EGFR/PI3K/AKT pathway. As described in Chapter 3, we found aPKCλ/ι to play a significant role 
in EGFR/PI3K/AKT signaling in GBM cells as it’s silencing and/or inhibition lead to reduced 
EGFR-dependent gene transcription, migration, invasion, and proliferation. Interestingly, we 
found most GBM samples to have a significant over-expression of aPKCλ/ι while expressing little 
to no aPKCζ (Chapter 3). 
TNF-α, aPKC and NF-κΒ signaling in GBM  
While we found aPKCλ/ι  to be activated downstream of EGFR signaling in GBM, we also 
found it to participate in NF- κΒ signaling.  Nuclear factor κΒ (NF-κΒ) is an important 
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heterodimeric transcription factor playing a critical role in the transcription of numerous genes. It 
consists of a heterodimer of p50 and p65 subunits, which when inactive, are found in the 
cytoplasm bound to IκΒ, an inhibitory protein. Upon stimulation, such as tumor necrosis factor 
alpha (TNF-α) ligand binding to TNFR, IKB is phosphorylated, dissociates from the NF- κΒ 
complex, and is degraded. This exposes the nuclear localization signal on NF- κΒ allowing it to 
translocate to the nucleus where it may bind to response elements on gene promoters and 
activate transcription of genes necessary for survival, inflammation, angiogenesis, invasion, 
apoptosis, and proliferation (Figure 1.6).  NF- κΒ is found to be constitutively active in most 
cancers (Chaturvedi, Sung, Yadav, Kannappan, & Aggarwal, 2011b) and high levels of NF- κΒ 
are considered a hallmark of inflammation.  Furthermore, several oncogenic signaling pathways 
involve NF- κΒ activation (Chaturvedi et al., 2011b) and its inhibition has been shown to result in 
better patient outcomes (Drappatz, Norden, & Wen, 2009; Yamagishi & H. Takebe, 1997; 
Zanotto-Filho et al., 2011). Specifically in GBM, heterozygous deletions of NFKBIA, the gene 
which encodes for the NF- κΒ inhibitor, IκΒα, are found in an estimated 25% of GBMs (Markus 
Bredel et al., 2011) and has been associated with poor patient outcome. Several factors influence 
activation of NF- κΒ in cancers, including inflammatory cytokines and chemokines such 
interleukin 1β (IL-1β) and TNF-α. Our comprehensive analyses found aPKCλ/ι  to be a mediating 
factor between TNF-α and NF- κΒ signaling in GBM cells (Chapter 3).  
 TNF-α is a cytokine that was isolated in 1984 from macrophage-conditioned media 
(Aggarwal, Schwarz, Hogan, & Rando, 1996; Pennica et al., 1984). Originally considered to be 
anti-tumorigenic, TNF-α is now recognized as a mediator of cancer (Aggarwal et al., 1996) as its 
activation of NF- κΒ controls oncogenic processes such as survival, proliferation, invasion, 
angiogenesis and metastasis (F. Balkwill, 2002). GBM cells have been shown to produce TNF-α 
and are also capable of responding to TNF-α through TNFRs (Aggarwal et al., 1996).  However, 
other cells in the tumor microenvironment may also be responsible for the production of TNF-α. 
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As a cytokine initially found in macrophages, we examined the production of TNF-α from brain 
tumor associated microglia in GBM (Chapter 3).  We found microglia to produce TNF-α upon their 
contact with GBM cells, thus indicating a paracrine signaling interaction between the two cell 
types. In recent years the tumor microenvironment has gained attention as providing a supportive 
environment for oncogenicity (Hanahan & Weinberg, 2011). For instance, inflammation is 
considered an enabling characteristic of cancer and is often called pro-tumorigenic (Hanahan & 
Weinberg, 2011). Various signaling molecules are secreted within the tumor microenvironment 
during the inflammatory response including growth factors, survival factors, and angiogenic 
factors, which may lead to an oncogenic environment. Paradoxically, we found microglia-
dependent TNF-α to be a pro-tumorigenic factor secreted by the tumor microenvironment 
(Chapter 3).  
Given that GBM cells express TNFR, we found that they were able to respond to the 
paracrine microglia secreted TNF-α signal by signaling through aPKC and leading to activation of 
NF- κΒ in GBM cells.   Thus, overall, we found aPKCλ/ι  to be a central player in the signaling of 
two pathways in GBM: the EGFR/PI3K/AKT signaling pathway and the microglia secreted 
TNFα/NF−κΒ signaling pathway. Inhibition or silencing of aPKC reduced GBM cell proliferation, 
invasion, and migration, thus proving aPKCλ/ι  to be a better therapeutic target than the targeting 
of EGFR or NF- κΒ alone.  This data is presented in full as a manuscript in Chapter 3.  
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Figure 1.1. Receptor tyrosine kinase (RTK) signaling. RTKs are able to directly phosphorylate 
tyrosines on their intracellular domain and on other intracellular signaling proteins. Upon ligand 
binding, the receptor dimerizes, which allows for the cross-phosphorylation (or 
transautophosphorylation) of the receptor chains. Adapted from Schlessinger, J. (Schlessinger, 
2000). 
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Figure 1.2. The PI3K/AKT signaling pathway. Upon ligand binding and 
transautophosphorylation, PI3K binds to phosphorylated tyrosine targets and converts inactive 
PIP2 into active PIP3. PTEN is a negative regulator of PI3k and converts active PIP3 back into 
inactive PIP2. AKT is recruited through an SH2 domain to bind to PIP3. Upon binding, AKT is 
phosphorylated by PDK1. This subsequently leads to AKT phosphorylation of numerous 
downstream targets involved in cell survival, proliferation, protein synthesis, cell growth, 
metabolism, and others.  Adapted from Hennessy et al. (Hennessy, Smith, Ram, Lu, & Mills, 
2005).  
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Figure 1.3. The PI3K/AKT/mTOR signaling pathway. Activation of AKT results in stimulation of 
the TSC1-TSC2 heterodimer complex. TSC1-TSC2 then acts as a GAP for Rheb, which binds to 
mTORC1 in its active GTP-bound conformation. mTORC1 kinase activity is then stimulated. 
Negative regulation of mTORC1 occurs via TSC1-TSC2 as it also converts Rheb into inactive 
GDP-bound conformation causing Rheb and mTORC1 to dissociate. mTORC1 also 
phosphorylates S6K1 which then inhibits PI3K in a negative feedback manner. Adapted from 
Laplante, M. and Sabatini, D.M. (Laplante & Sabatini, 2012). 
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Figure 1.4. TCGA analyses of GBM tumor mutations. The 2013 TCGA study profiled ~500 
cases of GBM in an effort to identify oncogenic mutations. Results showed an RTK signaling 
alteration in 90% of samples.  An EGFR amplification or gain-of-function mutation (EGFRVIII) 
was seen in 57%, while PI3K gain-of-function mutation was found in 25%. Homozygous loss of 
the PI3K negative regulator, PTEN, was found in 41% of cases. P53 signaling was altered in 86% 
overall, and (c) RB signaling was altered in 79% of cases studied.  Adapted from Brennan et al., 
2013 (Brennan et al., 2013). 
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Figure 1.5. Atypical Protein Kinase C.  The PKC family consists of 12 broadly conserved 
isoforms classified into three subgroups based on regulatory and functional characteristics (a). 
aPKCι/λ/ζ binds to proteins via its PB1 domain. When aPKC is associated with p62, it is usually 
found to participate in NF-κΒ signaling whereas its association with Par6 has been shown to be 
important for cell polarity functioning, such as astrocyte directional migration (b). Two distinct 
aPKC genes encode for three proteins (c). Adapted from Moscat, J., Diaz-Meco, M., and Wooten, 
M. (Jorge Moscat, Diaz-Meco, & Wooten, 2007; J. Moscat, Diaz-Meco, & Wooten, 2009b) and 
Parker et al. (Parker et al., 2013b) 
A 
B 
C 
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Figure 1.6. TNF-α/NF-κB Signaling. NF-κB is a heterodimer transcription factor found in the 
cytoplasm bound to IκΒ, an inhibitory protein. Upon TNF-α ligand binding to TNFR, IκΒ is 
phosphorylated, ubiquitinated and degraded, freeing NF-κB to enter the nucleus via its nuclear 
localization signal. Once in the nucleus, NF-κB binds to the DNA where it begins transcription of 
various genes including cytokines, chemokines, apoptotic factors, cell cycle genes, and 
inflammatory genes.  Adapted from Hayden, M.S., and Ghosh, S. (Hayden & Ghosh, 2008). 
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CHAPTER 2 
MTOR SIGNALING IN NEURAL DEVELOPMENT AND AGING 
INTRODUCTION TO MANUSCRIPT 
mTOR in Embryonic Neural Development & Neurodevelopmental Disorders 
 The development of the mammalian brain is a complex and highly regulated process 
involving numerous signaling pathways. Without appropriate signaling events and regulation, the 
embryo may not develop normally leading to birth defects and often death in-utero. The proper 
signaling cascades lead to brain development and the development of neurons, or neurogenesis. 
Prior to neurogenesis during embryonic development, polarized neuroepithelial cells function as 
neural stem cells and first undergo symmetrical cell divisions in order to expand their population. 
Neuroepithelial cells span from the ventricle to the basal membrane of the epithelial sheet and 
are polarized along their apical-basal axis.  They have compartmentalized expression of 
transmembrane proteins, such as the apical expression of the ternary complex aPKC/Par3/Par6 
and the basal expression of integrin a6, a receptor shown to bind to the basal lamina. As they 
divide, the cells undergo interkinetic nuclear migration (INM) along this polar axis, as the nucleus 
migrates basally for replication and back to the apical surface for mitosis. 
At approximately E9-E12 in the developing mouse embryo, these neuroepithelial cells 
begin to divide asymmetrically and produce radial glia, a related neuronal progenitor. While radial 
glia retain several aspects of the neuroepithlial cells, including their apical basal polarity (i.e., 
apical localization of aPKC/Par3/Par6); they also begin to express various astroglial properties, 
including the expression of GFAP and GLAST.  These cells extend a long process which contacts 
the basal lamina and a short process that maintains contact with the apical ventricular lumen, 
where aPKC/Par3/Par6 is located. Similar to neuroepithelial cells, radial glia also undergo INM. 
INM was first discovered in 1935 after Sauer observed and reported a differential nuclear 
positioning during different stages of cellular division (Sauer, 1935).   During replication, the 
nuclei travel basally and return to the apical surface for mitosis. Cells in G1 and G2 phase are 
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found in between the apical and basal regions. Therefore, apical-basal polarity may be critical for 
interkinetic nuclear movement and neural progenitor cell division in general or specifically for 
asymmetric cell division and differentiation. 
 In addition to the regulation of division by apical-basal polarity, various signaling 
mechanisms have been shown to regulate the appropriate proliferation and differentiation of 
radial glia. For example, Notch, a protein found apically localized, has been shown to impact the 
process of cellular differentiation (Dorsky, Chang, Rapaport, & Harris, 1997; Gaiano & Fishell, 
2002). Notch is a cell-surface receptor that upon ligand binding, undergoes cleavage of its 
intracellular domain which then eventually travels to the nucleus to regulate transcriptional 
programs. Activation of Notch has been shown to maintain the proliferative status of neural stem 
cells as well as radial glial cells and block their differentiation (Dorsky et al., 1997; Gaiano, Nye, & 
Fishell, 2000).  Through its ability to enter the nucleus and participate in transcriptional regulation, 
Notch is able to activate genes such as hes1 and hes5, which then block normal cell 
differentiation by neutralizing genes which promote neuronal identity (Gaiano et al., 2000; Iso, 
Kedes, & Hamamori, 2003). This, among other elegant studies, has shown the importance of the 
Notch signaling cascade in the control of neural stem cell proliferation and differentiation 
programs.  
In addition to Notch signaling, mTOR signaling has been implicated in embryonic neural 
development. Using transgenic mouse technologies, Shiota, et al (2006) disrupted the normal 
expression of rictor, a binding partner of mTORC2 (Shiota, Woo, Lindner, Shelton, & Magnuson, 
2006). At E9.5, rictor null embryos experience halted growth until death at E11.5. These embryos 
displayed reduced phosphorylation of AKT at Ser473, an mTORC2 phosphorylation site, 
indicating a significant reduction in mTORC2 signaling (Shiota et al., 2006). Furthermore, AKT-
null mice displayed in a reduction of mTOR activity as evidenced by ribosomal protein S6 
phosphorylation in the brain (Easton et al., 2005).  These mice developed significantly smaller 
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brains than their wild type littermates (Easton et al., 2005), thus providing evidence towards the 
important role of the PI3K/AKT/mTOR pathway in proper embryonic neural development.  
A striking report in 2012 by Lee, et al (2012) found that the PI3K/AKT/mTOR pathway 
was responsible for the development of hemimegalencephaly in postnatal children (J. H. Lee et 
al., 2012). This malformation, where one half of the brain becomes abnormally larger than the 
other, occurs during brain development and results in seizures and mental retardation. Patients 
with hemimegalencephaly may begin showing abnormal hemispheric growth in-utero (Sarnat, 
Flores-Sarnat, Crino, Hader, & Bello-Espinosa, 2012). Hemimegalencephalic brains display 
cortical dyslamination and abnormal immature neurons, which indicate abnormalities in neuroglial 
differentiation and migration (J. H. Lee et al., 2012). Using mass spectrometry and exome 
sequencing in samples from patients with hemimegalencephaly, Lee et al (2012) found gain of 
function mutations in PI3K/AKT/mTOR genes in 30% of cases. In addition, the authors reported 
an increase in S6 protein phosphorylation in the affected brain tissue, providing evidence of a 
deregulated and over-activated mTOR signaling (J. H. Lee et al., 2012). 
Interestingly, the pathological abnormalities found in hemimegalencephaly patients are 
also seen in patients with tuberous sclerosis (TS), which results from mutations in TSC1 and 
TSC2 (J. Huang & Manning, 2009; Inoki, Corradetti, & Guan, 2005). In addition to the abnormal 
neuronal differentiation and migration seen in patients with hemimegalencephaly, patients with 
TSC develop hamartomas in various organs (J. Huang & Manning, 2009; Inoki et al., 2005). 
During embryonic development and beyond, cortical tubers may appear, which are characterized 
by an abnormal pathologic disorganization of the laminar cortex. These cortical tubers may later 
become the cause of epileptic seizures. In addition, cells may appear abnormal, including 
dysplastic neurons and large astrocytes.  Furthermore, subependymal nodules may appear 
during fetal development in TSC patients (J. Huang & Manning, 2009; Inoki et al., 2005). These 
result from benign lesions within the ventricles of the brain, which eventually evolve into 
subependymal giant cell astrocytomas, a type of tumor.  The mutations of TSC1 and TSC2 in 
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patients with TSC typically result in reduction or loss of function of the TSC complex, leading to 
hyperactivated mTOR signaling, as in hemimegalencephaly (J. Huang & Manning, 2009; Inoki et 
al., 2005).  Furthermore, TSC patients often times present with symptoms of autism spectrum 
disorders (ASDs), including abnormal social interactions and inhibited intellectual ability.  Murine 
models of TSC and patients with TSC have been treated with rapamycin in order to inhibit mTOR 
and the results have proven encouraging (Franz et al., 2006; H. Kenerson, Dundon, & Yeung, 
2005; H. L. Kenerson, Aicher, True, & Yeung, 2002; Krueger et al., 2010; L. Lee et al., 2005; 
Meikle et al., 2008). For instance, treatment of TSC heterozygous mice with deficits in learning 
and memory, show significant improvement upon rapamycin treatment (Auerbach, Osterweil, & 
Bear, 2011) and several NIH clinical trials are currently underway to evaluate the efficacy of 
mTOR inhibitors for autism.  
Mice which lacked TSC1 in emx1-expressing embryonic telencephalic neural stem cells 
displayed the abnormal neuropathologies associated with TSC affected patients, including ASD 
phenotypes (Magri et al., 2011). A loss of TSC1 in these cells resulted in hyperactivation of the 
mTOR pathway which resulted in a variety of clinically relevant pathological symptoms. Due to an 
increase in embryonic SVZ neural stem cell proliferation and abnormal premature differentiation, 
the brains of these mice displayed cortical lamination defects, neuropathological lesions, and 
epileptic seizures (Magri et al., 2011), as seen in patients with TSC. Embryonically at E16.5, the 
mutant mice displayed differences in brain size and cortical thickness, indicating abnormal 
proliferation, differentiation, and lamination (Magri et al., 2011).  Using BrdU at E15.5, the authors 
found that the mutant mice had a significant increase in BrdU positive cells.  Furthermore, the 
amount of Pax6+ radial glial cells, TBR2+ and PH3+ intermediate progenitor cells participating in 
mitosis was significantly increased, which indicates that the proper differentiation of these 
progenitor cells was disrupted (Magri et al., 2011). Given that patients with TSC are generally 
treated with rapamycin, the authors treated these transgenic mice with rapamycin from p8-p60 to 
inhibit mTOR signaling. This treatment resulted in the cessation of seizures in the mice, and a 
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normalization of cortical thickness and layering which was identical to the wild type vehicle-
treated control (Magri et al., 2011).   
The deletion of PTEN in mice using different brain specific cres resulted in macrocephaly, 
hypertrophy and seizures. PTEN lies upstream of mTORC1 and participates as a negative 
regulator of the AKT pathway, thus increasing mTORC activity, mimicking a loss of TSC complex.  
Using the neuron specific Eno2 cre, PTENfl/fl mice displayed seizures, impaired learning abilities 
and impaired social interactions (Zhou et al., 2009).  These mice develop macrocephaly 
progressively as well as dendritic and axonal cortical neuron hypertrophy, beginning at 4-5 weeks 
of age, which correlates with their behavioral phenotypes (Zhou et al., 2009).  Interestingly, 
treatment of these PTEN mutant mice at 5-6 weeks of age inhibited the cellular abnormalities of 
cortical neuron hypertrophy, reduced the frequency of seizures, and improved the social ability of 
the mice (Zhou et al., 2009).  Similar positive results were obtained when PTENfl/fl;GFAP-cre 
mice, who display comparable symptoms, were treated with CC1-779, an analog of rapamycin  
(Kwon, Zhu, Zhang, & Baker, 2003).   
Various other neurodevelopmental diseases result from dysreugulation of the mTOR 
signaling pathway including Neurofibromatosis type 1 (NF1), Cowden Syndrome, Proteus 
syndrome and Lhermitte-Duclos disease (Inoki et al., 2005). These pathologies are caused by 
mutations in genes which regulate or participate in mTOR signaling and result in hamartomas in 
multiple organs including the brain, indicating abnormal proliferation regulation of CNS cells.  
Thus, the mTOR pathway is a critical component of appropriate neural stem cell proliferation and 
differentiation in the developing brain and dysregulation of its function may lead to 
neurodevelopmental disorders. 
mTOR in Adult Neural Stem Cell Proliferation, Differentiation, and Neurogenesis 
In the adult, neurogenesis occurs in two specialized regions of the brain – the 
subventricular zone (SVZ) of the lateral ventricles and the subgranular zone (SGZ) of the dentate 
gyrus in the hippocampus.  In the SVZ, adult neural stem cells, or GFAP+ type-B cells, 
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differentiate to give rise to GFAP- type-C Cells, or transit amplifying cells. Type-C cells then 
divide to produce DCX+ type-A cells, or neuroblasts. Neuroblasts then leave the SVZ and migrate 
up to a distance of 5mm as a neuroblast chain through the rostral migratory stream (RMS) until 
reaching the olfactory bulb (OB). Upon reaching the olfactory bulb, the neuroblasts mature into 
NeuN+ granule or periglomerular neurons. In contrast to the SVZ, SGZ neural stem cells are 
classified as Type 1 GFAP+ hippocampal progenitors, which have a radial process spanning the 
granule layer.  These cells give rise to Type 2 GFAP- progenitors, which only have a short 
process. Type 2 transit amplifying cells then give rise to a DCX+ progenitor cell, which will mature 
to express mature neuronal markers, such as NeuN and Tuj1. Newborn neurons from the SGZ do 
not migrate nearly as far as SVZ neurons, as upon reaching the granule cell layer of the DG (from 
the SGZ), they stop migrating to become dentate granule cells. Both newborn neurons generated 
in the SVZ and SGZ become integrated into the existing circuitry and have been shown to receive 
functional input (Zhao, Deng, & Gage, 2008).  
Methods used to study neurogenesis and adult neural stem cell proliferation or 
differentiation include the use of 5’-bromo-2’-deoxyuridine (BrdU), a thymidine analog that 
incorporates into the DNA during S-phase of dividing cells as they undergo DNA synthesis. Cells 
which are born of the BrdU+ cell will maintain BrdU in their DNA, as well, as it is passed on to 
progeny through division. Based on the time of BrdU treatment, as well as the time after 
treatment and before sacrifice, different cell populations may be labeled, allowing the investigator 
to answer various experimental questions. For example, the intraperitoneal injection of BrdU 2-4 
hours prior to sacrifice will label the dividing type-B cells in the SVZ and type-1 cells in the SGZ, 
thus providing an idea of the cells in S-phase at the time of injection. The use of Ki67, a nuclear 
protein which is expressed from late G1 through cell cycle exit, as an endogenous marker of 
cellular proliferation is also quite popular in the neural stem cell and neurogenesis field.  
Furthermore, Ki67 is frequently used as a proliferation marker in cancer studies. The use of both 
BrdU and Ki67 provides further information regarding cellular proliferation. For example, the 
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injection of BrdU 24 hours prior to sacrifice and the co-immunostaining of brain tissue using anti-
Ki67 antibody as well as anti-BrdU antibody will result in BrdU+Ki67- cells and BrdU+Ki67+ cells. 
BrdU+Ki67- cells represent cells which were undergoing mitosis at the time of injection, but have 
since left the cell cycle and are no longer dividing.  Cells which are BrdU+Ki67+ represent cells 
which were dividing at the time of injection and still active through the cell cycle at the time of 
sacrifice. BrdU can also be injected and then “chased” with an interval of time at which point no 
more BrdU is given. An example of this experimental paradigm includes the consecutive injection 
of BrdU+ for 3 days, followed by 2 weeks sans BrdU prior to sacrifice. After fixation and 
immunostaining with anti-BrdU antibody, BrdU+ cells may be found in the SVZ, along the RMS, 
and within the OB. This is because the cells which were dividing at the time of injection may have 
since differentiated into type-C cells, progressed into type-A cells, and migrated through the RMS 
and made their way into the OB while still expressing BrdU. Thus the use of this experimental 
paradigm allows an overall snapshot of all of these processes, however does not provide the 
answer to specific questions such as the effect of an agent to the proliferation of type-B neural 
stem cells, or the effect of an agent on the migration of type-A neuroblasts. Other markers of 
proliferation include phosphor-histone H3, which is expressed during M-phase, proliferating cell 
nuclear antigen (PCNA), which is expressed most significantly during S-phase and MCM2, a 
protein required for initiation of S-phase and is expressed throughout the cell cycle.  Tools such 
as these have allowed for the discovery of adult neurogenesis in both the mouse and the human.  
 Studies examining the regulation of adult neurogenesis and the factors which promote it 
are extremely abundant. Evidence suggests that both intrinsic and extrinsic factors may control 
neurogenesis of neural stem cells (NSCs) in the adult brain (Lledo, Alonso, & Grubb, 2006). 
Extrinsic factors for SVZ neurogenesis include neurotransmitters such as serotonin (5-HT) and 
acetylcholinesterase (ACh), hormones such as thyroid hormone and prolactin, and growth factors 
such as brain derived neurotrophic factor (BDNF) and epidermal growth factor (EGF). Similar 
extrinsic factors regulate neurogenesis in the DG; however, in addition DG neurogenesis is also 
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regulated by environmental conditions, such as running, environmental enrichment, and stress (J. 
Brown et al., 2003). Katoh-Semba, et al. (2002) showed that stimulation of BDNF enhances DG 
neurogenesis and this BDNF-induced increased neurogenesis can be blocked by using 
antibodies specific to BDNF (Katoh-Semba et al., 2002). Early studies looked at the effect of 
BDNF for SVZ neurogenesis in-vitro (Ahmed, Reynolds, & Weiss, 1995; Kirschenbaum & 
Goldman, 1995). These studies found that BDNF supports the survival of newborn neurons in-
vitro, and therefore increases neurogenesis in the adult. Zigova, et al. (1998) confirmed that 
ventricular infusion of BDNF led to an in-vivo increase in BrdU+ cells in the OB (Zigova, Pencea, 
Wiegand, & Luskin, 1998).  Using a knock-in mouse with a variant form of BDNF which impairs its 
activity dependent secretion and a BDNF haploinsufficient mouse (BDNF+/-), Chen, et al., (2008) 
found no change in the proliferation of B cells in the SVZ (Z. Y. Chen, Bath, McEwen, 
Hempstead, & Lee, 2008). However, they did find a significant decrease in the number of BrdU+ 
A cells in the OB in both strains. The authors explored the mechanism of this effect and 
determined that BDNF, though TrkB receptors are critical for A cell survival and migration (Z. Y. 
Chen et al., 2008). An interesting study by Doetsch, et al., (2002) found that infusion of EGF into 
the ventricle of adult mice led to an increase in the number of B and C cells, and an increase in 
their mitotic index (dividing versus non-dividing cells) (F. Doetsch, Petreanu, Caille, Garcia-
Verdugo, & Alvarez-Buylla, 2002). They reported, however, no increase in neuroblasts, and 
therefore suggest that EGF infusion led to an increase in self-renewing divisions of the B cells 
and C cells, at the expense of new neuron production.  Therefore, EGF is acting to regulate the 
self-renewal of B cells and C cells in the SVZ, but not their differentiation into A cells. However, it 
is interesting to note that EGF had no proliferative effect on hippocampal precursor cells (Kuhn, 
Winkler, Kempermann, Thal, & Gage, 1997). Recently, another study described the importance of 
Insulin-like growth factor 2 (IGF2) in DG neurogenesis (Bracko et al., 2012). Using transcriptome 
analyses, the authors compared differences in gene expression between adult NSCs and 
immature neurons. They found significantly higher levels of IGF2 in DG NSCs compared to 
 28 
immature neurons and knocked out IGF2 in-vivo to confirm a reduction in adult DG NSC 
proliferation (Bracko et al., 2012). Interestingly, another report found that IGF2 is secreted in the 
CSF by the choroid plexus and stimulates the proliferation of adult NSCs in the SVZ (Lehtinen et 
al., 2011).  
 Given the importance of growth factor signaling regulation of adult neural stem cell 
proliferation, differentiation and neurogenesis, it is not surprising to learn that mTOR has been 
shown to play a role as well.  BDNF, for example, can activate mTOR (Schratt, Nigh, Chen, Hu, & 
Greenberg, 2004; Slipczuk et al., 2009; Takei et al., 2004; Yang, Hu, Zhou, Zhang, & Yang, 
2013), and BDNF has been implicated in various psychiatric disorders, including depression.  
Successful treatment of depression using selective serotonin reuptake inhibitors (SSRIs) has 
been shown to require neurogenesis (David et al., 2009; Santarelli et al., 2003).  In addition, the 
infusion of BDNF into the hippocampus resulted in increased neurogenesis (Scharfman et al., 
2005) and reduced depression symptoms (Shirayama, Chen, Nakagawa, Russell, & Duman, 
2002).  Although these studies did not directly examine the effect of BDNF on mTOR signaling, it 
can be hypothesized that mTOR activity was increased due to its strong activation downstream of 
BDNF (Schratt et al., 2004; Slipczuk et al., 2009; Takei et al., 2004; Yang et al., 2013).  
 Perhaps more direct evidence of the role of mTOR in adult neurogenesis comes from a 
study by Paliouras et al (2012). These authors found mTOR activation to be increased in 
embryonic neurogenesis and maintained in the adult SVZ niche. Interestingly, within the SVZ, 
they found that approximately 95% of phosphorylated S6 positive cells were positive for Ki67, a 
proliferation marker. Their results also found that approximately 80% of the phosphorylated S6 
positive cells were also positive for Mash1, a neuronal progenitor cell marker. The authors 
infused rapamycin into the mouse ventricles and found a reduction in Ki67+ Mash1+ progenitors. 
No changes were found in caspase-3 staining, indicating that the effect of rapamycin on the 
neuronal progenitors in the SVZ was an effect of proliferation, rather than apoptosis (Paliouras et 
al., 2012). Furthermore, in-vitro treatment of neural progenitors grown as neurospheres with EGF 
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resulted in an increase in phosphorylated S6 and phosphorylated mTOR, indicating mTOR 
activation downstream of EGF stimulation in these cells. When these cells were treated with 
rapamycin or KU0063794, which inhibits both mTORC1 and mTORC2, the result was a reduction 
in the number and size of the neurospheres, indicating a deficit in progenitor cell proliferation 
caused by mTOR inhibition. In addition, the authors found that while mTOR was activated in 
neural progenitors expressing proliferative markers, it was reduced during differentiation (EGF-
withdrawal) of these cells (Paliouras et al., 2012).  
 Given that neural stem cell proliferation and neurogenesis declines with age, the authors 
conducted immunohistochemistry for phosphorylated S6 and Ki67 in the SVZ of aging mice 
(Paliouras et al., 2012). Their results showed a reduction in both of these markers, providing a 
correlation between decreased mTOR activation and reduced SVZ neural stem cell proliferation. 
Interestingly, upon infusion of EGF into the ventricles of aged mice, the authors found re-
activation of mTOR activity and increased proliferation of neural stem cells in the SVZ.  However, 
mice that received a co-infusion of EGF with rapamycin did not display the same effects. Instead, 
these mice failed to show an increase in proliferation or mTOR activation in SVZ neural 
progenitors (Paliouras et al., 2012).  
Kim, et al (2009) studied the function of Disrupted-in-schizophrenia 1 (DISC1) in adult 
hippocampal newborn neurons (Ju Young Kim et al., 2009). A DISC1 genetic alteration was 
discovered to correlate with schizophrenia, bipolar disorder and depression from studies 
examining a Scottish family (Blackwood et al., 2001; Ju Young Kim et al., 2009; Millar et al., 
2000). It is now well recognized that DISC1 is a risk factor for many psychiatric illnesses, 
including schizophrenia, bipolar disorder, and depression. In 2009, Kim, et al. found that 
suppression of DISC1 in newborn dentate granule cells of the hippocampus led to increased 
activation of AKT (J. Y. Kim et al., 2009). The authors note increased phosphorylation of S6 
ribosomal protein, indicating increased mTOR activation. These increased signaling changes 
resulted in defects in both the growth and morphogenesis of the adult newborn neurons and their 
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positioning in the dentate gyrus of the adult hippocampus. The newborn cells also displayed 
limited dendritic growth and reduced synapse formation. Furthermore, the treatment of these 
mice with rapamycin to inhibit AKT and mTOR activation was successful in rescuing the abnormal 
defects (Ju Young Kim et al., 2009). Given these results and the association of DISC1 with 
psychiatric disorders, some researchers have postulated that abnormal adult neurogenesis may 
play a significant role in the development of adult onset psychiatric disorders (Kimberly Christian, 
2010; Ming & Song, 2011).  This study, among others, and those described above in relation to 
embryonic neural stem cell proliferation and differentiation, provide evidence regarding the 
importance of mTOR signaling for these biological processes.  
Stabilization, Survival and Integration of Adult Newborn Neurons 
Initial proliferation and differentiation of NSCs is not the only important factor in 
neurogenesis, stabilization and survival of newborn neurons is also an important regulatory 
process. Evidence has shown that only ~50% of SVZ & DG-newborn neurons will survive longer 
than a month (Dayer, Ford, Cleaver, Yassaee, & Cameron, 2003; Petreanu & Alvarez-Buylla, 
2002). After young OB neurons are matured and have made stable synaptic connections, their 
survival is dependent on the level of activity they receive (Petreanu & Alvarez-Buylla, 2002). 
Similar conclusions can be drawn regarding the survival of newborn neurons in the DG. The full 
integration and synaptic connectivity of these newborn cells is important for their survival.  
 Data regarding the functional integration of adult-born young neurons came from studies 
using viral vectors. In 2002, Carlen, et al. injected a GFP-expressing virus into the brain which 
selectively infects and replicates in neurons (Carlen et al., 2002).  The virus is transported along 
axons and dendrites to infect other neurons in a functioning circuit. In order to investigate the 
integration of SVZ-born OB neurons, mice were given BrdU for 4 weeks, followed by a 3 week 
chase period. This chase allows for the subsequent detection of integrated newborn neurons. 
Newborn neurons are mostly periglomerular, and these neurons extend axons only locally. 
However, these new cells do receive inputs from other neurons in the OB which project axons to 
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the piriform cortex (projection neurons). Therefore, the investigators injected the GFP virus into 
the piriform cortex and upon analyses, found GFP expression in BrdU+ periglomerular neurons of 
the OB (Carlen et al., 2002). Because this virus requires synaptic transmission, this experiment 
indicates that the new neurons were connected into a functional circuit. They conducted a similar 
experiment to evaluate functional connectivity of SGZ-born neurons and found GFP expression in 
BrdU+ neurons of DG neurons. This initial report was one of the first to show successful synaptic 
connections on adult-newborn neurons (Carlen et al., 2002).  
 More recent evidence using patch clamp techniques and immunohistochemistry has 
shown that within 24hrs of reaching the OB, SVZ-newborn neurons receive GABAergic and 
glutamatergic input synapses (Panzanelli et al., 2009).  Three days later, cells take on a mature 
morphology and extend dendrites with clearly defined spines into the external plexiform layer 
(Panzanelli et al., 2009). Interestingly, OB neurons can generate either granule cells or 
periglomerular cells. The different fate acquired occurs at the maturation stage.  In periglomerular 
cells, voltage-dependent sodium current precedes synaptic contacts. However, granule cells first 
establish synaptic connections and then develop the sodium current (Belluzzi, Benedusi, 
Ackman, & LoTurco, 2003; Carleton, Petreanu, Lansford, Alvarez-Buylla, & Lledo, 2003).  
Although correlative, other evidence of fully functioning newborn neurons comes from decreased 
olfactory discrimination and odor memory upon genetic manipulation to reduce newborn cells in 
the OB (Breton-Provencher, Lemasson, Peralta, & Saghatelyan, 2009; Z. Y. Chen et al., 2008; 
Enwere et al., 2004; Gheusi et al., 2000).  
 Similar to the OB, in the DG, newborn neurons also make connections almost 
immediately after the immature neurons exit the cell cycle. Around 10 days after birth, mossy 
fibers are detected and will extend until reaching the CA3 region before mature spines are formed 
(Zhao et al., 2008). Recent evidence indicates that the newborn cells receive afferent projections 
from the entorhinal cortex between 14-21 days after birth (Zhao et al., 2008).  At this age they do 
have glutamate receptors, however, most synaptic currents are GABA-mediated (Overstreet 
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Wadiche, Bromberg, Bensen, & Westbrook, 2005). In addition, electron microscopy studies 
showed that by 30 days of age, newborn neurons receive synaptic inputs from axosomatic and 
axodendritic connections, closely resembling their already matured DG neuron neighbors (Lledo 
et al., 2006). Various electrophysiological studies have showed that newborn neuron synaptic 
integration follows the sequence that embryonic neurons undergo -- including initial excitatory 
GABAergic inputs which later convert to inhibitory inputs (Ben-Ari, 2002). Interestingly, while the 
newborn neurons seem to function as their mature neighbors, they do display enhanced synaptic 
plasticity (Schmidt-Hieber, Jonas, & Bischofberger, 2004). It has been suggested that this may 
facilitate long-term changes in the network, as the neuron is hyperactive and thus has an 
advantage over the mature neurons for stabilization of its synaptic connections (Tashiro, Sandler, 
Toni, Zhao, & Gage, 2006; Toni et al., 2008). Using confocal microscopy, Ramirez-Amaya, et al., 
(2006) examined the expression of the immediate early gene Arc (Ramirez-Amaya, Marrone, 
Gage, Worley, & Barnes, 2006). Arc mRNA and its protein have been reported to be induced by 
spatial exploration in the same cells which are electrophysically activated in the hippocampus. By 
the evaluation of Arc expression after giving mice BrdU and subjecting them to a behavioral 
paradigm, the investigators were able to identify BrdU+ cells that respond to behavioral 
exploration. They found that matured (5 month old) newborn granule cells do express Arc after 
behavioral exploration, and that that a larger amount of BrdU+ cells expressed Arc as opposed to 
BrdU- cells (Ramirez-Amaya et al., 2006).  This data adds to the convincing evidence in the field 
that newborn neurons participate in preexisting hippocampal networks. Upon maturation and full 
integration, these newborn neurons become a permanent part of the functioning circuit, as BrdU-
labeled neurons were found to be stable at least 11 months after their neurogeneration 
(Kempermann, Gast, Kronenberg, Yamaguchi, & Gage, 2003; Leuner et al., 2004).  
 mTOR signaling has been implicated in the survival and integration of newborn neurons. 
For instance, rapamycin treatment reduced dendritic complexity, or arborization, of growing 
neurons, and transfection of constitutively active PI3K and AKT results in increased dendritic 
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arborization and an increase in phosphorylated S6, or mTOR activation (Kumar, Zhang, Swank, 
Kunz, & Wu, 2005). mTOR activation has been shown to regulate local protein synthesis at the 
synapse, regulating synapse formation, which is required for newborn neurons to live (Jacinto & 
Hall, 2003). Interestingly, mTOR activation is induced upon ketamine administration, a drug 
shown to result in anti-depressant effects (N. Li et al., 2010).  In accordance with the hypothesis 
that a potential mechanism for anti-depressant efficacy requires increased synaptic connectivity, 
ketamine treatment in mice results in increased synaptic protein synthesis and increased synaptic 
spines as well as increased synaptic strength (N. Li et al., 2010). The infusion of rapamycin prior 
to ketamine administration completely blocks the synaptic effects of ketamine in addition to 
blocking the anti-depressive effects (N. Li et al., 2010), suggesting a role for mTOR in synaptic 
stabilization.  
 In conclusion, the study of adult neurogenesis is of extreme interest to the scientific field. 
Uncovering the signaling mechanisms regulating neurogenesis and the division of neural stem 
cells harbors enormous potential for the treatment of neurodegenerative diseases. Data over the 
past 20 years has elucidated the strong role of growth factors and signaling cascades on this 
process and this has implications for potential therapies.  Furthermore, advances in 
electrophysiological techniques, viral labeling techniques and transgenic mouse production has 
led to the confirmation of the long-held hypothesis that newborn neurons are indeed fully 
functioning and integrated into existing circuits. Data has shown that the newborn cells are 
capable of receiving and inducing signals, as well as releasing neurotransmitters. In addition, the 
newborn neurons are hyperactive, therefore giving them an advantage for survival and 
integration, as they can respond faster to stimuli. Although many advances have been made in 
this field, a further more detailed look at the role of these new neurons in learning and memory is 
warranted. In addition, very little knowledge of neurogenic regulation has been gleaned from 
higher species or humans. The future of this field should attempt to enter more into human 
studies, as learning how to regulate this process for human application will prove invaluable.  
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MANUSCRIPT: CONTRASTING EFFECTS OF CHRONIC, SYSTEMIC TREATMENT WITH 
MTOR INHIBITORS RAPAMYCIN AND METFORMIN ON ADULT NEURAL PROGENITORS IN 
MICE 
ABSTRACT 
The chronic and systemic administration of rapamycin extends lifespan in mammals. 
Rapamycin is a pharmacological inhibition of mTOR. Metformin also inhibits mTOR signaling, but 
by activating the upstream kinase AMPK. Here we report the effects of chronic and systemic 
administration of the two mTOR inhibitors, rapamycin and metformin, on adult neural stem cells of 
the subventricular region and the dentate gyrus of the hippocampus in mouse. While rapamycin 
decreased the number of adult neural stem cells, metformin-mediated inhibition of mTOR had no 
such effect. Adult-born neurons are considered important for cognitive and behavioral health, and 
may contribute to improved health span. Our results demonstrate that distinct approaches of 
inhibiting mTOR signaling can have significantly different effects on organ function and 
underscore the importance of screening individual mTOR inhibitors on different organs and 
physiological processes for potential adverse effects that may compromise health span. 
INTRODUCTION 
The mTOR signaling pathway has a conserved role in the regulation of replicative and 
chronological life span in yeast and organismal life span in Caenorhabditis elegans, Drosophila, 
and mammals (S. C. Johnson et al., 2013). The inhibition of mTOR signaling with chronic, 
systemic 2.24-mg/kg (14 ppm) administration of rapamycin, a product of the soil bacteria 
Streptomyces hygroscopicus, extends life span in mice, even when introduced late in life 
(Harrison et al., 2009). Rapamycin 4.7, 14, and 42 ppm in food also slows age-dependent 
pathology of the liver, heart, and tendons (Wilkinson et al., 2012). A recent study demonstrated 
that chronic 2.24-mg/kg rapamycin inhibits age-associated cognitive decline (Halloran et al., 
2012). Furthermore, rapamycin treatment was associated with anxiolytic and anti-depressive 
effects (Halloran et al., 2012). 
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While neurogenesis occurs primarily during embryonic and early postnatal mammalian 
development, the adult mammalian brain does retain the ability to produce new neurons. 
Cognitive functions, learning and memory, and behavioral health can be improved by increased 
adult neurogenesis (Deng, Aimone, & Gage, 2010; Lazarov, Mattson, Peterson, Pimplikar, & van 
Praag, 2010; Ramirez-Amaya et al., 2006). Additionally, antidepressants function by stimulating 
adult neurogenesis (Yun Li et al., 2008; Malberg, Eisch, Nestler, & Duman, 2000). Neurogenesis 
in an adult mammal occurs in specialized regions of the brain such as the subventricular zone 
(SVZ) and the subgranular zone of the dentate gyrus (DG) (Kriegstein & Alvarez-Buylla, 2009). In 
these regions, slowly cycling B cells (GFAP+), the self-renewing adult neural stem cell population, 
give rise to transient amplifying C cells (EGFR+), which in turn produce neuroblasts marked by 
the expression of doublecortin (DCX+). Adult-born neurons integrate into functional circuits (Yan 
Li, Mu, & Gage, 2009). Adult neurogenesis decreases with aging and the loss of neurogenesis 
can be correlated with cognitive and behavioral decline (Kuhn, Dickinson-Anson, & Gage, 1996; 
Lazarov et al., 2010). Conversely, caloric restriction, which extends life span, increases adult 
neurogenesis (Lazarov et al., 2010; Levenson & Rich, 2007). 
From Drosophila to mice, multiple steps during neurogenesis—neural progenitor 
proliferation, survival, and differentiation into neurons—have been reported to engage the mTOR 
signaling pathway(Fishwick, Li, Halley, Deng, & Storey, 2010; Han et al., 2008; Ju Young Kim et 
al., 2009; L. Li et al., 2010; McNeill, Craig, & Bateman, 2008; Palazuelos, Ortega, Diaz-Alonso, 
Guzman, & Galve-Roperh, 2012; Paliouras et al., 2012; Raman et al., 2011). For example, the 
loss of activators of mTOR signaling, IgfR1, in neural precursors, results in reduced proliferation 
in the SVZ and microcephaly (Kappeler et al., 2008; Lehtinen et al., 2011; W. Liu, Ye, O'Kusky, & 
D'Ercole, 2009). Conversely, increased Igf activity resulted in increased proliferation in the SVZ 
and macrocephaly (Lehtinen et al., 2011). Two independent mTOR complexes—mTORC1 and 
mTORC2—are found in mammalian cells (Laplante & Sabatini, 2012). Rapamycin is a well-
characterized mTORC1 inhibitor (Guertin & Sabatini, 2009). This macrolide first binds to the 
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cyclophilin FKBP12 in mammalian cells, and the complex subsequently interacts with mTOR and 
inhibits its function. Paliouras et al. (Paliouras et al., 2012) demonstrated that rapamycin infusion 
(0.5 mM) into the left ventricle of mice for 7 days results in a 48 % reduction of proliferating neural 
stem cell numbers (Paliouras et al., 2012). Furthermore, rapamycin reduces neural stem cell 
proliferation in vitro; both the size and number of neural stem cells grown as neurospheres were 
reduced following rapamycin treatment (Paliouras et al., 2012). Additionally, neural stem cells fail 
to differentiate normally in the presence of this drug (Paliouras et al., 2012). Four weeks of 
rapamycin treatment (10 mg/kg) significantly decreased social interaction time in mice (Zhou et 
al., 2009). In contrast, 1 and 4 weeks of rapamycin treatment (20 and 10 mg/kg, respectively) 
have been reported not to affect gross morphology of the important neurogenic niche, DG, or 
normal, newborn neurons and the performance of mice in open field behavioral tests (Ju Young 
Kim et al., 2009). 
Metformin represents an additional pharmacological approach to inhibit mTORC1 
signaling (Mihaylova & Shaw, 2011). This anti-diabetic biguanide acts by increasing AMP 
activated protein kinase (AMPK) activity (Shaw et al., 2005). When activated, AMPK negatively 
regulates mTOR activation (Laplante & Sabatini, 2012). AMPK activation slows aging in C. 
elegans (Apfeld, O'Connor, McDonagh, DiStefano, & Curtis, 2004; Mair et al., 2011) and is being 
considered as a calorie restriction mimetic (Ingram et al., 2006). Therefore, metformin has been 
used for life extension in mammals and, in some studies although not all, has demonstrated 
gerosuppressive effects (Vladimir N. Anisimov et al., 2008; V. N. Anisimov et al., 2011; Berstein, 
2012). Interestingly, 12 days of treatment with metformin has been shown to increase adult 
neurogenesis and spatial memory (J. Wang et al., 2012). However, the effect of longer term 
treatment remains unknown. 
We directly investigated the effects of a chronic, systemic rapamycin or metformin 
treatment on proliferating neural progenitor cells of the SVZ and DG in mice. Here we report that 
a 9-week chronic administration of rapamycin, but not metformin, reduces the number of 
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proliferating neural progenitors in the mammalian neurogenic niches in adult mice. Additionally, a 
similar decrease in proliferation and in neuronal differentiation was observed in murine adult 
neural stem cells cultured in vitro upon rapamycin treatment. In contrast, metformin treatment did 
not significantly reduce neural stem cell proliferation or differentiation. Our studies indicate that 
two distinct methods of inhibiting mTOR activity differentially affect mammalian adult neural stem 
cells. 
MATERIAL AND METHODS 
Mice 
Adult male (12 weeks) C57BL/6J mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME). All mice were housed under specific pathogen-free conditions at the University of 
Arizona, maintained under a strict 12-h light cycle and given a regular chow diet. Upon arrival, the 
mice were rested for 1 week prior to manipulation. The mice were kept in individual metabolic 
cages for an initial 24-h adaptation period followed by a 24-h period during which food intake was 
measured. Baseline, 4- and 8-week measurements were performed. The mice were given free 
access to food and water for the entire study period. The mice were weighed before and after 
being placed into the metabolic cages. All experimental procedures were conducted with approval 
from the University of Arizona Institutional Animal Care and Use Committee. Rapamycin (LC 
Labs) and metformin (Sigma) were administered by daily i.p. injection during the treatment period. 
Rapamycin was administered in a high (2.5 mg/kg) or low (75 µg/kg) dose. Metformin was 
administered at a dose of 200 mg/kg. Control mice received daily PBS i.p. injections. BrdU (50 
mg/kg, Sigma) was given by i.p. injection every 12 h, beginning 48 h prior to harvest. 
Antibodies 
For immunoblotting, rabbit phospho-S6 ribosomal protein (Ser240/244, #5364) and 
mouse S6 ribosomal protein (#2317) antibodies were purchased from Cell Signaling and were 
used at a concentration of 1:1,000. For immunocytochemistry, mouse Tuj1 (MAB1637) and rabbit 
Nestin (MAB5922) antibodies were purchased from Millipore and used at a concentration of 1:250 
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and 1:500, respectively. For immunohistochemistry, rabbit DCX (ab18723), rat BrdU (ab6326), 
and rabbit Ki67 (ab16667) antibodies were purchased from Abcam and used at a concentration of 
1:100. Rabbit Phospho-S6 ribosomal protein (Ser235/236) conjugated to Alexa Fluor 647 was 
purchased from Cell Signaling (4851) and used at 1:100. Species-specific Alexa Fluor conjugated 
secondary antibodies were purchased from Invitrogen and used at 1:500. HRP-conjugated 
species-specific secondary antibodies were purchased from Promega and used at 1:2,000. 
Measurement of rapamycin and metformin 
Method was adapted from Streit et al (Streit, Armstrong, & Oellerich, 2002). 
Measurement of rapamycin and metformin in mouse blood were performed using a TSQ 
Quantum liquid HPLC-electrospray ionization-tandem mass spectrometry system (Thermo 
Finnigan, San Jose). Serial dilutions of a known amount of rapamycin or metformin spiked into 
blank EDTA mouse blood were used as internal standards for quantitation of the drugs in the 
blood. The scan for rapamycin was performed at 931.5 (M+NH4) +→864.7 at a collision energy of 
20 eV. Metformin was detected by selective reaction monitoring; parent mass/charge ratio for 
metformin is 130.1 and the fragment monitored is 71.1. The collision energy was 33 eV.  
Chemicals  
Rapamycin white powder was stored at -20 °C, Clarithromycin (internal standard; Sigma 
catalog # A3487) white powder stored at 4 °C, Methanol Optima LC/MS grade (Thermo Fisher 
Scientific), Zinc Sulfate (as heptahydrate) (Fisher Chemical), Water collected from an in-lab 
Barnstead water purification system.  Metformin white crystalline powder was stored at room 
temperature, Methanol Optima LC/MS grade (Thermo Fisher Scientific), Zinc Sulfate (as 
heptahydrate) (Fisher Chemical), Water collected from an in-lab Barnstead water purification 
system. 
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Immunohistochemistry 
Mice were euthanized and perfused with 30 mL PBS before the brains were quickly 
removed and flash frozen in isopentane. Specimens were then stored at −80 °C. The brains were 
mounted using OCT and sectioned at 14 µm. For BrdU staining, slides were first fixed in 4 % PFA 
for 15 min and subsequently washed 3× in PBS for 10 min each. Slides were denatured in 2 N 
HCl for 15 min at 37 °C, and then for  another 15 min in 2 N HCl at room temperature (RT). Slides 
were rinsed in boric acid buffer (0.2 M orthoboric acid, pH 8.4) and incubated for further 10 min at 
RT. They were then washed 3× in PBS, blocked in 5 % donkey serum with 0.1 % Triton X- 100 
for 2 h at RT. Sections were incubated in primary antibody in blocking buffer at 1:100 overnight at 
4 °C.  Slides were washed 3× in PBS with 0.1 % Triton X- 100 (PBST) for 10 min each and 
subsequently incubated with secondary antibodies for 2 h at RT. Slides were washed in 3× in 
PBS for 10 min, and fixed again in 4 % PFA. Slides were subsequently washed and denatured 
again prior to blocking and incubation in the second primary antibody (DCX) overnight at 4 °C. 
After overnight incubation, the slides were washed 3× in PBS and incubated for 10 min in 100 
ng/mL DAPI before being mounted in Prolong Gold Antifade Reagent (Invitrogen), cover-slipped 
and imaged using a Leica SP5 confocal microscope. For immunohistochemistry using p-S6 
ribosomal protein antibodies, sections were fixed in 4 % PFA, washed 3× in PBS and then 
blocked in 10 % donkey serum in PBST for 2 h at RT. Sections were incubated with primary 
antibody at 1:100 in blocking buffer overnight at 4 °C. Sections were washed 3× with PBS and 
incubated for 10 min in 100 ng/mL DAPI before being cover-slipped and imaged on a Leica SP5 
confocal microscope. 
Quantification of BrdU+ Cells 
Fourteen-micrometer sections were collected beginning at the olfactory bulbs and ending 
at the cerebellum. Series of every 15th section through each sample were processed for BrdU 
immunohistochemistry as described above and every adjacent section was stained with H&E. 
The SVZ was defined as beginning at the bregma 1.41 mm until −0.11 mm. Only cells existing 
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within 0.1 mm lateral to the ependymal lining were counted. No cells on the medial SVZ were 
considered. The total number of sections in which the SVZ appeared were ~85-100 (roughly 1.2 
mm rostralcaudal). The DG was defined as beginning at the bregma −1.077 mm until the bregma 
−3.39 mm. The total number of sections in which the DG appeared were ~130–170 (roughly 2 
mm rostral–caudal). The areas of the SVZ and DG were measured using ImageJ (NIH). For cell 
counting, the investigator was blinded to the experimental condition. BrdU-labeled cells were 
exhaustively counted on every 15th section through the entire DG or SVZ. 
Neural Stem Cell Isolation  
For both neurosphere and adherent neural stem cell culture, postnatal day 30 (p30) 
C57BL/6 mice were used. Briefly, the brains were removed and placed in ice-cold Leibovitz’s L15 
media (Invitrogen) for dissection. Using a microsurgery knife, a 1-mm coronal section was 
obtained corresponding to the region of the SVZ. Cuts were made vertically following the ventricle 
ventrally and horizontally following the ventricle dorsally. A small piece of SVZ was then dissected 
and placed into a 1.5-mL microcentrifuge tube containing 300 µL of 0.25 % Trypsin-EDTA in PBS 
and incubated at 37 °C for 20 min. Seven hundred mi croliter of complete media (see 
Supplementary Information) was added, and the tissue was gently triturated until single cell 
suspension was obtained. Cells were then plated either in complete media (for neurospheres) or 
N5 media (for adherent neural stem cell culture). The composition of N5 media is provided in the 
Supplementary Information. Overnight treatment with different concentrations of rapamycin and 
metformin were tested on neural stem cells and the concentrations showing maximal inhibition of 
mTOR (assayed by inhibition of rS6 phosphorylation) without significant cell death were used in 
the study (200 nM rapamycin and 500 µM metformin). 
Immunoblotting 
For immunoblotting, neurospheres were grown in the presence or absence of rapamycin 
or metformin for 3 h prior to lysing. For lysis, ice-cold 1 % NP-40 buffer (20 mM Tris–HCl at pH 8, 
137 mM NaCl, 10 % glycerol, 1 % NP-40) supplemented with phosphatase and protease 
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inhibitors (Halt protease and phosphatase inhibitor cocktail, Thermo Scientific) was used. Briefly, 
cells were washed 3× with ice-cold PBS and then resuspended in cold NP-40 buffer. Lysates 
were kept cold and sonicated ten times, 1 s each, and then centrifuged at 12,000×g for 5 min at 4 
°C. LDS sample loading buffer (Invitrogen) with DTT  was added, and the immunoprecipitates 
were boiled for 5 min prior to loading onto precast SDS-PAGE gels (Invitrogen). Gels were 
transferred onto methanol pre-soaked PVDF membranes and subsequently blocked with 5 % 
BSA in TBS for 2 h. The blot was incubated in phospho-S6 ribosomal protein antibody (Cell 
Signaling, #5364, 1:1,000) overnight at 4 °C, after  which blots were washed 3× with TBST 
(TBS+0.1 % Tween) for 15 min each, followed by incubation with secondary antibodies (1:2,000) 
for 1 h at RT. Blots were then washed 3× for 30 min each in TBST, with a final wash in TBS 
alone. Blots were stripped and reprobed using total S6 ribosomal protein antibody (Cell Signaling, 
#2317, 1:1,000) overnight at 4 °C prior to secondar y incubation and developing. All blots were 
developed using Super Signal West Dura (Thermo Scientific) on the UVP Imager. 
Neural Stem Cell Proliferation and Apoptosis  
Neurospheres and adherent neural stem cell cultures were treated overnight with 200 nM 
rapamycin and 500 µM metformin. For proliferation assays, cells were grown overnight in the 
presence of 10 µM BrdU. BrdU was detected using a BrdU-APC (BD Pharmingen #552598) kit 
according to manufacturer’s instructions. For cell cycle analysis, cells were washed 3× with PBS 
and resuspended in 1 mL of ice-cold PBS in polypropylene tubes. For fixation, cells were gently 
vortexed while adding 3 mL of ice-cold absolute ethanol dropwise and then fixed overnight at 4 
°C. For staining, cells were washed with ice-cold P BS and resuspended in 300 µL of propidium 
iodide solution (200 ng/mL RNAse A, 20 mg/mL propidium iodide, 0.1 % Triton X-100 in PBS) for 
15 min at 37 °C. Data were collected using an Accur i C6 (BD Biosciences) and was analyzed 
using FlowJo (Tree Star). In vitro apoptosis experiments were performed on dissociated adherent 
neural stem cells using the ApoDetect Annexin V-FITC kit (Invitrogen #33-1200) according to the 
manufacturers’ instruction. 
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Neural stem cell culture and differentiation 
Neurospheres were maintained in complete media. For differentiation, neurospheres 
were dissociated using TrypLE (Invitrogen) following manufacturer’s instructions and seeded onto 
acid-etched coverslips (70 % EtOH, 1 % HCL in PBS, 5 min followed by extensive PBS wash) in 
differentiation media #1 or without rapamycin or metformin for 2 days. The media was then 
changed to differentiation media #2 for 5 days with or without drug.  
For in vitro proliferation and differentiation experiments, rapamycin was used at 200 nM, 
metformin was used at 500 µM.  Differentiation Media #1 was composed of 49.9 mL Control 
Media, 100 µL heparin solution, and 0.5 µg bFGF2. Differentiation Media #2 consisted of 49 mL 
control media and 1 mL of FBS. 
Immunocytochemistry 
Following differentiation, coverslips were fixed with 4 % PFA for 15 min at RT, then 
washed 3× with PBS and permeabilized with PBST for 15 min at RT. Cells were blocked for 2 h 
with 2 % normal horse serum (Invitrogen) in PBS at RT. Primary antibodies were diluted in 2 % 
normal horse serum and cells were incubated overnight at 4 °C. Subsequently, coverslips were 
washed 3× with PBS and secondary antibodies (Alexa-Fluor-488 and 594) diluted in 2%normal 
horse serum were added for 2 h at RT. Following the secondary antibody incubation, cells were 
stained with 100 ng/mL DAPI for 10 min at RT. Finally, coverslips were washed 3× with PBS and 
mounted onto slides using ProLong Gold antifade reagent (Invitrogen) and sealed with nail polish. 
Images were obtained using a Leica SP5 confocal microscope. 
Statistical analysis 
Differences between the means of experimental groups were analyzed with a two-tailed t 
test (Prism GraphPad Software, Inc.). P values≤0.05 were considered significant. A minimum of 
five mice per category (control, rapamycin 75 µg/kg, rapamycin 2.5 mg/kg and metformin-treated 
groups) were tested for all in vivo experiments described. In vitro experiments were performed in 
triplicates. 
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SUPPLEMENTARY MATERIAL AND METHODS 
Neural stem cell culture 
Complete Media was prepared as follows: 49.7 mL of Control Media, 200 mg BSA, 100 
µL heparin solution, 1 µg EGF, and 0.5 µg bFGF2. Control Media consisted of 415 mL 
DMEM/F12, 10 mL 30% glucose, 7.5 mL 7.5% NaHCO3, 2.5 mL 1M HEPES, 5 mL of 200 mM L-
glutamine, 50 mL hormone mix and 1% penicillin/streptomycin. 10X Hormone mix consisted of 
400 mL DMEM/F12, 8 mL 30% glucose, 6 mL 7.5% NaHCO3, 2 mL 1M HEPES, 400 mg Apo-
transferrin, 40 mL insulin solution, 40 mL putrescine solution, 40 µL 200 µM Progesterone and 40 
µL 3mM sodium selenite. The solution was sterilized by filtering through a 0.2 µm filter. N5 media 
consisted of DMEM/F12, 5% FCS, 35 µg/mL bovine pituitary extract, 20 ng/mL EGF, and 20 
ng/mL FGF2.   
Neural stem cell differentiation  
Differentiation Media #1 was composed of 49.9 mL Control Media, 100 µL heparin 
solution, and 0.5 µg bFGF2. Differentiation Media #2 consisted of 49 mL control media and 1 mL 
of FBS.  
Chemicals 
Rapamycin white powder was stored at -20 °C, Clarit hromycin (internal standard; Sigma 
catalog # A3487) white powder stored at 4*C, Methanol Optima LC/MS grade (Thermo Fisher 
Scientific), Zinc Sulfate (as heptahydrate) (Fisher Chemical), Water collected from an in-lab 
Barnstead water purification system. 
Analytical System 
Analysis was performed on a TSQ Quantum system (ThermoFinnigan, San Jose, CA) 
consisting of a Surveyor MS Pump, Surveyor autosampler and TSQ Quantum Ultra triple 
quadrupole mass spectrometer. Analysis was done in MS/MS mode. The scan for rapamycin was 
931.5 (M+NH4)+ 864.7 at a collision energy of 20 eV. The scan for clarithromycin was 747.9 
(M+H)+ 590.6 at a collision energy of 37 eV. Analytes were ionized using electrospray ionization 
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with spray voltage of 5000 V, sheath gas (nitrogen) and auxiliary gas at respective flow rates of 
49 and 24 arbitrary units (au) and a capillary temperature of 311°C. Argon was used as collision 
gas at a constant pressure of 0.8 mTorr. Chromatographic separation was achieved on a Luna C-
18(2) HPLC column 50 mm X 2.0mm, 5 with 4mm X 2.0 mm guard cartridge. Mobile phase 
consisted of 30 mM ammonium acetate (A) and methanol (B). The flow rate was 300 µl/min with 
initial solvent proportion of 20% B until 1 minute increasing to 97% B from 1 minute to 2 minutes, 
holding at 97% B from 2 minutes to 5 minutes with re-equilibration at 20% B from 5.1 minutes to 8 
minutes. Injection volume was 10 µl and total analysis time was 8 minutes. 
Preparation and Extraction of Standards and Samples 
25 µl of standard and 25 µl of clarithromycin internal standard were added and 
subsequently evaporated to dryness in a speed-vac. For unknown samples, only internal 
standard was added. 25 µl of whole blood was then added and vortexed. 150 µl of 70:30(v/v) 
Methanol:0.3 M ZnSO4 was added and vortexed to mix. Samples were then centrifuged at 12000 
rcf for 10 minutes at 4°C. 100 µl of supernatant was transferred to autosampler vials for analysis. 
Chemicals  
Metformin white crystalline powder stored at room temperature, Methanol Optima LC/MS 
grade (Thermo Fisher Scientific), Zinc Sulfate (as heptahydrate) (Fisher Chemical), Water 
collected from an in-lab Barnstead water purification system. 
Analytical System 
Analysis was performed on a TSQ Quantum Ultra triple-quadrupole mass spectrometer in 
conjunction with a Finnigan Surveyor Autosampler and Finnigan Surveyor quaternary HPLC 
pump (Thermo Finnigan, San Jose, CA). The mass spectrometer was operated in the positive 
ionization mode utilizing atmospheric pressure chemical ionization (APCI). Spray voltage was 
3500 V, sheath gas (nitrogen) flow was 21 (arbitrary units), auxiliary gas (nitrogen) flow was 5, 
vaporizer temperature was 395°C, capillary temperat ure was 200°C and argon was used as the 
collision gas at a pressure of 0.8 mTorr. Detection utilized selective reaction monitoring (SRM); 
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parent mass/charge ratio for metformin was 130.1 and the fragment monitored was 71.1. The 
collision energy was 33 eV. HPLC separation was achieved using a 3 BDS Hypersil Cyano 50 X 
4.6 mm column (Thermo Scientific, Bellefonte, PA). Mobile phase was 60:20:20 10 mM 
ammonium acetate:acetonitrile:methanol (v/v) Flow rate was 650 µl/minute.  
Injection volume was 20 µl. The autosampler needle was washed with 200 µl of 50% 
acetonitrile followed by 200 µl of 100% acetonitrile following each injection.  During the first 
minute of analysis time, eluent was diverted to waste.  Total analysis time was 5 minutes. 
Metformin eluted at ~2.6 minutes. 
Preparation and Extraction of Standards and Samples 
12.5 µl of standards (12. 5 µl of methanol for blank) were added to 25 µl of mouse serum 
and mixed by vortexing. Unknown samples were stored at -80°C and thawed before analyses. 
12.5 µl of methanol were added to the unknown samples and mixed by vortexing. 300 µl of cold 
acetonitrile was added and mixed by vortexing before centrifuging for 5 minutes at 12000 g at 
4°C. 100 µl of supernatant was transferred to autosampler vials for analysis. 
RESULTS 
Chronic and systemic administration of rapamycin, but not metformin, decreases BrdU 
incorporation in SVZ and DG neurogenic niches 
We used an ~9-week regimen of daily intraperitoneal (i.p.) injection of rapamycin at 75 
µg/kg (low dose) or 2.5 mg/kg (high dose), or metformin at 200 mg/kg daily in adult C57BL/6J 
mice (Fig. 2.1a). The low-dose rapamycin was selected to match previously reported dosage that 
enhanced CD8 memory T cell generation (Araki et al., 2009). The high rapamycin dosage was 
selected to match the concentration reported to extend life span (Miller et al., 2011). The animals 
were 3 months old at the beginning of the treatment. Age-matched controls received daily PBS 
injections. The mice did not show any increase in food intake or body weight during this study; 
mice on high-dose rapamycin showed weight loss (Table 2.1). Sixteen hours following the last 
injection, the mice were harvested, and rapamycin concentration in the blood and metformin 
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concentration in the plasma were quantitated (Fig. 2.1b). The inhibition of mTOR activity in the 
brain following the pharmacological treatments was confirmed by fluorescent 
immunohistochemical analyses of phosphoribosomal S6 (rS6~P) on brain sections. Our results 
demonstrate that both concentrations of rapamycin used in this study, as well as metformin, 
effectively reduced rS6~P-specific immunostaining, indicating that mTOR signaling is inhibited in 
the brain following rapamycin and metformin treatment (Fig. 2.1c). To quantitate adult neural 
stem cell numbers, the mice were injected with BrdU 2 days prior to sacrifice (Fig. 2.1a). BrdU is 
incorporated in the DNA during S-phase and has been utilized to detect slowly cycling B cells and 
the proliferating C cells in adult neurogenic niches (Kee, Sivalingam, Boonstra, & Wojtowicz, 
2002). First, BrdU incorporation in SVZ (Fig. 2.2a) was measured by analyses of serial sections 
encompassing the entire SVZ of adult mice. This experiment revealed that the number of BrdU+ 
cells was significantly decreased in both low and high-dose rapamycin-treated mice (Fig. 2.2b 
and c). Interestingly, metformin treatment did not significantly alter the number of BrdU+ cells 
(Fig. 2.2b and c). Next, the number of BrdU+ cells was quantified as described in the 
“Experimental procedures” section, and statistical analyses revealed a significant difference in 
BrdU incorporation between control and rapamycin-treated, but not in metformin-treated, mice 
(Fig. 2.2d). To independently confirm the reduction in neural progenitor numbers, SVZ sections 
were stained with Ki67. While BrdU can be incorporated in apoptotic cells, Ki67 is a cell cycle 
marker. Consistent with the effect of the drug treatment on BrdU incorporation, a decreased 
number of Ki67+ cells were detected following rapamycin, but not metformin treatment 
(Supplementary Fig. 2.S1). We also measured BrdU incorporation in the DG, an additional 
neurogenic niche (Fig. 2.3a). Sections corresponding to DG were stained with anti-BrdU antibody, 
and the number of BrdU+ cells were counted and compared between control, rapamycin-treated 
and metformin-treated mice. We observed fewer BrdU+ cells in the DG of the rapamycin-treated 
mice, in comparison to control or metformin-treated mice (Fig. 2.3b and c). Taken together, our 
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results demonstrate that chronic, systemic rapamycin, but not metformin, significantly reduced the 
number of cycling mammalian adult neural stem cells. 
Neural progenitor proliferation in vitro is reduced by rapamycin but remains unaffected by 
metformin 
To directly test the effects of rapamycin and metformin on neural progenitor proliferation, 
apoptosis and/or differentiation, we measured the effects of these drugs on primary, adult neural 
stem cells isolated from the SVZ of postnatal day 30 (p30) C57BL/6 mice and cultured in vitro. 
Neural stem cells were grown under two independent culture conditions, either as neurospheres 
or as an adherent monolayer. In vitro cultures were treated with 200 nM rapamycin or 500 nM 
metformin overnight, and the inhibition of mTOR was confirmed by rS6~P immunoblotting. Under 
these conditions, both rapamycin and metformin treatment inhibited mTOR activity in these neural 
stem cells (Fig. 2.4a).  
Next, proliferation of the neural stem cells was measured by BrdU incorporation. Cells 
were incubated overnight with BrdU in the presence of rapamycin or metformin. Rapamycin 
treatment significantly inhibited the rate of proliferation as indicated by decreased proportion of 
BrdU+ cells (Fig. 2.4b; Table 2.2). Unlike rapamycin, metformin treatment did not reduce the 
proliferation of neural stem cells in vitro. Finally, we performed cell cycle analyses of control, 
rapamycin, and metformin-treated adult neural stem cells. Neural stem cells were grown under 
adherent conditions in the presence of rapamycin or metformin, and cell cycle analyses were 
performed by propidium iodide (PI) labeling and FACS. Similar to previous reports (Bez et al., 
2003; Merlo et al., 2007), we found that under control conditions 78.73±1.59 % of neural stem 
cells was in G1 phase, 9.0±0.85 % in the S phase, and 11.40±0.35 % in the G2/M phase (Table 
2.3). Metformin treatment did not significantly alter this profile (Fig. 2.4c; Table 2.3). In contrast, 
rapamycin treatment increased the percentage of cells in the G1 phase and resulted in a 
consequent decrease in S and G2/M-phases (Fig. 2.4c; Table 2.3). Rapamycin is known to cause 
G1 arrest in differentiated cells (S. Huang, Bjornsti, & Houghton, 2003), and reduced S phase in 
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the presence of rapamycin may account for reduced BrdU incorporation observed in vivo. Neither 
rapamycin nor metformin induced significant apoptosis (Fig. 2.4d). Taken together, these results 
are consistent with our in vivo BrdU incorporation studies and suggest that rapamycin inhibits the 
proliferation of neural progenitors. 
Rapamycin, but not metformin, reduces neuronal differentiation 
We directly tested the effects of rapamycin and metformin on neuronal differentiation in 
vitro by using isolated neural stem cells. Following neurosphere cultures, differentiation was 
induced as described in the “Experimental procedures” section. Undifferentiated neural 
progenitors were identified as Nestin+, while differentiated neurons in culture were identified by 
Tuj1+ staining. Both control, as well as metformin treated cells lost their Nestin-expression, and 
some cells became Tuj1+ upon neuronal differentiation (Fig. 2.5). Treatment with rapamycin 
inhibited this differentiation in vitro. Rapamycin-treated cells failed to express Tuj1 and retained 
Nestin expression (Fig. 2.5). These results are also consistent with the longer G1 observed in 
rapamycin-treated neural stem cells in vitro. Alterations in the precise length of G1 phase in stem 
cells have been correlated with defects in differentiation (Lange, Huttner, & Calegari, 2009; V. C. 
Li, Ballabeni, & Kirschner, 2012). In summary, our in vitro results indicate that rapamycin inhibits 
neural progenitor proliferation and differentiation. 
Since the SVZ and DG neural progenitors are the source of adult born neurons, we 
hypothesized that neuronal differentiation may decrease following chronic, systemic rapamycin 
treatment. Consistent with this hypothesis, we observed that the number of DCX+ cells in the 
SVZ was reduced upon chronic, systemic rapamycin treatment in comparison to control brain 
(Supplementary Fig. 2.S2). DCX is a widely used marker for identifying neuroblasts and immature 
neurons in vivo (Mina J. Bissell & William C. Hines, 2011). However, metformin treatment did not 
alter the number of DCX+ cells (Supplementary Fig. 2.S2). Therefore, the reduced proliferation of 
neural progenitors observed in vivo and in vitro in this study, along with the inhibition of in vitro 
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differentiation, indicate that chronic, systemic rapamycin treatment results in reduced adult-born 
neurons. 
DISCUSSION 
Our experiments demonstrate that ~9-week systemic administration of the mTOR 
inhibitor rapamycin reduced the number of neural progenitor cells in the adult mammalian brain. 
In contrast, a different pharmacological strategy of inhibiting mTOR indirectly through AMPK 
activation, did not significantly affect proliferation in the neurogenic niche. The molecular 
mechanisms accounting for the observed differences between the mTOR inhibitor rapamycin and 
metformin remain unclear at this point and will be the subject of future analyses. Differential 
effects of rapamycin and metformin could be ascribed to the unique effects of these drugs on 
mTORC1 versus mTORC2 complex, differential inhibition of downstream signaling components 
or alternative engagement of feedback regulatory pathways. The first possibility is the reported 
effect of rapamycin on the mTORC2 complex. Prolonged rapamycin treatment has been reported 
to inhibit mTORC2 (Sarbassov et al., 2006). Similarly, rapamycin-induced insulin resistance 
results from the disruption of the mTORC2 complex (D. W. Lamming et al., 2012). It is possible 
that the inhibition of adult neurogenesis by rapamycin may result from similar undesirable effects 
on mTORC2. Metformin-dependent AMPK signaling is likely to be restricted to the regulation of 
the mTORC1 complex. Secondly, differential effects on mTORC1 substrates can also account for 
the observed differences. For example, 4E-BP1 is the major effector for the cell cycle effects of 
rapamycin (Dudkin et al., 2001). Additionally, unique targets of AMPK such as Acetyl CoA 
carboxylase (Mihaylova & Shaw, 2011), may offset the negative effects of rapamycin through 
unknown mechanisms. It will be interesting to perform an unbiased, comparative assessment of 
differential downstream target engagement in neural stem cells following chronic rapamycin and 
metformin treatment. Finally, differences in the response of the IRS/Akt or Grb10 feedback loops 
(Hsu et al., 2011; J. Huang & Manning, 2009) following rapamycin versus metformin treatment in 
neural progenitors may account for the observed effects. Metformin and rapamycin have been 
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reported to have opposing effects on Akt activation (Zakikhani, Blouin, Piura, & Pollak, 2010). 
Additionally, AMPK activation in sensory neurons inhibits incision-induced acute and chronic pain 
and neuropathic pain by the simultaneous attenuation of both mTOR and ERK signaling 
(Melemedjian et al., 2011). In contrast, we observe that both pharmacological and genetic 
inhibition of mTORC1 evokes spontaneous pain, mechanical hypersensitivity, and increased 
sensory neuron excitability (Melemedjian et al., 2011). Rapamycin releases the feedback 
inhibition of Grb10, which is an upstream regulator of MAPK pathway (Hsu et al., 2011)and has 
previously been shown to increase ERK activation in TSC2−/− murine embryonic fibroblasts 
(Ghosh et al., 2006). 
Adult neural progenitor cells and adult neurogenesis are generally considered positive 
characteristics that may improve or preserve cognitive function and behavioral health in aging. In 
our study, rapamycin reduces neural progenitor numbers. Additionally, rapamycin, or the 
inhibition of the mTORC1 and mTORC2 complexes, have been reported to inhibit dendritic 
arborization of hippocampal neurons (Urbanska, Gozdz, Swiech, & Jaworski, 2012). Therefore, 
chronic rapamycin treatment may have a paradoxical, negative effect on health span. It remains 
to be seen if metformin treatment, which lacked the adverse effects associated with rapamycin in 
our studies, would be suitable for extending both life span and health span across mammalian 
species. However, we cannot formally rule out the possibility that abnormal integration of adult-
born neurons into pre-existing circuits contributes to aging and the inhibition of adult 
neurogenesis may be beneficial to health span. It is interesting to note that at least in the 
nematode C. elegans, the loss of certain neurons has been correlated with extended life span 
(Alcedo & Kenyon, 2004). Careful assessment of a causal link between rapamycin effects on 
adult neurogenesis and learning, memory, and behavior in mammalian models of aging will be 
required for a comprehensive understanding of the impact of long term rapamycin treatment in 
cognitive health span. 
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In summary, our study reveals that distinct approaches of inhibiting the mTOR pathway, 
especially in the context of long-term, systemic treatment consistent with life span extension, can 
have significantly different outcomes in terms of physiological or pathological responses. The 
effects of mTOR inhibitors on cellular correlates of health span must therefore be carefully and 
comprehensively analyzed in individual organs and systems. While here we examine the effects 
of two distinct pharmacological approaches for mTOR inhibition only on adult neural progenitor 
cells, immune function, for example, will constitute another important physiological parameter for 
the assessment of improved health span. Rapamycin being an immunosuppressant, a thorough 
assessment of its effect on innate and adaptive immune function in old mice is merited. 
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Figure 2.1. Chronic, systemic rapamycin and metformin administration in mice inhibits 
mTOR activity in the brain. A) Schematic representation of chronic rapamycin and metformin 
treatment regimens and BrdU administration prior to tissue collection. Intraperitoneal (i.p.). B) 
Rapamycin and metformin concentration in the blood and plasma, respectively, collected from 
mice before tissue collection. The last dose of rapamycin and metformin were given 16 h before 
sacrificing the mice. C) Ribosomal S6 phosphorylation (rS6~P) as detected by 
immunofluorescence, in sections from the cortex of control mice or mice treated with the indicated 
doses of rapamycin or metformin. Scale bar=100µm. Data are presented as representative of >5 
mice per group 
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Table 2.1  
Neither rapamycin nor metformin significantly increase food intake or body weight 
 
Average food intake (per mouse per gram) during the study (A) and average body weight (per 
mouse) at the end of study (B) with standard error of the mean (SEM) 
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Figure 2.2. Chronic rapamycin treatment, but not metformin, inhibits the proliferation of 
neural progenitors in the SVZ region of the adult mammalian brain. A) Schematic indication 
a region of interest (boxed area) in SVZ. B) BrdU (red) incorporation as detected by 
immunofluorescence in the SVZ of control and treated mice. DAPI-stained nuclei are shown in 
blue. Scale bar=100µm. Arrows point to BrdU+ cells. C) BrdU (green) and DAPI (blue) in the SVZ 
of control and treated mice. Scale bar=25µm. D) Quantification of BrdU+ cells per square 
millimeter in the SVZ in control and treated mice. Data are presented as representative individual 
images or as mean+/- SEM from >5 mice per group. **p<0.01, ns is nonsignificant  
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Figure 2.3. Chronic rapamycin treatment, but not metformin, inhibits the proliferation of 
neural progenitors in DG. A) Schematic outlining DG. B) BrdU incorporation (red) and DAPI 
(blue), as detected by immunofluorescence, in DG of control and treated mice. Scale bar=100µm. 
Arrow points to BrdU+ cells. C) Quantification of BrdU+ cells per square millimeter in the DG in 
control and treated mice. Data are presented as representative individual images or as mean +/- 
SEM from >5 mice per group. **p<0.01, ns is nonsignificant 
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Figure 2.4. Rapamycin, but not metformin, inhibits proliferation of neural stem cells in 
vitro. A) Ribosomal S6 phosphorylation (rS6~P) and total ribosomal S6 in neural stem cells 
cultured in vitro, as detected by immunoblotting after overnight rapamycin or metformin treatment. 
B) Representative FACS plots of BrdU incorporation in adult neural stem cells after rapamycin or 
metformin treatment. C) Representative FACS cell cycle analysis of neural stem cells after 
rapamycin and metformin treatment. D) Representative FACS analysis of annexin V/PI staining in 
neural stem cells after rapamycin or metformin treatment. Data are presented as representative 
of three independent experiments 
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Table 2.2  
 
Rapamycin, but not metformin, inhibits the proliferation of neural progenitors in vitro 
 
 
Percentage inhibition of BrdU incorporation in neural stem cells isolated from p30 SVZ and grown 
in vitro as neurospheres or as an adherent monolayer. Data are presented as mean +/- SEM of 
greater than or equal to three independent experimental repeats 
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Table 2.3  
 
Rapamycin, but not metformin, causes G1 phase arrest in vitro 
 
 
Percentage of neural stem cells at different stages of the cell cycle following in vitro rapamycin 
and metformin treatment, as determined by PI staining and FACS analyses. Data are presented 
as mean +/- SEM of greater than or equal to three independent experimental repeats 
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Figure 2.5. Rapamycin, but not metformin, inhibits differentiation of neural stem cells in 
vitro. Representative images of undifferentiated or differentiated p30 neural stem cells after 
rapamycin or metformin treatment. Scale bar=30µm. Data are representative of three 
independent experiments 
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Figure 2.S1. Chronic rapamycin, but not metformin, treatment reduces neural progenitor 
numbers in the SVZ region of the adult mammalian brain. Ki67 staining in the SVZ of control 
and treated mice. Scale bar = 100µm. Arrow points to Ki67+ cells. Data are presented as 
representative images. >5 mice were included per group. 
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Figure 2.S2. Chronic rapamycin treatment, but not metformin, reduces neuroblasts and/or 
immature neuron numbers. DCX (green) and DAPI (blue), as detected by immunofluorescence, 
in the SVZ of control, rapamycin and metformin-treated mice. Scale bar =50µm. Data are 
presented as representative images. >5 mice were included per group. 
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CHAPTER 3 
 
SIGNALING IN GLIOBLASTOMA 
 
INTRODUCTION TO MANUSCRIPT 
 
Glioblastoma Multiforme 
Glioblastoma (GBM) is defined by the World Health Organization (WHO) as a grade IV 
diffuse glioma, a tumor arising from the astrocytic cells of the brain (Scherer, 1940). First 
identified by Rudolf Virchow in 1863 as a glial tumor (Virchow, 1863), GBM was originally referred 
to as a spongioblastoma multiforme until two physicians in 1926 renamed it by its current name, 
GBM (Bailey, 1926). It is the most common and most malignant of the variant glioma 
classifications (Kleihues, 2000). Prognosis for GBM patients is dismal due to the highly invasive 
and extreme heterogeneity of the cells comprising the GBM tumor. Interestingly, in 1928, a 
neurosurgeon named Walter Dandy removed the entire hemisphere of two GBM patients (Dandy, 
1928).  Unfortunately, both patients invariably died from GBM despite this aggressive surgery, 
providing evidence towards the highly invasive nature of GBM cells (Agnihotri, 2013; Dandy, 
1928). Standard of care therapy includes surgical resection, radiation and chemotherapy with 
temozolomide. Nevertheless, despite the aggressive tactics taken by clinicians at targeting GBM, 
the median survival remains roughly 15 months (Huse et al., 2013). This is likely due to the 
aggressive invasion of the cells and their ability to evade chemotherapy. In addition, the 
dysregulation of signaling pathways in these cells promoted by aggressive genetic mutations 
renders potential successful therapies obsolete.   
GBM tumors can be classified into either primary or secondary GBM, with primary GBM 
comprising more than 90% of surgically removed cases (Roger McLendon et al., 2008). Primary 
GBM arises de novo, without any previous history of disease, while secondary GBM arises from 
previously diagnosed low-grade glioma, such as low grade astrocytoma (WHO grade II) or 
anaplastic astrocytoma (WHO grade III). Interestingly, these two classifications develop through 
different genetic mutations, maintain different dysregulation of signaling mechanisms, and have 
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differential responses to treatment (Ohgaki & Kleihues, 2007). Furthermore, the age of onset 
differs quite significantly between those with primary and those with secondary GBM. The mean 
age of primary GBM patients is 62 years, while the mean age for secondary GBM patients is 35 
years (Ohgaki & Kleihues, 2007). Genetically, EGFR and/or PTEN mutations tend to occur more 
often in primary GBM patients. While TP53 mutations do occur in primary GBM patients, 
secondary GBM tumors more frequently experience this mutation. However, a loss of 
heterozgyozity (LOH) in 10q occurs in both primary and secondary GBM with nonsignificant 
differences, while LOH in 10p or complete loss of chromosome 10 presents more frequently in 
primary GBM (Ohgaki & Kleihues, 2007).  
Transcriptionally, distinct profiles comprise these two subgroups. Using microarray 
technologies, Tso et al., (2006) investigated the differences in gioblastoma-associated genes 
(GAG) within GBM tumors compared to low-grade astrocytomas (Tso et al., 2006). In comparison 
to low-grade astrocytomas, both primary and secondary GBMs shared 15 GAGs in common 
which included genes such as MET, a proto-oncogene (Boccaccio & Comoglio, 2006), and 
VEGF, an angiogenic factor (Ferrara & Henzel, 1989; Tso et al., 2006). Other common genes 
were shared between the primary and secondary GBM subgroups which the low-grade 
astrocytomas did not express including CDC2, ADM, and FCGBP, among others. Interestingly, 
however, these genes had quantitative differences between the primary and secondary subgroup. 
For instance, the expression of CDC2, a cell cycle regulation gene, was expressed higher in the 
secondary subgroup while the expression of ADM and FCGBP, extracellular response associated 
genes, were expressed higher in primary GBM samples. When compared to low grade 
astrocytomas, secondary GBM samples expressed genes such as GAS1 (growth arrest-specific 
1), CDKN2 (cyclin-dependent kinase inhibitor 3), CCNB1 (cyclin B1), and PRC1 (protein regulator 
of cytokinesis; (Tso et al., 2006) – which are genes associated with an intracellular cell cycle or 
mitotic response. In contrast, primary GBM tumors, when compared to low grade astrocytomas, 
expressed GAGs which were indicative of a tumor stromal response. VEGF was more highly 
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expressed in primary GBM, as was COL5A1, COL6A2 and MMP-9. COL5A1 and COL6A2 genes 
produce the proteins collagen type Vα1 and VIα2, which, along with MMP-9, are extracellular 
matrix remodeling factors. MMP-9 is a matrix metalloprotease which contributes to the 
invasiveness of GBM cells (Kessenbrock, Plaks, & Werb, 2010; Lakka et al., 2004). Other genes 
Tso et al., (2006) found to be expressed higher in primary GBM compared to low-grade included 
angiogenic factors such as IL-8, CA1 and CA2, as well as inflammation, coagulation, immune 
response genes such as SERPINA1/SERPINA3, SERPINE1, PTX3, TIMP1, among others (Tso 
et al., 2006). Overall, the authors concluded that the pattern of enriched GAGs associated with 
secondary GBM were linked with a more intracellular mitotic cell cycle regulation response and 
genes expressed in primary GBM were more associated with a stromal response, indicating a 
more extracellular signaling environment (Tso et al., 2006).  
The Heterogeneity of GBM  
 The name “multiforme” arises from early characterizations of GBM histology which 
identified many different cell types within a single tumor section (Rudy Bonavia, Cavenee, & 
Furnari, 2011). It was also found that these different subpopulations within the same tumor 
display different karyotypes as well as different growth characteristics (Shapiro, Yung, & Shapiro, 
1981). Even within a single GBM passaged cell line, early reports found differential antigen 
expressivity as well as significant differences in cellular karyotypes (Wikstrand, Bigner, & Bigner, 
1983).  In addition, studies have shown that different regions of GBM tumors will express different 
protein abnormalities (R. Bonavia, Inda, Cavenee, & Furnari, 2011).  For example, the various 
popular genetic mutations identified by the TCGA have been shown to be mutually exclusive. 
Subpopulations of EGFR amplified cells exist and subpopulations of PDGFRA amplified cells 
exist within the same tumor sample (Szerlip et al., 2012).  The proliferative marker, Ki67, was 
shown to be heterogeneously expressed within GBM tumors, and usually expressed significantly 
within clusters of cells (Coons & JOHNSON, 1993).  By studying multiple sections from the same 
tumor, Sottoriva et al (2012) found that different subtypes of GBM can be classified within the 
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same patient tumor (Sottoriva et al., 2013).  In fact, 6 out of 10 patients expressed different 
molecular subtype transcriptomes belonging in the proneural, neural, classical and mesenchymal 
subgroups (discussed below) (Sottoriva et al., 2013).   
In addition, EGFRVIII+ cells were found to be diffusely located within GBM tumors, and 
only 1/20 can be classified as displaying homogenous staining (Nishikawa et al., 2004). Inda et al 
(2010) hypothesized that this EGFRVIII+ subpopulation, although a minority within the tumor, is 
responsible for increased tumorigenicity as well as the maintenance of heterogeneity (Inda et al., 
2010).  Using non-tumorigenic primary EGFR wild-type over-expressing astrocytes from Ink4a/Arf 
-/- mice which have been previously shown unable to form a tumor in intracranial xenografts, the 
authors showed that co-injection with astrocytes overexpressing EGFRVIII in a 9:1 ratio resulted 
in increased tumor volumes (Inda et al., 2010). Furthermore, in-vitro, using the conditioned media 
from EGFRVIII cells to grow EGFR wild-type cells resulted in increased soft-agar colony 
formation while the reverse experiment did not (Inda et al., 2010). Both in-vitro and in-vivo, the 
authors found that a minority population of EGFRVIII+ cells was able to increase the proliferation 
and survivability of EGFR wild-type cells (Inda et al., 2010). Mechanistically, it was discovered 
that EGFRVIII+ cells up-regulate cytokines, such as IL-6, which can lead to tumor growth 
enhancement of the surrounding cells (Inda et al., 2010).  Thus, the authors concluded that a 
minor population of EGFRVIII cells mixed with EGFR wild-type expressing cells results in a more 
aggressive tumor.  
 Reasons for this differential expression of proteins within a single tumor may occur via 
multiple mechanisms. It is possible that each tumor represents various different cellular origins. 
That is, the tumor originated from multiple cells with varying oncogenic mutations, as opposed to 
one singular cell, giving rise to multiple different cell types. Furthermore, it is also possible that a 
single cell mutated and as it continued to pathologically proliferate, new mutations were gained 
based on the location of the cell. There are various tumor microenvironments within the GBM 
tumor itself. Within a single GBM tumor specimen, there are areas of necrosis, hypoxia, 
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angiogenesis and immune cell infiltration.  Therefore, a cell incurring beneficial oncogenic 
mutations to adapt to its environment may lead to the development of a heterogenous tumor.  
Furthermore, various cell types make up the tumor, including microglia, macrophages, astrocytes, 
oligodendrocytes, neurons, glial progenitors, and endothelial cells and this may lead to differential 
signaling between specific cells. This extreme heterogeneity in cell type, subtype, and micro-
environment within a single GBM tumor likely contributes to the lack of a breakthrough 
therapeutic.  
The GBM Tumor Stroma & Extracellular Signaling 
 Multiple cell types make up the GBM tumor microenvironment which can contribute to 
extracellular GBM signaling. These cells may include vascular cells, microglia, and peripheral 
immune cells, which may secrete signaling factors to which the GBM cells are capable of 
responding. It has been reported that microglia, the resident macrophages of the brain, may 
contribute up to 30% of the brain tumor mass. While the origin of GBM microglia has not yet been 
fully elucidated (Nikki A. Charles, Eric C. Holland, Richard Gilbertson, Rainer Glass, & Helmut 
Kettenmann, 2011), it has been shown that normal brain microglia are derived from blood 
monocytes which migrate into the brain tissue during embryonic fetal development (Davis, Foster, 
& Thomas, 1994). Furthermore, it is accepted that the microglia comprise a significant portion of 
the tumor and contribute to GBM cell signaling (Hoelzinger, Demuth, & Berens, 2007).  
  Activated microglia within the GBM tumor may secrete various interleukins such as IL-
12, IL-14, IL-1 and IL-1β (Watters, Schartner, & Badie, 2005). Interestingly, the quantity of 
microglia within the brain tumor has been correlated with grade (Roggendorf, Strupp, & Paulus, 
1996b), suggesting a pro-tumorigenic contribution. Furthermore, many of these cytokines have 
been found to increase glioma cell proliferation or invasion. For instance, IL-1β has been 
correlated with invasion and angiogenesis and its expression has been associated with an 
increase in TGF-β (Naganuma et al., 1996) in glioma cells. TGF-β is a protumorigenic factor 
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which has been shown to increase angiogenesis, proliferation and invasion of glioma cells 
(Watters et al., 2005). Interestingly, microglia have even been found to secrete EGF upon 
activation which leads to proliferation of the microglia themselves, in addition to the proliferative 
effect on the glioma cells (Briers, Desmaretz, & Vanmechelen, 1994; Nolte, Kirchhoff, & 
Kettenmann, 1997). Microglia are capable of secreting VEGF, a strong angiogenic factor and are 
also capable of responding to it, inducing their proliferation and migration (Forstreuter, Lucius, & 
Mentlein, 2002) as well as providing a pro-angiogenic environment for GBM.  
 In addition to microglia, other cell types have been shown to be present in GBM, as well. 
An increase in leukocytes was found by Farmer et al., (1989) and correlated with GBM grade 
(Farmer et al., 1989). T lymphocytes were identified to be present in GBM tissue in 1971 by 
Ridley and Cavanagh who found them in a third of the GBM tissues they examined (RIDLEY & 
Cavanagh, 1971). T lymphocytes are white blood cells able to secrete different cytokines, 
including IL-10 and adenosine, during an immune response. These signaling factors are not 
benign, as IL-10 and IL-6 have been reported to promote glioma cell proliferation (Goswami, 
Gupta, & Sharma, 1998; Huettner, Czub, Kerkau, Roggendorf, & Tonn, 1996) and increase in-
vitro glioma cell migration (Huettner et al., 1996). Regulatory T-cells (Tregs) are also found in 
GBM (Nikki A. Charles et al., 2011). They are thought to be attracted via the chemokines MCP-1 
secreted by glioma cells (Jordan & (C. E. Brown et al., 2007) and a positive correlation has been 
reported between Tregs and tumor grade (El Andaloussi & Lesniak, 2006, 2007). Given that 
Tregs express the surface antigen CD25, El Andalouissi and  Lesniak (2006) treated a mouse 
model of GBM with anti-CD25 antibodies and found treated mice to live significantly longer than 
nontreated GBM mice (Andaloussi, Han, & Lesniak, 2006), therefore providing evidence of a 
possible direct protumorigenic effect of Tregs on GBM growth.  
 The GBM tumor is highly vascularized and many vascular cells are present within the 
tumor, including endothelial cells, pericytes, and astrocytes (Nikki A. Charles et al., 2011). De 
Palma et al (2005) found that Tie2 receptor expressing monocytes (Tie2+CD11b+CD45+; termed 
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TEMs), a hematopoietic cell type, are recruited to the site of a mouse model of GBM and are 
proangiogenic (De Palma et al., 2005). Furthermore, they found that mice which were depleted of 
TEMs had on average smaller tumors than untreated mice. The TEM depleted tumors were 
mostly comprised of nonviable, necrotic tissue, unlike the non-treated control tumors (De Palma 
et al., 2005), indicating a strong reliance of tumor cells on TEMs and angiogenesis for 
proliferation and growth.  
 Interestingly, glial cells, the support system for the brain, have been reported to play an 
important protumorigenic role in glioma cell signaling as well (Hoelzinger et al., 2007). Astrocytes 
may secrete various neurotrophic factors such as GDNF, CXCL12 and TGF-α (Nikki A. Charles 
et al., 2011; Hoelzinger et al., 2007), and GBM cells have been shown to over-express the 
receptors necessary to respond to these factors (Wiesenhofer et al., 2000). Treating rat glioma 
cells with GDNF resulted in increased glioma cell migration (Song & Moon, 2006). In addition, co-
culture of glioma cells with astrocytes led to enhanced invasive capacities of glioma cells due to 
the astrocytic production of proMMP, a precursor matrix metalloprotease (Le et al., 2003). Thus, 
the astrocyte-glioma interaction provides protumorigenic signaling factors to the glioma cells, 
causing them to be more aggressive.   
 Given the infiltration of these various cell types within the GBM tumor stroma and given 
the ability for the glioma cells to respond to signaling factors secreted by these cell types, 
studying their contribution to GBM signaling may yield new therapeutic advances. For instance, a 
closer look at the ability to target TEMs within GBM patients is warranted, given the significant 
effects reported by De Palma et al., (2005). Furthermore, the ablation of Tregs led to increased 
survival in a GBM mouse model (Andaloussi et al., 2006). 
Primary GBM Intracellular Signaling 
Glioma cells are able to respond to the ligands, chemokines and cytokines that they 
themselves produce in an autocrine signaling manner. For example, glioma cells are capable of 
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producing their own growth factors such as EGF which stimulates motility, invasion and 
proliferation. In addition, glioma cells secrete factors such as G-CSF and MCP-1 which recruit 
microglia to the site of the tumor. While microglia are able to respond to these factors among 
others (Nikki A. Charles et al., 2011), glioma cells themselves have been shown to express 
receptors for both of these chemoattractants (Mueller et al., 1999; Platten et al., 2003) and thus 
may induce a protumorigenic signaling cascade autonomously. Signals such as MCP-1 and G-
CSF led to increased proliferation and increased migration in glioma cells upon exposure (Mueller 
et al., 1999; Platten et al., 2003).  
Other signaling aberrations occur in glioma cells as a consequence of their numerous 
oncogenic mutations. In 2008, The Cancer Genome Atlas (TCGA) profiled 206 GBM tumors 
using high-throughput genomic microarray technology in an effort to identify molecular targets for 
therapeutic discovery (Roger McLendon et al., 2008). This study was updated and expanded in 
2013 to 543 samples (Brennan et al., 2013). Using only tumor samples which had 80% glioma 
cells (so to exclude collecting data from cells within the environment), the researchers collected 
specimens from newly diagnosed GBM patients representing predominantly primary GBM. The 
results showed a strikingly significant amount of GBM specimens with mutations found in PTEN, 
EGFR, PIK3CA, PIK3R1 (Figure 1.5). 57% of tumors have an amplification or gain of function 
mutation in EGFR and 41% of tumors have a deletion or loss of function mutation in PTEN, the 
negative regulator of this over-activated RTK pathway (Brennan et al., 2013; R. McLendon et al., 
2008). Furthermore, 25% have an amplification or gain of function mutation in PIK3K, a 
downstream signaling kinase responsible for numerous oncogenic signaling events (reviewed in 
chapter 1) (Brennan et al., 2013; R. McLendon et al., 2008). A striking 61% of tumors have a 
deletion or loss of function mutation in CDKN2A/CDKN2B. CDKN2A and CDKN2B are genes 
involved in cell cycle control, and their deletions and/or mutations results in highly proliferative 
cells. Nearly 80% of all tumors have a dysregulation of cell cycle control due to a genetic 
aberration (Brennan et al., 2013; R. McLendon et al., 2008). These mutations produce a 
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compounding signaling effect resulting in extremely virulent oncogenic cells which are highly 
invasive, proliferative, and unresponsive to treatment.    
An analysis of the transcriptional data was conducted in order to delineate distinct 
subclasses within the analyzed GBM samples. Results revealed four subclasses of GBM – 
proneural, neural, classical and mesenchmyal (Phillips et al., 2006; Verhaak et al., 2010). These 
subgroups displayed differential associations between patients. For instance, younger patients 
were significantly more likely to present with the proneural subtype.  However, the proneural 
subtype patients failed to respond to aggressive therapy (Phillips et al., 2006; Verhaak et al., 
2010).  This is contrast to patients with classical or mesenchymal, who showed a significant 
beneficial response to aggressive therapy. Survival data was correlated with subtype, as the 
median survival of the proneural subtype was significantly longer when compared to the 
proliferative or mesenchymal subtypes (Verhaak et al., 2010). Interestingly, while it was 
previously thought that MGMT methylation was a predictor of therapy response (Hegi et al., 
2005), the authors did not find any correlation or association of MGMT methylation between 
subtypes (Phillips et al., 2006). However, the authors did find a significant correlation with PTEN 
loss and poor survival (Phillips et al., 2006).  
  The authors also discovered that the molecular signatures of these subtypes were 
altered upon recurrence, and tended to shift towards the mesenchymal subtype (Phillips et al., 
2006). Genes which are upregulated in the mesenchymal subtype included CD44, STAT3, VIM, 
and YKL40, all of which have shown to be protumorigenic signaling factors. YKL40 is a secreted 
protein shown to be upregulated in glioma, as well as other cancers, and is reported to be 
associated with overall shorter survival in addition to being a predictor of radio resistance 
(Pelloski et al., 2005).  
The possibility exists that these subtypes arise from different cells of origin in the brain 
and thus the study of their differences may prove imperative to reaching clinical success. 
Furthermore, it is important to consider the strong effects of the tumor microenvironment on GBM 
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signaling and its progression. Thus studying glioma cells in-vitro only may yield misleading 
results. It is now well accepted that mutations may arise from passaging cells in-vitro and can 
therefore change the signaling of the original specimen (Ajay Pandita, Kenneth D. Aldape, 
Gelareh Zadeh, Abhijit Guha, & C. David James, 2004). Therefore, the study of these tumors 
within their natural environment is a necessity to finding better, more successful therapeutics and 
impacting the prognosis for GBM patients.  
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MANUSCRIPT: TARGETING APKC DISABLES CELL AUTONOMOUS AND NON-CELL 
AUTONOMOUS ONCOGENIC SIGNALING IN GLIOBLASTOMA 
ABSTRACT 
EGFR kinase inhibitors have failed to improve survival in Grade IV Glioblastoma (GBM). 
Here we show that the activation of protein kinase aPKC (atypical Protein Kinase C) by TNF-α in 
the GBM microenvironment provides a molecular rationale for EGFR kinase inhibitor resistance. 
Additionally, we identify a bimodal signaling role of aPKC in both paracrine TNF α -dependent 
NF-κΒ activation, as well as in tumor cell-intrinsic receptor tyrosine kinase signaling. Inhibiting 
tumor cell autonomous and non-tumor cell autonomous oncogenic signaling by targeting aPKC is 
an effective pharmacological approach in mouse models of GBM, including in EGFR kinase 
inhibitor resistant GBM. Finally, aPKC expression and activity is significantly increased in human 
GBM tumor cells and high aPKC expression correlates with poor prognosis. 
INTRODUCTION 
WHO Grade IV glioblastoma or GBM is a frequently occurring brain tumor with poor 
prognosis (Furnari et al., 2007). The relative survival estimate for GBM indicates that only 4.46% 
of patients diagnosed between 1995-2006 survived five years post diagnosis (CBTRUS). While 
strategies to improve the currently dismal survival in GBM primarily involve identifying and 
targeting oncogenic signaling pathways (Furnari et al., 2007; Gilbert, 2011; Kesari, 2011; I. K. 
Mellinghoff, Schultz, Mischel, & Cloughesy, 2011; Ingo K. Mellinghoff, Schultz, Mischel, & 
Cloughesy, 2012), the therapeutic success of EGFR kinase inhibitors in vivo has been limited (I. 
K. Mellinghoff et al., 2005). The activation of additional receptor tyrosine kinases (RTK) and/or 
downstream tumor intrinsic mutations can provide oncogenic stimuli to GBM tumor cells and 
account for EGFR kinase inhibitor resistance (Ingo K. Mellinghoff et al., 2012; I. K. Mellinghoff et 
al., 2005). Identifying and targeting such pathways can provide improved therapeutic efficacy, 
despite the fact that such efforts may require simultaneously disabling multiple, parallel oncogenic 
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signals. The serine-threonine kinase atypical protein kinase C (aPKC) is activated downstream of 
multiple RTK (Akimoto et al., 1996; Victoria Aranda et al., 2006; Berra et al., 1993). We had 
demonstrated that aPKC regulates neural progenitor cell proliferation and migration during the 
embryonic development of the spinal cord (Ghosh et al., 2008a, 2008b). Abnormal activation and 
altered intracellular localization of aPKC resulted in increased proliferation, abnormal migration 
and rosette-like structures reminiscent of brain tumors (Ghosh et al., 2008a). Therefore, we 
hypothesized that the abnormal or unscheduled activation of the developmentally important aPKC 
signaling pathway may be associated with GBM progression and that aPKC inhibition may 
provide an improved avenue for molecular therapeutics in GBM. 
MATERIAL AND METHODS 
Animals 
Female 6- to 8-wk-old NOD-SCID mice were acquired from Charles River. TNFα-/- 
(B6.129S6-Tnftm1Gkl/J, stock 5540) and control C57BL/6J (stock 664) were acquired from the 
Jackson laboratory. All animal procedures conformed to protocols approved by the University of 
Arizona Institutional Animal Care and Use Committee. 
Antibodies and Reagents 
Rabbit anti-aPKC (sc-216) and rabbit anti-p65-NF-κB phosphoSer311 (sc-101748) were 
purchased from Santa Cruz. Rabbit anti-aPKC phosphoThr410/403 (#9378), rabbit anti-p65-NF-
κB phosphoSer536 (#3033), rabbit anti-Akt phosphoSer473 (#9271), mouse anti-Akt (#2920), 
rabbit anti-Src phosphoTyr516 (#6943), rabbit anti-Src (#2123), rabbit anti-MAPK p44/42 (#4695), 
rabbit anti-p65 (#4764) and rabbit anti-IκBα (#9242) were obtained from Cell Signaling. Rabbit 
anti-PAR6 (ab49776), rabbit anti-aPKC phosphoThr560 (ab62372) and mouse anti-p62 
(ab56416) were purchased from Abcam. Rabbit anti-EGFR phosphoTyr1086 (44790) and mouse 
anti-EGFR (44796) were purchased from Invitrogen. Mouse anti-β-tubulin (T-2046) and mouse 
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anti-MAPK p44/42 phosphoThr183phosphoTyr185 (M-8159) were purchased from Sigma. Mouse 
anti-human CD68 antibody (#M0814) was purchased from Dako. Mouse anti-human TNFα 
neutralizing antibodies from Novus Biologicals (# NB120-10204) or from R&D (MAB2101) were 
used at a concentration of 100 ng/mL. Mouse IgG1 isotype control (MAB002) or (NBP1-97005) 
were purchased from Novus Biologicals and R & D Systems and used at identical concentrations 
as the TNFα neutralizing antibodies. Rat anti-mouse Cd11b-PE (#12-0112-85), mouse anti-
human TNFα-APC (#17-7349-82) and Mouse IgG1 isotype control (#17-4714-81) antibodies 
were acquired from eBioscience. PE-mouse anti-human TNFα (#502908), PE-mouse IgG1k 
isotype control (#400139), anti-human CD11b-PB (#101235), anti-human-CD64-AF647 
(#305012), anti-human CD23-APCCy7 (#338520), anti-human CD14-PECy7 (#325617), anti-
human CD80-FITC (#305205) and anti-human CD163 (#333608) antibodies used for FACS were 
obtained from Biolegend. Species-specific secondary antibodies for IHC/IF conjugated to Alexa 
488 or 594 were obtained from Life Technologies. Secondary antibodies for Western (anti-
mouse-HRP, anti-rabbit-HRP) were obtained from Promega. Erlotinib was purchased from 
Selleck Chemicals (S1023) and was used at a concentration of 10 µM. All other inhibitors were 
purchased from Calbiochem. AG1478 (#658548) was used at 10 µM, PI3K inhibitors LY294002 
(#44024) at 20 µM, Wortmannin (#681675) at 100 nM, MEK inhibitor U0126 (#662005) at 10 µM, 
and Src kinase inhibitor, SU6656 (#572636) was used at 10 µM. NF-κΒ-Reporter:GFP lentivirus 
was obtained from SA Biosciences (CLS-013G). The IκBαM adenovirus was purchased from 
Imgenex (IMG-2500). Lentiviruses expressing GFP or aPKC shRNA constructs were produced at 
Viral Vector Core, The Salk Institute according to methods described in Tiscornia et al (Tiscornia, 
Singer, & Verma, 2006). VSVg pseudotyped constitutively active IKK (S177, 181E) retrovirus was 
generated as described in Ghosh et al (Ghosh et al., 2006) with minor modifications. pCLXSN-
IKK Ser177,181E was transiently transfected into HEK293T cells using linear 25 Kd 
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polyethyleneimine (Polysciences Inc. PA, USA) with an N/P ratio of 10 (1 mg/ml in DPBS, pH 
4.5). Cells were co-transfected with pCL-CMV-GAG-POL and pMD2.G. Virus containing medium 
was harvested at 48 h and 72 h post transfection, treated with DNAse1 (1 µg/ml, Sigma) and 
filtered through a 0.22 µm filter (Durapore, Millipore USA) before aliquoting and storage at -80 °C. 
Infectious viral titers were determined by RT-qPCR of genomic DNA extracted from HEK293T 
cells 48 h post infection with a 10-fold dilution series of retroviral vector. PZ09 was synthesized in 
house following the procedure described in Trujillo et al (Trujillo et al., 2009) with some 
modifications and the inhibitor was validated by mass spectrometry and in vitro kinase assays. 
PZ09 was used at 10 µM. 
Cell lines and cell culture 
U87/EGFRvIII and U251/EGFR human GBM cell lines were a gift from Dr. Zhimin Lu, MD 
Anderson. GL261, a murine glioma cell line, was acquired from NCI. The primary GBM line 6 
(GBM6) was established directly from a patient surgical sample and maintained as a 
subcutaneous flank xenograft through serial passaging in immune deficient mice. GBM6 flank 
tumor xenografts were harvested, mechanically disaggregated, and grown in short-term culture 
(5–7 d) in DMEM containing 2.5 % fetal bovine serum, 1 % nonessential amino acids, 2 mmol/L 
glutamine, 100 units/mL penicillin, and 10 µg/mL streptomycin for lentiviral transduction (Giannini 
et al., 2005b). Primary glioma cells were dissociated from fresh patient tumors using Miltenyi 
Biotec brain tumor dissociation kit (#130-095-939) and the Miltenyi Gentle Macs Dissociator.  For 
isolation of glioma cells, the protocol published by Pistollato et al  (Pistollato, Persano, Puppa, 
Rampazzo, & Basso, 2011) was used with no modification.  Samples were taken from patients 
diagnosed with GBM and the use of the patient tissues received prior Barrow Neurological 
Institute/St. Joseph’s Hospital Institutional Review Board authorization. Unless indicated 
otherwise, all cell types were grown in DMEM supplemented with 10 % FBS and 1 % 
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penicillin/streptomycin (p/s) (Invitrogen) at 37 °C, 5 % CO2. THP1 cells were maintained in DMEM 
supplemented with 10 % FBS, 1 % penicillin and streptomycin and 0.05 mM 2-mercaptoethanol. 
THP1 cells were differentiated with 50 ng/mL PMA (Cell Signaling) overnight, and were 
subsequently washed 3 times with PBS. Media was then replaced and the cells were cultured for 
an additional 24 h prior to experiments. Transfection of siRNA and shRNA were done using 
Lipofectamine (Life Technologies) or Effectene (Qiagen), respectively. siRNAs were purchased 
from Life Technologies. Transfection was performed according to established protocols from the 
manufacturers. Cells were analyzed 48 h post-transfection. Average knockdown efficiency for 
PRKCZ, PRKCI, PAR6A, PAR6B and P62 relative to control (luciferase) siRNA is shown in 
Supplementary Fig. 1. U87/EGFRvIII cells were transduced with lentivirus GFP or with lentivirus 
aPKC-shRNA to generate stable lines (U87VIII-GFP and U87VIII-aPKC-shRNA). Glioma cells 
were incubated with 1:5,000 dilution of virus in serum-free media overnight. Subsequently the 
cells were washed 3 times with PBS and cultured according to standard protocols. The cells were 
cultured for additional 48 h post-infection before conducting experiments. For EGF and TNFα 
treatments, cells were serum starved for 24 h, and then treated with 100 ng/mL EGF (Millipore) or 
10 ng/ml TNFα (Calbiochem) for various time points. PZ09 was used at 10 µM. For other 
inhibitors, cells were serum starved overnight and pre-incubated with inhibitor for 30 m. For NF-
κΒ Reporter activity, U251/EGFR or U251/EGFR-aPKC-siRNA cells were incubated with 1:1,000 
dilution of Lenti NF-κΒ-Reporter:GFP in serum-free media overnight. Subsequently the cells were 
washed 3 times with PBS and cultured for 72 h prior to overnight serum starvation. After serum 
starvation cells were treated for 30 min with 10 ng/mL TNFα in serum free media in the presence 
or absence of 10 µM PZ09 or monoclonal anti-human TNFα antibody. Changes in GFP 
fluorescence was detected and quantified using a Tecan Infinite F500 microplate reader. Results 
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were normalized to NF-κΒ reporter transduced cells which were serum starved and not treated 
with TNFα.  
Human Monocyte isolation and monocyte-derived macrophages 
Peripheral blood mononuclear cells (PBMCs) were obtained from 50 mL of buffy coats 
(New York Blood Center) by Ficoll gradient centrifugation. Human monocytes were isolated by 
CD14 positive selection (STEMCELL) from PBMCs. CD14+ monocytes were co-cultured with 
GBM6 at 1:1 ratio for in-vitro proliferation or invasive assay.  300,000 to 500,000 CD14+ 
monocytes per mL were plated in RPMI 1640 plus 10 % of FBS and in vitro differentiated to 
macrophages by adding 25 ng/mL of M-CSF. IFN-γ (50 ng/mL), IL4 (40 ng/mL) or IL10 (50 
ng/mL) polarizing cytokines were added on day 3 and M0, M1, M2a and M2c monocytes-derived 
macrophages were harvested on day 7. Macrophage polarized phenotype was confirmed using 
anti human CD11b, CD64, CD23, CD80, CD163 and CD14 (Biolegend). Recombinant cytokines 
were purchased from R&D. 
Co-culture and ELISA 
For transwell co-culture experiments, 1x106 glioma cells were plated into a 6-well plate. 
Cell culture inserts (Millicell, 0.4 µm micropore polycarbonate filter) were placed in the wells. 
GBM6 cells were serum starved for 24 h before adding 1x105 GBM6 cells alone, plus 1x105 THP1 
cells or primary monocytes (CD14+) to the insert. After specified time points, cell culture inserts 
were removed and RNA was isolated from the GBM6 cells alone. In addition, media supernatants 
were collected, snap frozen with liquid nitrogen, and stored at -80 °C. The media from co-culture 
of macrophages and tumor cell lines were collected after 24 and 48 h and detection of TNFα in 
the supernatants was performed using an anti-TNFα ELISA kit (eBioscience). For proliferation 
assays, starved 1x105 GBM6 were co-cultured with 1x105 CD14+ monocytes in 6 well plate and 
EdU incorporation was assessed following manufacturer´s instruction (Click-iT® EdU Flow 
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Cytometry Assay Kit, Life Technologies). CD11b staining was included to discriminate 
monocytes. 
RNA isolation and RT-qPCR 
For acutely isolated in-vivo mouse brain mRNA analyses, whole mouse brain was 
homogenized in Trizol using a glass homogenizer. Samples were centrifuged and 0.2 mL 
chloroform per 1 mL of Trizol was added to the supernatant. Samples were vigorously shaken for 
15 seconds, incubated at RT for 3 min, and centrifuged for 15 min at 10,000 x g at 4 °C. Addition 
of chloroform and centrifugation was repeated. After second centrifugation, the aqueous phase 
containing RNA was precipitated by mixing with isopropyl alcohol for 20 min at -20 °C. RNA 
precipitants were washed 3 times with 75 % ethanol and spun at 7500 xg for 5 min at 4 °C. RNA 
was air dried, resuspended in RNase-free water and stored at -80 °C. For cellular mRNA 
analyses, total cellular RNA was isolated with RNeasy kit (QIAGEN). mRNA was reverse 
transcribed into cDNA using the Superscript III Kit (Life Technologies). Real-time PCR was 
performed on a 7900HT cycler with SYBR-Green Mastermix (Applied Biosystems), and primers 
(IDT) summarized in Supplementary Table. For NF-κΒ target gene profiling, cDNA was obtained 
as described and plated onto a custom TaqMan 96-well Gene Expression Signature Plate 
according to manufacturer’s instructions. Real-time PCR was performed on a 7900HT cycler with 
TaqMan Universal PCR Master Mix (Life Technologies). Primer sequences are provided in 
Supplementary Table. 
Immunofluorescence 
Glioma cells were seeded onto acid-etched coverslips (70 % EtOH, 1 % HCL in PBS, 5 
min) in a 24-well plate overnight. Upon confluency, media was removed and the cells were 
washed 3 times with PBS. The cells were fixed with 4 % PFA for 15 min at room temperature 
(RT), then washed 3 times with PBS and permeabilized with 0.1 % Triton-X-PBS for 15 min at 
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RT. Cells were blocked for 2 h with 2 % normal horse serum (Life Technologies) in PBS at RT. 
Primary antibodies were diluted in 2 % normal horse serum and cells were incubated overnight at 
4 °C. Subsequently, coverslips were washed 3 times with PBS and secondary antibodies (Alexa-
Fluor-488 and 594) diluted in 2 % normal horse serum were added for 2 h at RT. Following the 
secondary antibody incubation, cells were stained with DAPI (diluted at 1:5,000 in PBS) for 10 
min at RT. Finally, coverslips were washed 3 times with PBS and mounted onto slides using 
Prolong Gold Antifade Reagent (Life Technologies) and sealed with nail polish. Images were 
obtained using a Zeiss 710 confocal using a 63x objective lens.  
Flow Cytometry analysis 
Glioma cell lines, undifferentiated or PMA-differentiated THP1 cells, and CD14+ primary 
monocytes were cultured alone and together in complete DMEM medium at a 1:1 ratio. 6 h prior 
to harvesting, Brefeldin A was added to cells at a final concentration of 3 µg/ml. CD11b surface 
staining was included to discriminate primary monocytes from glioma cells. Cells were fixed with 
1 % PFA and permeabilized with 0.5 % saponin. Anti-TNFα antibody or isotype control was 
added to cells and incubated on ice for at least 30 min. Cells were then washed with Dulbecco-
PBS and suspended in 1 % BSA solution. For Ser536 phospho- NF-κΒ p65 (Cell Signaling 
Technology) staining, GBM6 were treated with 100 ng/mL of TNFα (Calbiochem) for 1 h. After 
harvesting, cells were immediately fixed with 1 % PFA for 15 min, washed 2 times with PBS and 
then permeabilized with cold methanol for 30 min on ice. Cells were washed 3 times, blocked with 
PBS + 5 % human AB serum for 15 min and then incubated with anti phospho-NF-κΒ p65 PE 
antibody for 30 min at 4 ºC. Cells were finally washed and re-suspended in PBS for FACS 
analysis. For BrdU incorporation experiments, 1x106 U87/EGFRvIII or GBM6 cells were plated in 
a 6-well plate. Cell culture inserts (Millicell, 0.4 µm micropore polycarbonate filter) were placed in 
the wells. Glioma cells were serum starved for 24 h before adding 1x105 U87/EGFRvIII or GBM6 
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cells and 1x105 THP1 to the insert. 10 µM BrdU (BD Pharmingen, 552598) was added to the 
media for 24 h.  Cell culture inserts were removed, and glioma cells were fixed, permeabilized 
and stained for BrdU using an APC BrdU Flow Kit (BD Pharmingen, 552598) according to 
manufacturer’s instructions. For EdU incorporation, starved 1x105 GBM6 were co-cultured with 
1x105 CD14+ monocytes isolated from PBMC in 6 well plate for 24 h. EdU was added into the 
culture at the last two hours. After harvesting, cells were immediately fixed with the fixative buffer, 
supplied with the kit (Click-iT® EdU Flow Cytometry Assay Kit, Life Technologies). Staining was 
performed following manufacturer´s instruction. CD11b staining was included to discriminate 
monocytes. For in-vivo phenotypic analyses of tumor infiltrating macrophages within human GBM 
tumors, 3 patient samples were dissociated using Miltenyi Biotec brain tumor dissociation kit and 
Gentle Macs dissociator. Dissociated cells were blocked using 3% FBS in PBS for 30 min on ice 
and subsequently stained with a cocktail of anti-human CD23, anti-human CD64 and anti-human 
CD11b in 3% FBS/PBS for 30 min on ice. Cells were washed 3 times with PBS and fixed in 1% 
PFA for 30 min on ice.  FACS calibur, FACS Aria or LSRII (BD) were used to analyze samples 
and WinMiDi software (freeware from The Scripps institute) or FlowJo were used to analyze and 
plot the data. 
Immunoblotting and immunoprecipitation 
Ice-cold 1 % NP-40 buffer (20 mM Tris-HCl at pH 8, 137 mM NaCl, 10 % glycerol, 1 % 
NP-40) supplemented with phosphatase and protease inhibitor (Halt Protease and Phosphatase 
Inhibitor Cocktail, Thermo Scientific) was used for protein isolation and immunoprecipitation. 
Briefly, cells were washed 3 times with ice-cold PBS and scraped in NP-40 buffer. Lysates were 
kept cold and sonicated 10 times, 1 sec each, and then centrifuged at 12,000 x g for 5 min at 4 
°C. For immunoprecipitation, the supernatant was pre-cleared using protein-A beads for 30 min at 
RT. The supernatant was subsequently added to protein-A beads pre-bound to aPKC antibody 
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(Santa Cruz, sc-216), and incubated overnight on a shaker at 4 °C. Immunoprecipitates were 
then washed 2 times with ice-cold NP-40 buffer, and a final wash with PBS. Sample loading 
buffer with DTT was added, and the immunoprecipitates were boiled for 5 min prior to loading 
onto precast SDS-PAGE gels (Life Technologies). Gels were transferred onto methanol pre-
soaked PVDF membranes and subsequently blocked with 5 % BSA in PBS for 2 h. Primary 
antibodies were incubated overnight at 4 °C, after which blots were washed 3 times with TBST 
(TBS + 0.1 % Tween) for 15 min each, followed by incubation with secondary antibodies (1: 
2000) for 2 h at RT. Blots were then washed 3 times for 30 min each in TBST, with a final wash in 
TBS alone. Blots were developed using Super Signal West Dura (Thermo Scientific) on the UVP 
Imager.  
Immunohistochemistry for Tissue microarrays 
Tissue microarrays were prepared from archival blocks of WHO grade IV glioblastoma 
formalin fixed paraffin embedded specimens. All tumor cases were histologically reviewed and 
representative tumor areas marked on the corresponding donor paraffin blocks. Blocks were cut 
at 4 µm thickness for routine hematoxylin and eosin (H&E) staining and immunohistochemistry. 
Sources for TMAs include TGen (Phoenix, AZ), Armed Forces Institute of Pathology (Bethesda, 
MD) and Barrow Neurological Institute (Phoenix, AZ).  Immunohistochemistry was performed 
using Ventana automated Discovery XT or Benchmark XT system (VMSI - Ventana Medical 
Systems, a Member of the Roche Group, Tucson, Arizona). All steps were performed on this 
instrument using VMSI validated reagents, including deparaffinization, cell conditioning (mild CC1 
for CD68 and standard CC1 for aPKC, phospho-aPKC and TNFα), primary antibody staining, 
detection and amplification using a biotinylated-streptavidin-HRP and ultraview Universal DAB 
(Diaminobenzidine) detection system and hematoxylin counterstaining. Primary antibodies were 
incubated for 30 min (CD68, TNFα) or 1 h (aPKC, phospho-aPKC) at 37 °C. Appropriate positive 
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and negative (secondary antibody only) controls were stained in parallel for each round of 
immunohistochemistry. Following staining on the instrument, slides were dehydrated through 
graded alcohols to xylene and coverslipped with mounting medium.  
Ex vivo Invasion assay 
Ex-vivo orthotopic invasion assays were performed as described by Valster et al (Aline 
Valster et al., 2005) with some modifications. Brains were obtained from 4-week-old rats and 
placed in ice-cold aCSF (126 mM NaCl, 3 mM KCl, 1.5 mM MgCl2, 24 mM CaCl2, 1.2 mM 
NaH2PO4, 11 mM glucose and 26 mM NaHCO3). Brains were sectioned into 400 µm slices on a 
vibratome in ice-cold aCSF. Slices were placed on a cell culture insert (Millicell, 0.4 µm micropore 
polycarbonate filter) in a 6-well plate with 1.5 mL DMEM with 10 % FBS and 1 % p/s 500 µL of 
media was added to the insert that was placed inside the wells of a 6-well plate. The brain slices 
were kept in the incubator under standard culture conditions (37 °C, 5 % CO2).  GFP+ GBM6 
and/or U87/EGFRvIII cells were resuspended in serum-free DMEM at 2x108 cells/ml. Prior to the 
addition of cells, media was removed from the upper chamber of the 6-well plate so the slice was 
semidry before implantation. 105 GFP+ GBM6 and/or U87/EGFRvIII cells were placed on the 
putamen in 0.5 µL volumes, and after 45 min, 500 µL of serum-free media was added back to the 
upper chamber. The plates were kept in the incubator for 4-5 days and subsequently fixed 
overnight in 4% PFA at 4 °C. The polycarbonate membrane was carefully removed and the brains 
were placed on a slide for imaging on a confocal microscope. Imaging and quantification was 
performed as described by Valster et al (A. Valster et al., 2005). Fluorescence at various depths 
into the tissue was calculated after confocal imaging. Intensity at each layer was normalized to 
total intensity across all depths and linear regression analysis was performed to determine the 
slope of invasion for each replicate.  R2 (coefficient of determination) for each slope was 
calculated and was greater than 0.88 with an average value of 0.96.  Average inverse slope was 
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used to calculate the invasion index.  Error bars represent the standard deviation of at least three 
repeats. 
Orthotopic xenografts 
Female 6- to 8-wk-old NOD-SCID, TNFα-/- and control mice were anesthetized by i.p. 
injection of 1.25 % avertin (200 mg/kg). Cells (U87EGFRvIII-GFP, U87/EGFRvIII-aPKC-shRNA, 
or GL261) were resuspended in standard media (DMEM with 10 % FBS, 1 % p/s) at a 
concentration of 1.25 x 105 cells/µL and kept on ice until injection. Intracranial injections were 
performed using a Hamilton syringe (Hamilton Company, Reno, Nev.). Briefly, the animal was 
secured onto the small animal stereotaxic apparatus (Kopf Instruments) and a midline incision 
was made to expose the skull.  Subsequently, a burr hole was drilled 1 mm lateral and 2 mm 
anterior to bregma. Cells were injected at a rate of 1 µL/min (total 4 µL 5x105 cells) to a depth of 3 
mM below the skull, which corresponds to the area of the caudate nucleus. Following intracranial 
injection, mice were observed daily for changes in weight or modified gait, and were euthanized 
upon moribund symptoms. Brains were then removed and processed for histopathology.  
Statistical Analysis 
Data are expressed as mean ± SEM. Differences between the means of experimental 
groups were analyzed with either two-tailed Student's t-test or ANOVA (Prism GraphPad 
software, Inc.). Survival was calculated using Kaplan-Meier analysis (Prism GraphPad software, 
Inc.). P values ≤ 0.05 were considered significant. 
RESULTS 
aPKC expression inversely correlates with GBM survival and targeting aPKC reduces 
tumor progression in a mouse model of GBM resistant to EGFR kinase inhibitors 
We examined the expression of aPKC in human non-tumor brain and GBM tissue. 
Immunohistochemical staining of non-tumor brain tissue sections revealed very little aPKC 
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staining in the brain parenchyma (Fig. 3.1A). Some cytoplasmic staining was observed in neurons 
(fig. 3.S1A) and trace staining was occasionally detected in oligodendrocytes. In contrast, strong 
aPKC staining was observed in GBM tumor cells (Fig. 3.1B,C). The distribution of staining was 
consistent across variable histologic patterns that define GBM such as, pseudopalisading 
necrosis (Fig. 3.1C and fig. 3.S1B), areas of microvascular proliferation (fig. 3.S1C), infiltrative 
single cells, clusters and confluent cell sheets. Next, we stained tissue microarrays (TMA) 
consisting of 330 GBM cases. The aPKC staining was validated using both negative and positive 
staining on control cores of non-neoplastic cortical grey matter, white matter, cerebellum, 
placenta, testis, lung, liver, kidney, and tonsil within each TMA. Within most, but not all GBM 
cores, tumor cells showed increased aPKC staining relative to non-tumor cells. aPKC staining 
within tumor cells was compared to adjacent non-tumor cells within each core and the core was 
assigned a numerical score of 0, 1, 2 or 3 representing negative, weak positive, intermediate 
positive or bright staining. Interestingly, a subset of GBM tumors was aPKC bright (100/330), and 
other subsets had intermediate (73/330) or weak (107/330) positive levels. A smaller fraction of 
GBMs were aPKC negative (50/330). This indicates that GBM tumors overall tend to express 
higher levels of aPKC, however the expression level of aPKC between individual GBM tumors 
varies and GBM tumors can be stratified based on aPKC intensity (Fig. 3.1D). Furthermore, 
staining a smaller set of GBM TMA (44 cases) with the aPKC activation specific, phosphoThr 
410/403 antibody revealed that not only total protein level, but also aPKC activity is commonly 
high in GBM (Fig. 3.1E,F). The range of staining intensity for phosphorylated aPKC, compared to 
total aPKC, was somewhat reduced. This may be due to the reduced affinity of phosphorylation-
specific antibodies relative to total aPKC antibody. 
To further examine the clinical relevance of aPKC staining in GBM, we compared the 
association between aPKC immunoreactivity and survival. In a TMA annotated for survival data of 
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patients, 7 cases had no detectable aPKC staining, 17 cases were weak positive, and 20 cases 
showed bright aPKC staining. Statistical analyses demonstrated that there was a significant 
difference in overall survival between the bright aPKC staining and aPKC negative or weak 
positive cases (Log-rank [Mantel-Cox] test p= 0.0145). The decrease in survival was restricted to 
the aPKC bright group; statistically significant difference in survival between the lower categories 
of aPKC intensity was not detected. While the median survival of aPKC bright staining cases was 
176.5 days, aPKC weak positive had a median survival of 413 days and aPKC negative cases 
532 days (Fig. 3.1G). Survival was not found to correlate with gender and age in the sampled 
population. All together, these results demonstrate that increased aPKC expression is detected in 
GBM and that there is a strong negative correlation between aPKC protein expression and 
survival.  
To directly test the function of aPKC in GBM progression in vivo, we performed orthotopic 
xenograft experiments in NOD/SCID mice using U87/EGFRvIII and U87/EGFRvIII in which aPKC 
expression was silenced by shRNA. We used a viral vector encoding shRNA targeting both 
isoforms PRKCZ and PRKCI and obtained ~70-80% knockdown efficiencies (fig. 3.S2A). 0.5 x 
106 cells were stereotactically injected into the caudate nucleus and mice were euthanized upon 
detection of neurological symptoms as approved by IACUC. Tumor growth was confirmed by 
histopathological analyses. Silencing aPKC in U87/EGFRvIII cells resulted in a significant 
increase in median survival following orthotopic xenografts (Log rank [Mantel Cox] test p= 
0.0005). Mice bearing U87/EGFRvIII aPKC shRNA showed a median survival of 35 days, in 
comparison to the median survival of 11 days in WT U87/EGFRvIII (Fig. 3.1H). Histopathological 
examination 6 days post implantation revealed that tumors derived from U87/EGFRvIII aPKC 
shRNA were significantly smaller in size, in comparison to tumors derived from WT U87/EGFRvIII 
(Fig. 3.1I). Subsequently, we tested the efficacy of a small molecule, benzoimidazole ATP-
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competitive aPKC inhibitor PZ09 (Trujillo et al., 2009) in inhibiting tumor growth in vivo. 3 days 
post implantation, 10 µM PZ09 was delivered by ALZET osmotic minipumps directly at the site of 
U87/EGFRvIII tumors, similar to convection-enhanced delivery of molecules to the brain, for 7 
days. Mice were euthanized and tumor size was measured by sectioning the entire brain, staining 
with hematoxylin-eosin (H&E) and tumor volume was calculated using ImageJ. These 
experiments reveal that inhibition of aPKC reduced tumor volume by 64.68 ± 9.23 % after 7 days 
of treatment (Fig. 3.1J).  
Next, we tested the efficacy of aPKC inhibition in patient-derived, EGFR kinase 
insensitive, orthotopic xenografts. GBM6 patient-derived xenograft cells retain the clinically 
relevant biochemical characteristics of clinical GBM, including EGFR amplification and EGFRvIII 
mutation (Giannini et al., 2005a; A. Pandita, K. D. Aldape, G. Zadeh, A. Guha, & C. D. James, 
2004). Furthermore, GBM6 xenografts are insensitive to the EGFR kinase inhibitor erlotinib 
(Sarkaria et al., 2007). The acute inhibition of aPKC by PZ09 significantly reduced tumor volume 
in orthotopic xenografts.  2 x 106 GBM6 cells were implanted in the caudate nucleus and 10 µM 
PZ09 was delivered by ALZET minipumps, 3 days after implantation and for a treatment period of 
14 days.  At 10 µM, PZ09 effectively decreased aPKC activity in GBM6 cells in culture (Fig. 
3.S2D). 10 µM PZ09 in vivo resulted in 84.06  ± 6.27 % decrease of tumor volume after 14 day 
treatment (Fig. 3.1K). 
aPKC functions downstream of receptor tyrosine kinases in GBM 
 Both wild type (WT) EGFR and EGFRvIII are frequently co-expressed in GBM (Q. W. Fan 
et al., 2013) and both populations were detected in GBM6, albeit EGFRvIII was the predominant 
population (Fig. 3.S3A). Serum starved GBM6 showed an activation of aPKC following EGF 
stimulation (Fig. 3.2A). Similarly, U251 stably expressing EGFR (U251/EGFR) showed aPKC 
activation (Fig. 3.2B). The kinetics of phosphorylation of EGFR in GBM6 and U251/EGFR (Fig. 
 88 
3.S3B,C) are faster than that of aPKC, suggesting that aPKC is an indirect downstream target of 
EGFR. Importantly, EGF-induced expression of CD44, MMP9 and VCAM were inhibited by PZ09 
treatment in GBM6 (Fig. 3.2C). Similarly, aPKC silencing with siRNA in U251/EGFR reduced the 
mRNA levels of EGF-induced genes (Fig. 3.2D). Therefore, aPKC mediates EGFR signaling in 
GBM. Our findings are consistent with the reported function of this kinase downstream of EGFR 
family in tumor progression in breast cancer and squamous cell carcinomas of head and neck (V. 
Aranda et al., 2006; Cohen et al., 2006). Why is inhibition of aPKC effective in EGFR-insensitive 
GBM? aPKC was also activated downstream of activated Ras, PI3-K and Src (Fig. 3.2E). EGFR 
kinase inhibitor resistance is often associated with PTEN mutations (I. K. Mellinghoff et al., 2005). 
Furthermore, multiple RTKs are simultaneously activated in GBM (Stommel et al., 2007) or 
compensatory pathways, such as the transcriptional upregulation of Met in EGFR kinase inhibitor-
resistant glioblastoma mouse models (Jun et al., 2011) render EGFR kinase inhibitors ineffective. 
Being a kinase which functions further downstream of PTEN and which participates in signaling 
downstream of Ras and Src, aPKC may function downstream of multiple RTKs and therefore has 
intrinsic advantages over EGFR as a target in GBM. 
TNFα functions as a paracrine oncogenic signal in GBM  
Another possibility why EGFR kinase inhibitor fails in vivo, whereas aPKC inhibition is 
effective, is the existence of paracrine factors and the induction of EGFR-independent, parallel 
oncogenic signals through non-cell autonomous mechanisms. For example, the tumor 
microenvironment is recognized to play a significant role in influencing tumor progression (M. J. 
Bissell & W. C. Hines, 2011; Bissell & Labarge, 2005; Coussens & Werb, 2002; Liotta & Kohn, 
2001; Lukashev & Werb, 1998). We detected significant CD68+ cell infiltration within the tumor 
area in GBM tissue (Fig. 3.3A), in contrast to non-tumor brain, in 37 of the 44 (~84 %) cases 
examined. Interestingly, the orthotopic GBM model using GBM6 implanted in NOD/SCID mice 
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also showed increased Iba1+ cells in the tumor microenvironment (fig. 3.S4A) in contrast to 
contralateral control regions (fig. 3.S4B). Furthermore, we characterized the phenotype of GBM 
infiltrating myeloid cells in three independent GBM cases. Freshly resected GBM samples were 
dissociated and GBM-associated macrophages were characterized by FACS analyses. While the 
predominant population was of the M2 macrophage subtype (CD23+), a smaller but significant 
population of M1 subtype (CD64+) macrophages was consistently observed upon FACS 
characterization of the tumor-associated CD11b+ myeloid cells (Fig. 3.3B). Pro-inflammatory 
cytokines such as TNFα are produced by tumor-associated myeloid cells and have been shown 
to promote tumor initiation and progression (F. R. Balkwill & Mantovani, 2012; Wynn, Chawla, & 
Pollard, 2013). In vitro differentiated M1 macrophages, as well as M2 macrophages, when 
activated, secreted TNFα (Fig. 3.S4C). Consistent with this observation, we detected TNFα 
expression in all GBM tissues (44 cases) examined, while TNFα was undetectable in non-tumor 
brain (Fig. 3.3C). 
Activation of the NF-κB pathway is a strong oncogenic signal in many tumors, including 
GBM (Atkinson, Nozell, & Benveniste, 2010; Ben-Neriah & Karin, 2011; Chaturvedi, Sung, Yadav, 
Kannappan, & Aggarwal, 2011a; Karin, 2009; Laver, Nozell, & Benveniste, 2009; Naugler & 
Karin, 2008; Staudt, 2010; H. Wang, Zhang, Huang, Liao, & Fuller, 2004). The deletion of 
NFKBIA, which encodes the NF-κB inhibitor IκBα, is seen in about 20 % of GBM cases (M. 
Bredel et al., 2011) and the activation of NF-κB predicts identical prognosis as EGFR gain-of-
function in GBM (M. Bredel et al., 2011). Nonetheless, the loss of IκBα overlaps with EGFR 
amplification in only 5 % GBM cases suggesting that these two independent tumor-intrinsic 
mutations do not occur simultaneously (M. Bredel et al., 2011). Loss of IκBα driving NF-κB 
activation is in fact rare in cancers; rather an inflammatory tumor microenvironment such as, 
paracrine TNFα more commonly drives NF-κB activation in cancers such as colon cancer 
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(Grivennikov & Karin, 2010; Karin, 2009; Mantovani, Allavena, Sica, & Balkwill, 2008). aPKC is a 
well-established regulator of NF-κB (Diaz-Meco et al., 1994; Duran, Diaz-Meco, & Moscat, 2003; 
Leitges et al., 2001). We hypothesized that aPKC regulates paracrine TNFα driven NF-κB 
activation in GBM and therefore targeting aPKC confers improved efficacy in GBM by dually 
inhibiting RTK and NF-κB pathways. First, we tested if NF-κB signaling is more active in GBM 
harboring EGFR gain-of-mutation but without IκBα loss of function. Freshly resected GBM tumor 
tissues were dissociated and tumor cells were confirmed to contain EGFR amplification and/or 
EGFRvIII mutation. Comparison of IκBα mRNA expression levels between GBM and normal 
human astrocytes revealed that IκB expression was unaffected. Furthermore, sequencing 
showed that the locus did not contain non-synonymous mutations in these samples (data not 
shown). Subsequently, these tumor cells were subjected to NF-κB-target gene profiling by RT-
qPCR. These GBM tumors had upregulated NF-κB target gene expression in comparison to 
normal human astrocytes (Fig. 3.3D). We also extended our analyses to orthotopic murine 
models of GBM described above. Acutely isolated tissue from the side of NOD/SCID mouse brain 
bearing GBM6 tumors showed NF-κB activation in comparison to contralateral, non-tumor 
bearing brain (Fig. 3.3E). Similarly, C57BL6 brains with GL261-derived tumors showed increased 
NF-κB-target gene expression in comparison to contralateral, non-tumor bearing brain (Fig. 
3.S4D). To validate the function of microenvironment-derived TNFα in GBM tumor progression in 
vivo, C57BL6-derived GL261 mouse glioma cells were stereotactically injected into the caudate 
nucleus in either WT control or mice lacking the TNFα gene (TNFα-/-). The genetic ablation of 
TNFα resulted in a significant increase in survival after orthotopic xenograft of GL261 (Log rank 
[Mantel-Cox] test p = <0.0001). While WT mice bearing GL261 orthotopic xenografts had a 
median survival of 16.5 days, TNFα-/- mice showed a median survival of 23 days (Figure 3.3E). 
These results demonstrate that NF-κB signaling is active in GBM, and is likely driven by paracrine 
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TNFα.  This TNFα/ NF-κB axis promotes GBM progression and acts as an EGFR-independent 
oncogenic signal. 
Paracrine TNFα-induces aPKC activation and EGFR kinase inhibitor resistance in GBM 
To directly test the role of myeloid cells and myeloid-cell derived factors, such as TNFα, 
on GBM proliferation and invasion, we isolated primary human monocytes from peripheral blood 
and co-cultured these cells with GBM6 in vitro. Co-culture of monocytes with GBM6 led to the 
production of TNFα by the monocytes (Fig. 3.4A, Fig. 3.S5A and B). We also detected high 
TNFα levels in the culture media when GBM6 cells were co-cultured with in vitro differentiated 
monocytic THP1 cells (Tsuchiya et al., 1982) (Fig. 3.S5C). Differentiated, but not undifferentiated 
THP1 cells were the source of TNFα production (Fig. 3.S5D). Co-culture of GBM6 with 
monocytes led to a significant increase in proliferation of GBM6 cells as assayed by EdU 
incorporation (Fig. 3.4B,C). This increased proliferation was blocked when an anti-human-TNFα 
antibody was included in the culture media to neutralize TNFα (Figure 3.4B,C and Fig. 3.S5E).  
Rapid invasion of GBM cells into the surrounding parenchyma is a defining characteristic 
of this disease and is believed to be an important contributor to the failure of surgery and directed 
radiotherapy. Therefore, we compared GBM6 invasion in the absence or presence of monocytes 
in a modified organotypic invasion assay (A. Valster et al., 2005). GBM6 cells were transduced 
with GFP lentivirus and were subsequently placed on an organotypic culture of rat brain slice and 
allowed to invade into the tissue for 4 days. The intensity of GFP fluorescence was calculated at 
10 µm increments from the top of the slice and the fluorescence intensity at each point was 
divided by the total intensity. The rate of invasion was defined as the inverse of the slope 
obtained by linear regression analysis of the normalized fluorescence at various depths. These 
experiments showed that GBM6 retained the ability to invade into the brain parenchyma. GBM6 
invasion was enhanced when implanted onto rat brain slices ex vivo together with monocytes, 
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while anti-human-TNFα antibody blocked this enhanced invasion (Fig. 3.4D). Similar results were 
obtained when GBM6 and differentiated THP1 cells were co-cultured. Differentiated THP1 
increased GBM6 proliferation (Fig. 3.S6A) and invasion (Fig. 3.S6B) and the effect of THP1 was 
inhibited by anti-human-TNFα antibody (Fig. 3.S6A,B). The effect of myeloid cells on GBM 
proliferation and invasion is independent of PTEN status of the GBM cells as similar increase in 
proliferation and invasion were observed in U87/EGFRvIII co-cultured with differentiated THP1 
(Fig. 3.S6C,D). Our results are consistent with the well-known role of tumor-associated 
macrophages in facilitating tumor-associated inflammation in cancers such as breast and colon 
cancer (Grivennikov & Karin, 2011; Mantovani & Sica, 2010; Ruffell, Affara, & Coussens, 2012; 
Terzic, Grivennikov, Karin, & Karin, 2010). Interestingly, aPKC phosphorylation status associated 
with monocyte-stimulated GBM proliferation and invasion. aPKC phosphorylation was enhanced 
in GBM6-monocyte co-cultures and was reduced when TNFα was neutralized under co-culture 
conditions (Fig. 3.4E,F). We also co-cultured B6-derived GL261 mouse glioma cells with mouse 
bone marrow-derived macrophages as an independent model of GBM-myeloid cell interaction. 
Analogous to GBM6-monocyte co-cultures, mouse primary macrophages also produced TNFα in 
the presence of GL261 (Fig. 3.S7A). Tumor cell proliferation (Fig. 3.S7B) and invasion (Fig. 
3.S7C) were increased in the presence of macrophages.  
Finally, we directly tested whether paracrine TNFα can indeed reduce the efficacy of 
EGFR kinase inhibitors in GBM. Treatment of GBM6 cells with the EGFR inhibitor erlotinib in vitro 
resulted in a significant inhibition of proliferation (Fig. 3.4G,H) and invasion (Fig. 3.4I). The 
addition of TNFα to GBM6 treated with erlotinib essentially obliterated these inhibitory effects 
(Fig. 3.4G,H,I). aPKC phosphorylation, but not EGFR phosphorylation, correlated with GBM6 
proliferation and invasion. Erlotinib reduced both aPKC and EGFR phosphorylation in GBM6, but 
addition of TNFα that led to increased GBM6 proliferation and invasion in the presence of 
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erlotinib, correlated with enhanced aPKC phosphorylation but failed to affect EGFR 
phosphorylation (Fig. 3.4J). Our results are consistent with myeloid cells increasing GBM cell 
proliferation, invasion and contributing to the reduced efficacy of EGFR kinase inhibitor through 
the production of TNFα in the tumor microenvironment.   
Oncogenic TNFα/NF-κB signaling in GBM is dependent on aPKC activation 
Next, we directly tested if aPKC activity was increased in GBM6 cells in response to 
TNFα.  Phosphorylation of both aPKC and the p65 subunit of NF-κB (p65-NF-κB) were 
significantly increased in GBM6 following the addition of TNFα (Fig. 3.5A). Additionally, PZ09 
treatment resulted in a significant reduction of NF-κB targets induced by TNFα (Fig. 3.5B). 
Analyses of Ser536 phosphorylation on p65-NF-κB in GBM6 by FACS indicated that PZ09 
treatment inhibited the TNFα-dependent increase at this phosphorylation site (Fig. 3.5C). 
Similarly, aPKC (Fig. 3.5D) and p65-NF-κB (Fig. 3.S8A) was activated upon TNFα stimulation in 
the glioma cell line U251. Silencing aPKC in U251 cells using siRNA sequences targeting both 
PRKCI and PRKCZ inhibited TNFα induced NF-κB targets (Fig. 3.5E). Silencing aPKC in U251 
prevented the TNFα-dependent phosphorylation of Ser311 on p65-NF-κB (Fig. 3.5F). However, 
TNFα-induced IκBα degradation was not inhibited (Fig. 3.S9). These results are consistent with a 
previous report demonstrating that aPKC regulates IKK activity and/or p65-NF-κB 
phosphorylation in the NF-κB pathway in a cell type specific manner (Leitges et al., 2001). Finally, 
we tested the effect of PZ09 and aPKC siRNA on NF-κB:GFP reporter activity in U251 following 
TNFα stimulation. Both PZ09, as well as aPKC siRNA, reduced TNFα-dependent NF-κB:GFP 
reporter activity to levels comparable with neutralization of TNFα using an anti-human-TNFα 
antibody (Fig. 3.5G). 
We also tested the effects of inhibiting aPKC under GBM6-myeloid cell co-culture 
conditions. Co-culture of GBM6 and monocytes results in the phosphorylation of both aPKC and 
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p65 in GBM6 approximately 1 h following mixing of these cell types (Fig. 3.S8B). To assay 
monocyte induced NF-κB gene expression in GBM6 by qRT-PCR, we utilized a transwell culture 
system. GBM6 alone or GBM6 plus monocytes were grown in the top chamber of a transwell 
system, while GBM6, uncontaminated by monocytes, yet exposed to the co-culture media, were 
grown in the bottom chamber separated by a 0.4 µm filter. GBM6 from the bottom chamber of the 
transwell system described above were harvested and processed for RT-qPCR profiling. GBM6 
exposed to the co-culture media showed increased mRNA levels of a number of inflammatory 
cytokine genes and other NF-κB targets, such as COX2, IL-1β, IL6, IL8, MCP-1, MMP9, 
TNFα and VEGF, in comparison to GBM6 grown in as monoculture (Fig. 3.5H). Similar results 
were obtained when the human pre-monocytic cell line THP1 was differentiated in vitro (Tsuchiya 
et al., 1982) and co-cultured with GBM6. Under these conditions we observed aPKC 
phosphorylation in GBM6 in the lower chamber approximately 1 h following plating (Fig. 3.S10A). 
NF-κB gene expression in GBM6 (Fig. 3.S9B) or U87/EGFRvIII (Fig. 3.S9C) were enhanced 
under co-culture conditions with differentiated THP1. Importantly, treatment with PZ09 inhibited 
the induction of NF-κB target genes observed in GBM6-monocyte co-culture conditions (Fig. 
3.5H). These results demonstrate that tumor-associated myeloid cells activated aPKC-dependent 
NF-κB signaling. This aPKC-dependence is also observed in PTEN deficient U87/EGFRvIII cells 
indicating that aPKC functions downstream of PTEN. 
Consistent with our hypothesis that aPKC-dependent NF-κB signaling induced by 
myeloid cells contributes to GBM proliferation, PZ09 was also effective in inhibiting monocyte-
induced increase in GBM6 proliferation (Fig. 3.5I,J). Additionally, PZ09 was effective in inhibiting 
the monocyte-induced increase in invasion (Fig. 3.5K). PZ09 dependent inhibition of proliferation 
and invasion also correlated with inhibition of aPKC and p65-NF-κB phosphorylation (Fig. 
3.5L,M). In comparison to untreated GBM6-differentiated THP1 co-cultures, PZ09 treatment of 
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co-cultured GBM6 with differentiated THP1 similarly reduced proliferation (Fig. 3.S11A) and 
invasion (Fig. 3.S11B). We silenced aPKC expression in PTEN deficient U87 cells stably 
expressing EGFRvIII (U87/EGFRvIII) by using shRNA. In comparison to U87/EGFRvIII-
differentiated THP1 co-cultures, U87/EGFRvIII aPKCshRNA cells co-cultured with differentiated 
THP1 showed reduced proliferation (Fig. 3.S11C) and invasion (Fig. 3.S11D). Neither, PZ09 or 
aPKC siRNA affected the levels of EGFR or EGFR phosphorylation in GBM6 or U251/EGFR (Fig. 
3.S12A,B).  
Distinct aPKC-containing signaling complexes mediate oncogenic TNFα and RTK 
signaling  
Does GBM cell autonomous EGFR and paracrine TNFα signals converge on a unique 
aPKC-containing signal module in GBM cells? While both EGF and TNFα signaling in GBM 
resulted in aPKC activation and were critically dependent on aPKC, these pathways resulted in 
largely distinct transcriptional outputs at early time points. For example, EGF-induces CD44, 
MMP9, VCAM and uPAR in U251/EGFR at 6 h (Fig. 3.S13A), while TNFα treatment for 1 h led to 
the expression of a different set of genes including IL-1β, IL-8, MCP-1 and TNFα (Fig. 3.S13B). 
This discrete expression profile is not apparent after overnight treatment since long term TNFα 
treatment leads to increase in EGF. Furthermore, the ERK-inhibitor U0126 treatment indicated 
that MAPK signaling downstream of aPKC was mostly relevant to EGF-specific gene expression 
and not TNFα-dependent gene expression (Fig. 3.S13C,D). In contrast, IκBαM inhibited only 
TNFα-dependent gene expression, and not EGF-dependent gene expression with the exception 
of MMP9 indicating that aPKC-dependent NF-κB signaling was specifically required for the 
expression of the TNFα-dependent genes (Fig. 3.S13E,F). These results indicate that while 
aPKC participates in both signaling pathways, these pathways do not merely converge on aPKC. 
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To further investigate aPKC signaling downstream TNFα and EGF, we investigated the 
PB1-domain scaffolds necessary for aPKC activation in the context of these specific signals. EGF 
induced/stabilized an aPKC-Par6 complex (Fig. 3.6A). EGFR kinase inhibitor, PI3-K inhibitors or 
Src-inhibitor that effectively inhibited their targets (Fig. 3.S14), reduced aPKC activation and also 
reduced aPKC-Par6 co-immunoprecipation in U87/EGFRvIII (Fig. 3.6B). The effect of aPKC 
silencing was phenocopied by Par6 silencing, but not p62 silencing, for EGF-induced genes (Fig. 
3.6C). In contrast, the NF-κB signaling was dependent on the adaptor p62. Silencing p62 
phenocopied aPKC silencing in the inhibition of NF-κB signaling (Fig. 3.6D). Furthermore, Par6 
and p62 had distinct intracellular localization profiles. Immunofluorescence experiments 
demonstrated that the majority of cellular Par6 localized with actin at the leading edge of EGF-
treated U251/EGFR cells. In contrast, p62 was detected in an intracellular compartment, away 
from the leading edge, in TNFα treated U251/EGFR cells (Fig. 3.6E). Therefore, TNFα and EGF 
signaling pathways, despite sharing the important downstream kinase aPKC, use alternative 
PB1-domain scaffold proteins – p62 versus Par6. In vitro structural studies indicate that the PB1 
scaffolds Par6 and p62 compete for aPKC binding (Hirano et al., 2004; Noda et al., 2003; Wilson, 
Gill, Perisic, Quinn, & Williams, 2003) and this may explain the specificity of TNFα and EGF 
signaling. Interestingly, the constitutively active myr-aPKCζ indiscriminately activated CD44, 
MMP9, VCAM, uPAR, IL-1β, IL-8, MCP-1 and TNFα (Fig. 3.6F). Taken together, our results show 
that activation of aPKC is not only indispensable, but also sufficient for the induction of both EGF 
and TNFα dependent genes, and that the specificity of these pathways is determined by the 
differential use of adaptors Par6 and p62.  
DISCUSSION 
The success of single agent anti-tumor therapy can be limited by downstream mutations 
or the induction of parallel oncogenic pathways in tumor cells. EGFR gain-of-function accounts for 
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~45 % of GBM, while the homozygous deletion of PTEN leading to downstream PI3-K activation 
is seen in ~36 % cases and overall PI3-K activation (due to other RTK pathway activation) is 
seen in ~88 % of GBM (R. McLendon et al., 2008). Cancer cells with mutant EGFR are 
particularly sensitive to inhibition of NF-κB, and NF-κB activation through deletion of IκBα 
rescues EGFR-mutant cancer cells from the cytotoxic effects of the EGFR kinase inhibitor 
erlotinib (Bivona et al., 2011). Our results indicate that a pro-inflammatory microenvironment also 
increases the therapeutic challenge of targeting GBM tumor intrinsic mutations by providing 
parallel oncogenic signals (Fig. 3.7). Infiltration of innate immune cells within the GBM tumor 
mass has been described previously (Badie & Schartner, 2000; N. A. Charles, E. C. Holland, R. 
Gilbertson, R. Glass, & H. Kettenmann, 2011; Hussain et al., 2006; Parney, Waldron, & Parsa, 
2009; Roggendorf, Strupp, & Paulus, 1996a). However, traditionally, GBM is not considered an 
inflammation-driven tumor and macrophages/activated microglia in GBM have often been 
described as anti-tumorigenic (Galarneau, Villeneuve, Gowing, Julien, & Vallieres, 2007; Zhang 
et al., 2009). Here we demonstrate that the interaction of GBM tumor cells with tumor infiltrating 
myeloid cells leads to paracrine production of TNFα that contributes to tumor growth and spread, 
and renders EGFR kinase inhibitors less effective. These results are consistent with reports that 
macrophage/microglia enhance glioma invasion and growth. Microglia, but not oligodendroglia or 
endothelial cells, has been reported to increase GL261 glioma cell migration in vitro (Bettinger, 
Thanos, & Paulus, 2002; Zhai, Heppner, & Tsirka, 2011). Depletion of macrophage/microglia by 
treatment with clodronate liposomes in an ex vivo organotypic brain slice culture assay also 
reduced GL261 invasion (Markovic, Glass, Synowitz, Rooijen, & Kettenmann, 2005). In vivo 
deletion of macrophages/microglia in the brain or the inhibition of CSF-1R significantly reduced 
glioma growth (Coniglio et al., 2012; Markovic et al., 2009; Pyonteck et al., 2013). Additionally, 
higher grade gliomas, such as GBM and WHO Grade III anaplastic astrocytomas, show the 
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largest increase in macrophage infiltration, in contrast to lower grade gliomas (Roggendorf et al., 
1996a). A recent report has ascribed radio resistance in GBM to TNFα/NF-κB signaling and 
conversion to a more aggressive, mesenchymal-subtype (Bhat et al., 2013). Thus, targeting the 
tumor microenvironment can provide unique therapeutic opportunities (Coussens, Zitvogel, & 
Palucka, 2013; Shiao, Ganesan, Rugo, & Coussens, 2011). 
Intriguingly, aPKC has critical roles in distinct, but concurrent oncogenic signaling 
pathways. It functions downstream of EGFR and RTK signaling in GBM cells. It is also essential 
for tumor microenvironment-induced TNFα/NF-κB oncogenic signaling in GBM. Altered 
expression of the kinase aPKC has been reported to be associated with cancer, including GBM 
(do Carmo, Balca-Silva, Matias, & Lopes, 2013). However, the identity of the aPKC isoforms 
involved and the mechanism of aPKC function have heretofore remained unclear with frequently 
contrasting reports. For example, one isoform of aPKC, aPKCζ, has been reported to be both 
upregulated and down regulated in cancer, including specifically in GBM (do Carmo et al., 2013; 
J. Moscat, Diaz-Meco, & Wooten, 2009a). aPKCι, and not aPKCζ, is the aPKC isoform detected 
in most brain regions, except for cerebellum (Parker et al., 2013a). Our analyses reveal that most 
GBM tumor cell lines, as well as patient-derived xenografts show increased expression of aPKCι 
protein (fig. S15A,B). Interestingly, aPKC mRNA levels in GBM were not increased in comparison 
to normal human astrocytes, suggesting that aPKC expression in GBM is regulated through post-
translational mechanisms (fig. S15D,E). Targeting the bi-modal activity of aPKC in tumor cell 
autonomous and non-tumor cell autonomous signaling may provide a paradigm that affords 
simultaneously disabling of tumor intrinsic, as well as microenvironment-induced oncogenic 
signals in GBM. 
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Figure 3.1. Clinical association and therapeutic efficacy of targeting aPKC in mouse 
models of GBM. (A) Representative example of non-tumor brain parenchyma shows low aPKC 
staining, while (B,C) aPKC staining is increased in GBM.  (D) Stratification of 330 GBM cases 
according to immunohistochemical scores of aPKC. (E) Representative examples of aPKC 
phosphoThr410/403 staining in GBM tissue microarray. (F) Stratification of 44 GBM cases 
according to immunohistochemical scores of aPKC phosphoThr410/403 staining. (G) Kaplan-
Meier survival curve of 44 GBM cases showing correlation of bright aPKC staining with poor 
survival in human patients (p=0.0145). 
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Figure 3.1, cont. (H) Kaplan-Meier survival curves of mice bearing U87/EGFRvIII intracranial 
xenografts stably transfected with control or aPKCshRNA (p=0.0005). (I) Representative images 
of transplanted U87/EGFRvIII control and U87/EGFRvIII aPKCshRNA tumors after 6 days post-
implantation. Dashed lines circumscribe the tumor areas. Tumor volume quantification from 
U87/EGFRvIII (J) or EGFR kinase inhibitor-insensitive GBM6 (K) intracranial xenografts infused 
with 10 µM PZ09 through an Alzet osmotic minipump for 7 and 14 days respectively, beginning 3 
days post tumor implantation. Data are presented as representative individual samples or as 
mean ± SEM of at least 3 independent samples per group. *p < 0.05. 
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Figure 3.2. aPKC is activated downstream of tumor-intrinsic oncogenic RTK signaling 
pathways. (A) Activation of aPKC in GBM6 cells after 100 ng/mL EGF treatment for the indicated 
times. Active aPKC was detected after aPKC immunoprecipitation followed by aPKC 
phosphoThr410/403 immunoblotting. Total aPKC is shown as loading control. (B) Expression of 
indicated genes in GBM6 cells upon treatment with 100 ng/mL EGF treatment alone or in the 
presence of 10 µM of PZ09 or 10 µM of erlotinib (30 min pretreatment) for 6 h, as detected by 
RT-qPCR and normalized to GBM6 control. (C) Activation of aPKC in U251/EGFR cells after 100 
ng/mL EGF treatment for the indicated times. Total aPKC is shown as loading control. (D) 
Expression of indicated genes in U251/EGFR cells, U251/EGFR cells treated with 10 µM of 
erlotinib (30 min pretreatment) or in U251/EGFR cells treated with aPKC siRNA, upon treatment 
with 100 ng/mL EGF treatment for 6 h, as detected by RT-qPCR and normalized to U251/EGFR 
control. (E) Activation of aPKC in U251/EGFR cells after 48 h of transfection with vector alone or 
active Ras (H-RasV12), active PI3K (CAAXp110), or active Src (v-Src). Total aPKC is shown as 
loading control. Data are presented as representative images or as mean ± SEM of at least 3 
independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001. 
 
 102 
 
Figure 3.3.  Myeloid cells, paracrine TNFα and NF-κB signature are detected in GBM and 
favor progression. (A) Representative images showing increased CD68+ in GBM tissue in 
comparison to non-tumor brain. (B) Representative FACS analysis (top) and percentage of 
CD11b+ in GBM (bottom, n=3). (C) Representative images showing increased TNFα staining in 
GBM tissue in comparison to non-tumor brain. (D) NF-κB target gene profiling of primary human 
GBM cells from two independent patients vs. normal human astrocytes, as detected by RT-qPCR 
array. Gene expression of GBM cells was normalized to the gene expression in astrocytes. (E) 
Expression of NF-κB target genes in acutely isolated tissue from the side of NOD/SCID mouse 
brain bearing GBM6 tumors in comparison to contralateral, non-tumor bearing brain as detected 
by RT-qPCR. (F) Kaplan-Meier survival curves of wildtype (WT) and TNFα-/- mice bearing GL261 
intracranial xenografts (p =< 0.0001). 
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Figure 3.4. Myeloid cell-derived TNFα promotes GBM proliferation, invasion and EGFR 
kinase inhibitor resistance and correlates with aPKC activation. (A) Concentration of TNFα 
in conditioned media from monocytes, GBM6 cells, or GBM6 cells co-cultured with monocytes, as 
detected by ELISA. (B) Representative FACS analysis and (C) percentage (%) of EdU 
incorporation in GBM6 cells alone, GBM6 co-culture with monocytes in the presence of 100 
ng/mL monoclonal anti-human-TNFα antibody or an isotype control at 24 h. (D) Invasion Indices 
of GBM6 plus monocytes in the presence of 100 ng/mL monoclonal anti-human-TNFα antibody or 
isotype control. (E) Representative FACS histograms and (F) mean fluorescence intensity (MFI) 
of aPKC Thr560 phosphorylation in GBM6 cells alone, upon co-culture with monocytes in the 
presence of an isotype control antibody or upon co-culture with monocytes in the presence of 
monoclonal anti-human-TNFα antibody.  
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Figure 3.4, cont. (G) Representative FACS analysis and (H) percentage (%) of EdU 
incorporation in GBM6 cells alone, or in the presence of 10 µM erlotinib alone or together with 10 
ng/mL TNFα at 24 h. (I) Invasion indices of GBM6 alone, plus 10 µM erlotinib and plus 10 µM 
erlotinib and 10 ng/mL TNFα. (J) Representative FACS histograms of EGFR Tyr1086 
phosphorylation (left) and aPKC Thr560 phosphorylation (right) in GBM6 cells alone, or in the 
presence of 10 µM erlotinib alone or together with 10 ng/mL TNFα. Data are presented as 
representative individual samples or as mean ± SEM of at least 3 independent samples per 
group. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 3.5. TNFα-induced NF-κB signaling in GBM is dependent on aPKC. (A) 
Representative FACS histograms of aPKC Thr560 phosphorylation (left) and NF-κB p65 Ser536 
phosphorylation (right) at the indicated times in GBM6 cells or GBM6 cells treated with 10 ng/mL 
TNFα. (B) Expression of NF-κB target genes in GBM6 cells upon treatment with 10 ng/mL TNFα 
alone or in the presence of 10 µM of PZ09 for 1 h, as detected by RT-qPCR. mRNA levels were 
normalized to GBM6 control. (C) FACS analysis of phosphoSer536 p65 in GBM6 cells left 
untreated or treated with 10 ng/mL TNFα for 1 h in the presence or absence of 10 µM PZ09. 
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Figure 3.5, cont. (D) Activation of aPKC in U251/EGFR cells treated with 10 ng/mL TNFα for the 
indicated times. (E) Expression of NF-κB target genes in U251/EGFR cells or U251/EGFR cells 
treated with aPKC siRNA, upon treatment with 10 ng/mL TNFα for 1 h, as detected by RT-qPCR. 
mRNA levels were normalized to U251/EGFR control. (F) phosphoSer311 p65 immunoblots from 
U251/EGFR control or aPKC siRNA transfected cells after 10 ng/mL TNFα treatment for 1 h. 
Total p65 and β-tubulin immunoblots were used as loading controls and aPKC antibodies show 
the extent of aPKC silencing. (G) NF-κB fluorescent reporter activity following 30 min of 
incubation with 10 ng/mL TNFα in U251/EGFR cells alone or in the presence of 100 ng/mL anti-
human TNFα antibody, U251/EGFR transfected with aPKC siRNA or U251/EGFR in the 
presence of 10 µM PZ09. 
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Figure 3.5, cont. (H) Expression of NF-κB target genes in GBM6 alone, GBM6 exposed to 
monocyte co-culture media and exposed to co-culture media in the presence of 10 µM PZ09, as 
detected by RT-qPCR and normalized to GBM6 alone samples. (I) Representative FACS analysis 
and (J) percentage (%) of EdU incorporation in GBM6 cells alone or when co-cultured with 
monocytes for 24 h, with or without 10 µM PZ09. 
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Figure 3.5, cont. (K) Invasion indices of GBM6 cells alone or when co-cultured with monocytes 
with or without 10 µM PZ09. (L) Representative FACS histograms and (M) mean fluorescence 
intensity (MFI) of aPKC Thr560 phosphorylation (left) and NF-κB p65 Ser536 phosphorylation in 
GBM6 cells alone or when co-cultured with monocytes with or without 10 µM PZ09. Data are 
presented as representative images or as mean ± SEM of at least 3 independent samples per 
group. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 3.6. Bimodal function of aPKC in EGF and TNFα induced-signaling in GBM cells. (A) 
Co-immunoprecipitation of Par6 with aPKC in serum-starved U251/EGFR cells after treatment 
with 100 ng/mL EGF for 6 h. aPKC was immunoprecipitated and immunoblots were sequentially 
probed with Par6 and aPKC antibodies. Total aPKC is shown as loading control. (B) Activation of 
aPKC (top panel) and co-immunoprecipitation of Par6 (bottom panel) in U87/EGFRvIII cells 
grown in serum after incubation with 10 µM AG1478, 100 nM wortmannin, 20 µM LY294002 or 10 
µM SU6656 for 30 min. Total aPKC is shown as loading control. aPKC was immunoprecipitated 
and immunoblots were sequentially probed with phospho-aPKC Thr410/403 and aPKC or Par6 
and aPKC antibodies. (C) Expression of indicated genes after treatment with 100 ng/mL EGF for 
6 h in U251/EGFR control cells or transfected with aPKC, Par6 or p62 siRNA, as determined by 
RT-qPCR. Expression was normalized to EGF treated U251/EGFR control samples. (D) 
Expression of indicated genes after treatment with 10 ng/mL TNFα for 1 h in U251/EGFR control 
cells or transfected with aPKC, Par6 or p62 siRNA, as determined by RT-qPCR. Expression was 
normalized to TNFα treated U251/EGFR control samples.  
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Figure 3.6, cont. (E) Representative images showing the co-localization of aPKC and Par6 with 
phalloidin at the lamellipodia after EGF stimulation for 6 h in U251/EGFR cells (white arrows, left 
and middle panels), and co-localization of aPKC and p62 in the intracellular compartment after 
TNFα treatment for 1 h (white arrows, right panel). Some aPKC was detectable at the 
lamellipodia of the cells (grey arrow). (F) Expression of indicated genes in U251/EGFR cells 48 h 
after myr-aPKCζ transfection, as determined by RT-qPCR. Expression was normalized to mRNA 
level in U251/EGFR. Data are presented as representative images or as mean ± SEM of at least 
3 independent experiments. *p < 0.05, **p < 0.01, ***p < 0.001, ns is non-significant. 
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Figure 3.7. Schematic illustrating aPKC-containing signaling complexes in cell 
autonomous RTK and non cell-autonomous TNFα/NF-κB oncogenic signaling in GBM. 
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Table 3.S1. 
List of primers 
 
 
 
  
 113 
Table 3.S2.  
List of siRNA and shRNA Sequences 
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Figure 3.S1. aPKC expression in non-tumor brain and in histologically characteristic 
regions of GBM. Representative images of aPKC staining in (A) normal basal ganglia, (B) 
regions of pseudopalisading necrosis in GBM and (C) microvascular proliferation in GBM.  
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Figure 3.S2. Validation of aPKC knockdown efficiencies and PZ09 inhibitory effect. (A) 
Immunoblots of aPKC expression in U87/EGFRvIII control cells and U87/EGFRvIIIaPKCshRNA 
cells used for in vivo intracranial orthotopic xenograft experiments. (B) Immunoblots of aPKC 
expression in U251/EGFR cells transfected with luciferase or aPKC siRNA. (C) Immunoblot of 
Par6 expression in U251/EGFR cells transfected with luciferase or Par6 siRNA. (D) Graphical 
representation of knockdown efficiencies in U251/EGFR cells for each indicated genes, 
normalized to control (luciferase) siRNA, as measured by RT-qPCR. (E) Inhibition of aPKC 
activation in GBM6 with increasing concentration of PZ09 detected after aPKC 
immunoprecipitation followed by aPKC phosphoThr410/403 or phosphoThr560 immunoblotting. 
Blots were stripped and reprobed with aPKC antibodies for loading control. Data are presented as 
representative images or as mean ± SEM of at least 3 independent experiments. 
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Figure 3.S3. EGFR isoforms expression in GBM6 and EGFR phosphorylation kinetics in 
GBM6 and U251/EGFR. (A) Expression of EGFR WT and EGFRvIII in GBM6 as detected by RT-
PCR.U87EGFR (WT) and U87EGFRvIII were included as positive controls. (B) Representative 
FACS histograms of EGFR phosphorylation (p-Y1086) kinetics in GBM6. Serum was used to 
stimulate serum-starved GBM6 cells or serum-starved GBM6 cells pretreated for 30 min with 10 
µM erlotinib.(C) Representative immunoblots for EGFR phosphorylation (p-Y1086) in serum-
starved U251/EGFR cells at various time points as indicated after stimulation with 100 ng EGF 
alone or 100 ng EGF after 30 min pre-treatment with 10 µM erlotinib. Data are presented as 
representative images of at least 3 independent experiments. 
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Figure S3.4. Myeloid cells, TNFα production and NF-κB activation in mouse models of 
GBM. (A) Representative images of Iba1 staining of NOD/SCID mouse brain bearing GFP+ 
U87vIII/EGFR tumors in comparison to (B) contralateral, non-tumor bearing brain. (C) 
Representative FACS analysis of TNFα production by unstimulated human monocyte-derived 
macrophages (M0) and M0, M1, M2a or M2c stimulated with Ionomycin/PMA. (D) Expression of 
NF-κB target genes in acutely isolated tissue from the side of C57B6 mouse brain bearing GL261 
tumors in comparison to contralateral, non-tumor bearing brain as detected by RT-qPCR. Data 
are presented as representative images or as mean ± SEM of at least 3 independent 
experiments. 
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Figure 3.S5. TNFα is produced by myeloid cells when in contact with GBM cells. (A) 
Representative FACS analysis and (B) mean fluorescence intensity (MFI) of TNFα expression in 
CD11b+ human monocytes upon culture with GBM6 cells. (C) TNFα concentration as measured 
by ELISA in conditioned media from GBM6 cells alone, THP1 cells alone, or indicated cells upon 
co-culture. (D) Representative FACS analysis of TNFα from undifferentiated or differentiated 
THP1 cells upon culture with or without GBM6 cells expressing GFP. (E) TNFα concentration as 
measured by ELISA in conditioned media from GBM6 cells, monocytes, GBM6 co-cultured with 
monocytes alone or in the presence of 100 ng/mL of TNFα neutralizing antibody. Data are 
presented as representative plots or as mean ± SEM of at least 3 independent experiments. *p < 
0.01, ***p < 0.001. 
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Figure 3.S6. Human myeloid cell-derived TNFα contributes to increased GBM proliferation 
and invasion. (A) Proliferation of GBM6 cells upon culture with differentiated THP1 cells in the 
presence of isotype control or neutralizing monoclonal anti-TNFα antibody and normalized to the 
proliferation of GBM6 alone. (B) Invasion indices of GBM6 cells upon culture with differentiated 
THP1 cells in the presence of isotype control or neutralizing monoclonal anti-TNFα antibody and 
normalized to invasion index of GBM6 cells alone. (C) Proliferation of U87/EGFRvIII cells upon 
culture with differentiated THP1 cells and normalized to control. (D) Invasion indices of U87/ 
EGFRvIII cells upon culture with differentiated THP1 cells and normalized to control. Data are 
presented as mean ± SEM of at least 3 independent experiments. *p < 0.05, **p < 0.01,  
***p <0.001, ns is non-significant. 
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Figure 3.S7. Murine myeloid cell-derived TNFα contributes to increased GBM proliferation 
and invasion. (A) TNFα concentration as measured by ELISA in culture media of GL261 cells 
alone, primary mouse macrophages alone, or GL261 cells upon culture with primary mouse 
macrophages. (B) Representative FACS analysis (left panel) and percentage (%, right panel) of 
EdU incorporation in GL261 cells upon culture with primary mouse macrophages. (C) Invasion 
index of GL261 cells upon culture with primary mouse macrophages. *p < 0.05. 
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Figure 3.S8. Phosphorylation of aPKC precedes phosphorylation of p65. (A) Representative 
FACS histograms of aPKC Thr560 (left) and NF-κB p65 Ser536 (right) phosphorylation at the 
indicated times in U251 cells alone and upon stimulation with 10 ng/mL TNFα. (B) Representative 
FACS histograms of aPKC Thr560 (left) and NF-κB p65 Ser536 (right) phosphorylation in GBM6 
cells alone and upon coculture with monocytes at the indicated time points. Data are presented 
as representative histograms of at least 3 independent experiments. 
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Figure 3.S9. TNFα induced IκΒα degradation is not affected by aPKC silencing. Immunoblot 
of IκBα in control U251/EGFR (controlsiRNA) cells or U251/EGFR cells in which aPKC 
expression has been silenced (aPKCsiRNA) after 10 ng/mL TNFα treatment for the indicated 
times. β-tubulin blotting was used for loading control. 
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Figure 3.S10. Activation of aPKC and induced NF-κB gene signature in GBM cells upon 
coculture with myeloid cells. (A) GBM6 cells were grown on the bottom compartment of a 
transwell culture system and GBM6 together with differentiated THP1 cells were co-cultured on 
the top for the indicated times. Active aPKC in GBM6 from the bottom compartment at the 
indicated times was detected after aPKC immunoprecipitation followed by aPKC 
phosphoThr410/403 immunoblotting. Total aPKC is shown as loading control. (B) Expression of 
indicated genes in GBM6 cells and (C) U87/EGFRvIII cells upon culture with differentiated THP1 
cells for 24 h as measured by RT-qPCR. GBM6 cells or U87/EGFRvIII cells were grown on the 
bottom compartment of a transwell culture system and GBM6 or U87/EGFRvIII cells together with 
differentiated THP1 cells were co-cultured on the top for the indicated times. Data are presented 
as representative images or as mean ± SEM of at least 3 independent experiments. 
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Figure 3.S11. Myeloid cell-induction of GBM proliferation and invasion is dependent on 
aPKC . (A) Proliferation (percentage) of GBM6 cells upon culture with THP1 cells in the presence 
or absence of 10 µM PZ09. (B) Invasion indices of GBM6 cells upon culture with THP1 cells in 
the presence or absence of 10 µM PZ09. (C) Proliferation (percentage) of U87/EGFRvIII cells or 
U87/EGFRvIII-aPKCshRNA cells upon culture with differentiated THP1 cells. (D) Invasion indices 
of U87/EGFRvIII cells or U87/EGFRvIII-aPKCshRNA cells upon culture with differentiated THP1 
cells. Data are presented as mean ± SEM of at least 3 independent experiments. *p < 0.05, **p < 
0.01, ***p < 0.001. 
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Figure 3.S12. Erlotinib, but not aPKC inhibition, suppresses EGFR phosphorylation. (A) 
Immunoblots of EGFR phosphorylation in U251/EGFR cells alone (control), upon incubation with 
10 µM concentration of erlotinib, in U251/EGFR cells in which aPKC expression has been 
silenced (aPKCsiRNA) or upon incubation with 10 µM of PZ09. Total EGFR was used as a 
loading control. (B) Immunoblots of aPKC phosphorylation and total aPKC after 
immunoprecipitation (I.P.) in U251/EGFR cells treated as in A (top panels). Immunoblots of ERK 
phosphorylation and total ERK in U251/EGFR cells treated as in A (bottom panels). (C) 
Immunoblots of EGFR phosphorylation in GBM6 cells alone (control), upon incubation with 10 µM 
of erlotinib or 10 µM of PZ09. Total EGFR was used as a loading control. (D) Immunoblots of 
aPKC phosphorylation and total aPKC after immunoprecipitation (I.P.) in GBM6 cells treated as in 
C. Data are presented as representative blots of at least 3 independent experiments. 
  
 126 
 
Figure 3.S13. Induction of distinct sets of genes by EGF and TNFα signaling in GBM cells. 
(A) Expression of indicated genes in U251/EGFR cells treated with 100 ng/mL EGF for 6 h or (B) 
10 ng/mL TNFα for 1 h, as detected by RT-qPCR. (C) Expression of indicated genes in 
U251/EGFR cells treated with 100 ng/mL EGF for 6 h or (D) 10 ng/mL TNFα for 1 h with or 
without 10 µM U0126, as detected by RT-qPCR. (E) Expression of indicated genes in 
U251/EGFR cells transduced with IκBαM virus and treated with 100 ng/mL EGF for 6 h or (F) 10 
ng/mL TNFα for 1 h. Data are presented as mean ± SEM of at least 3 independent experiments. 
*p < 0.05, **p <0.01, ***p < 0.001, ns is non-significant. 
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Figure 3.S14. Validation of EGFR, AKT and Src inhibition in U87/EGFRvIII. (A) Immunoblots 
of phospho-EGFR, total EGFR, phospho-ERK and total ERK in cell lysates from U87/EGFRvIII 
control or after incubation with 10 µM of erlotinib or 10 µM of AG1478 for 30 min. (B) 
Immunoblots of phospho-AKT and total AKT in cell lysates from U87/EGFRvIII control or after 
incubation with 20 µM of LY294002 for 30 min. (C) Immunoblots of phospho-Src and total Src in 
cell lysates from U87/EGFRvIII control or after incubation with 10 µM of SU6656 for 30 min. Data 
are presented as representative blots of at least 3 independent experiments. 
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Figure 3.S15. PRKCI is the predominant GBM-associated isoform of aPKC. (A) Relative 
expression of aPKCι (PRKCI) and aPKCζ (PRKCZ) in patient-derived xenografts (GBM8, 
GBM10, GBM12, GBM14) and GBM cell lines (SF767, SNB19, T98G, U251, U373) as detected 
by RT-qPCR using isoform specific primers. Relative expression levels of the isoforms 
normalized to PRKCI are shown. (B) Expression of aPKCι and aPKCζ as detected by 
immunoblotting using isoform specific antibodies. Total aPKC was immunoprecipitated and 
probed with isoform specific antibodies. (C) Validation of isoform specific antibodies on HEK293 
cells expressing aPKC-GFP fusion protein as detected by western blotting using total aPKC 
antibody and isoform specific aPKC antibodies. (D) Relative expression of aPKCι in the indicated 
cells as detected by RT-qPCR using isoform-specific primers and normalized to human 
astrocytes. (E) Expression of total aPKC as detected by immunoblotting in the indicated cells. 
Tubulin is shown as loading control. The numbers below each lane indicate the relative 
expression of aPKC in the respective cell type normalized to its expression in human astrocytes. 
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CHAPTER 4 
DISCUSSION AND IMPLICATIONS 
mTOR Signaling in GBM 
Signaling pathways rarely operate in isolation. Although Chapter 2 and Chapter 3 
describe seemingly separate signaling pathways, evidence in the literature exists of the shared 
association and cross-talk between the signaling components. For example, mTOR signaling in 
GBM has been well characterized, given that mTOR is a downstream component of the highly 
mutated PI3K/AKT pathway (Akhavan, Cloughesy, & Mischel, 2010; Q.-W. Fan et al., 2009; Hu et 
al., 2005). Fan et al (2009) showed that mTOR phosphorylation and activation was directly 
correlated with EGFR abundance in PTEN wild-type GBMs and that phosphorylated mTOR could 
be used as a marker of EGFR inhibition (Q.-W. Fan et al., 2009). Another study showed that 
mTOR was required for the survival of GBM cells as inhibition of mTOR led to their apoptosis (Hu 
et al., 2005), Furthermore, several in-vivo mouse studies have showed the efficacy of mTOR 
inhibition for GBM with various mTOR inhibitors (Eshleman et al., 2002; Prasad et al., 2011). 
After showing successful inhibition of the PI3K/mTOR signaling pathway in GBM cells in-vitro, 
Prasad et al (2011) treated a mouse model of GBM with XL765, a dual mTOR and PI3K inhibitor. 
While control mice succumbed to the tumor by day 55, on average, mice treated with XL765 
survived on average 13 days longer (p=0.05).  Furthermore, although TMZ alone effectively 
increased the survival of these mice (p=0.001), the additive effect of combining XL765 with TMZ 
in these mice was also significant (p<0.001). Using rapamycin, Eshleman et al (2002) found a 
reduction of GBM cell proliferation in-vivo as well as increased efficacy to radiation therapy with 
rapamycin treatment in mice with GBM flank xenografts (Eshleman et al., 2002). Interestingly, in 
GBM stem-like cells (described below), Sunayama et al (2010) found that treatment with 
rapamycin led to a reduction in sphere formation and the decreased transcription of stem-like 
markers, indicating a change of cellular identity with rapamycin treatment (Sunayama et al., 
2010).  Furthermore, treatment of these cells with NVP-BEZ235, a dual rapamycin and a PI3K 
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inhibitor, led to the increased expression of differentiation markers, as well as a significant 
reduction in the tumorigenicity of the cells (Sunayama et al., 2010).  Given the potent tumorigenic 
properties of these stem-like cells in GBM and the hypothesis that they are capable of populating 
new tumors (see below), finding an effective therapeutic which targets their signaling cascades 
directly may prove to efficacious to human patients.  
A recent study published in the journal Science examined the differences in genetic 
mutations between initial low-grade glioma samples and recurrent glioma arising in the same 
patient (B. E. Johnson et al., 2014).  As described in the Introduction to Chapter 3, low-grade 
gliomas can recur with the same pathological grade, or can acquire new mutations and recur as a 
high-grade glioma (Westphal & Lamszus, 2011).  Over half of the TMZ-treated initial low-grade 
glioma patients whose tumor recurred as high-grade experienced new oncogenic mutations in the 
mTOR pathway (B. E. Johnson et al., 2014).  Specifically, the authors identified a TMZ-
associated mutation in PIK3CA in which glutamic acid is subsitutited by lysine at residue 542 was 
found to hyperactivate AKT and lead to mTOR activation and oncogenesis (B. E. Johnson et al., 
2014). Tumors which recurred as a grade IV GBM recurred with a heterozygous loss or a loss of 
function mutation in PTEN, while those recurring as grade II or III did not (B. E. Johnson et al., 
2014). Another low-grade glioma treated with TMZ recurred with a mutation in the MTOR gene 
itself. This mutation was a phenylalanine subsitution for a serine at 2215 (MTOR S2215F) and 
resulted in constitutive activation of mTOR. Sections of the tumor which immunostained strongly 
for mTORC1 showed increased Ki-67 staining, a proliferative marker described in the Introduction 
to Chapter 2. Importantly, the authors note that none of the low-grade recurrences displayed new 
mutations in the mTOR pathway, thus indicating the importance of this pathway as a possible 
driver of malignancy.   
Rapamycin, among other mTOR inhibitors, have not only been used in animal models 
and in-vitro on GBM cells, they have additionally been used in clinical studies to treat GBM 
patients (Cloughesy et al., 2008; Doherty et al., 2006; Galanis et al., 2005; Kreisl et al., 2009; 
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Prasad et al., 2011; Sami & Karsy, 2013). However, it should be noted that conflicting data exists 
in these studies. For instance, in 2005, a phase II study was conducted on 65 GBM patients who 
were treated with temsirolimus (CCI-779), a small molecule inhibitor of mTOR (Galanis et al., 
2005).  36% of treated patients showed radiographic improvement and experienced a longer time 
to progression than non-treated patients (Galanis et al., 2005).  The authors conclude that 
patients whose tumors express a high level of phosphorylated p70s6 kinase, a downstream 
effector of mTOR, are more likely to benefit from mTOR inhibition, and this may account for the 
lack of response in other non-treated GBM patients from this study (Galanis et al., 2005).  
Furthermore, patients were treated only weekly with rapamycin, and although the authors noted 
mTOR inhibition was successful, other clinical studies have since used daily rapamycin 
treatment. Enrolling only patients with a mutation in PTEN leading to reduced expression, a 
phase I neoadjuvant trial of daily rapamycin treatment was conducted in 2008 (Cloughesy et al., 
2008). This study showed that mTOR inhibition in the tumor cells was variable, although 50% of 
the patients showed a significant reduction in intratumoral Ki67 staining after 1 week of rapamycin 
treatment (Cloughesy et al., 2008). Given that rapamycin is an mTORC1 specific inhibitor, it is not 
surprising that 50% of rapamycin treated patients in this study experienced AKT activation which 
resulted in a reduced time to progression (Cloughesy et al., 2008).  This effect is likely due to the 
loss of negative feedback as mTORC1 negatively regulates the AKT pathway through 
phosphorylation of insulin receptor substrate 1 (IRS1) via S6K.  PRAS40 is a direct target of AKT 
phosphorylation and can be used as a marker of AKT activation. Patients who experienced a 
reduced time to progression had significantly increased levels of phosphor-PRAS40 (threonine 
246), indicating that in deed AKT activation correlated with lack of rapamycin efficacy (Cloughesy 
et al., 2008). While these studies reported rapamycin efficacy in GBM patients, others have failed 
to find such an effect. Another Phase II clinical study which administered weekly doses of CCI-
779 to 43 GBM patients found no evidence of efficacy (Chang et al., 2005).  Of 28 GBM patients 
treated with both an EGFR inhibitor and an mTOR inhibitor, 19% of patients showed a partial 
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response and 50% had stable disease, or a lack of tumor progression (Doherty et al., 2006). In 
another study of 22 patients treated with both an EGFR inhibitor and an mTOR inhibitor, while 
14% showed a partial response to treatment, the responses were not stable and the tumor 
eventually progressed so that only 1 patient remained progression free at 6 months (Kreisl et al., 
2009).  However, it is important to note that these studies are difficult to truly assess as most had 
small sample sizes and many other factors were not controlled, such as pretreatment with other 
modalities and genetic status of the tumors.  
In-vitro, metformin has proved promising for the treatment of GBM (Ferla, Haspinger, & 
Surmacz, 2012; Sato et al., 2012; Ucbek, Özünal, Uzun, & GepdĐremen, 2014). Treating the GBM 
cell line, T98G with metformin resulted in increased apoptosis and reduced viability (Ucbek et al., 
2014) and metformin treatment of LN18 and LN229 resulted in reduced inhibition of migration 
(Ferla et al., 2012). Furthermore, mice with intracranial xenografts that were pre-treated with 
metformin in-vitro survived significantly longer than mice treated with vehicle alone, as tumor 
formation was significantly delayed in the pre-treated metformin mice (Sato et al., 2012).  In-vivo, 
mice with intracranial xenografts that were treated systemically with metformin for 5 days only 1 
day after GBM implantation survived on average 12 days longer than mice treated with vehicle 
only (Sato et al., 2012).  Furthermore, mice treated for 10 days with metformin following this 
experimental paradigm survived an additional 12 days, on average, indicating the overall 
improved survival with systemic metformin treatment was approximately 25 days (Sato et al., 
2012).  Although currently no published data is available on the use of metformin in clinical trials, 
a phase I clinical trial is currently actively recruiting patients to assess the efficacy of neoadjuvant 
metformin therapy on progression free survival in GBM patients.  Given the promising in-vitro and 
animal model studies, an increase in progression free survival is hypothesized. However, given 
the complicated signaling mechanisms, it will be important to evaluate the genetic status of the 
tumors to account for other downstream signaling possibilities.  
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Given the complexity of GBM, studies continue to investigate other inhibitors with the 
hopes of increasing the survival for GBM patients. Current therapies are simply not effective 
enough and it may be that our strategies for treatment need to change. Similar to our findings 
presented in Chapter 3, a study by Huang et al (P. H. Huang et al., 2007) found that the use of an 
EGFR kinase inhibitor coupled with the use of a c-MET kinase inhibitor was significantly more 
effective in stopping glioma progression than the use of an EGFR inhibitor alone.   Given that 
prior studies using monotherapies have failed to prolong survival in patients with GBM 
(Sathornsumetee et al., 2007), targeting multiple signaling pathways by using combinatorial 
therapies may provide better therapeutic efficacy (Bello et al., 2004; Doherty et al., 2006; 
Sathornsumetee et al., 2007; Thaker & Pollack, 2009). Indeed, the future of GBM therapies may 
lie in combinatorial targeting, especially considering the complexity of genetic mutations and 
aberrant signaling pathways in GBM.  
aPKC and mTOR Signaling in Neural Stem Cell Proliferation and Differentiation 
Signaling pathways do not occur in isolation, as evidenced by GBM, where aberrant 
mutations lead to abnormal signaling resulting in oncogenesis. Oncogenesis can be considered 
development gone awry; many of the same pathways that contribute to cancer are relevant for 
embryonic neural development and neurogenesis. Multiple signaling pathways contribute to the 
appropriate patterning of the CNS.  While mTOR signaling has been shown to play a role in this 
process (Chapter 2); aPKC signaling (Chapter 3) has also been implicated in neurogenesis.  
Furthermore,  aPKC signaling is known to associate within the mTOR signaling pathway in NSCs 
as it has been shown to be activated upon metformin treatment (J. Wang et al., 2012).  
Using shRNA against aPKCζ and aPKCι, in separate experiments, Wang et al. (2012) 
described the role of aPKC in neural stem cell proliferation and differentiation. Given that in-vivo 
aPKC is localized apically along the ventricles in embryonic neural precursors, the author’s 
electroporated the shRNAs into the cortices of E13/14 mice and found differential effects of 
aPKCζ versus aPKCι knockdown (J. Wang et al., 2012). While there was no effect on cell 
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survival, aPKCζ knockdown led to a decrease in cells in the cortical plate and an increase in cells 
which were in the intermediate zone (J. Wang et al., 2012). This was explained by a decrease in 
neurogenesis and an increase in radial precursors. The authors concluded that aPKCζ is 
essential for neurogenesis in-vitro and in-vivo as it promotes differentiation of neural precursors 
into neurons.  
Interestingly, however, knockdown of aPKCι did not have the same effect in the cortical 
precursors. Instead, knockdown of aPKCι led to an alteration in the population of precursor cells 
(J. Wang et al., 2012).  The number of Pax6+ and Sox2+ radial precursors was significantly 
decreased, while the number of Tbr2+ basal progenitors was increased (J. Wang et al., 2012). 
Therefore, while aPKCζ functions to increase neurogenesis (as knockdown of aPKCζ led to a 
reduction of newborns neurons in-vitro and in-vivo), aPKCι functions to maintain radial precursors 
in their stem-like undifferentiated state.  
In-vitro treatment with metformin of cortical precursors resulted in a significant increase in 
neurons and a decrease in Pax6+ and Sox2+ precursors (J. Wang et al., 2012). In addition, 
metformin treatment in these cells led to an increase in aPKC phosphorylation. When aPKC was 
knocked down in the neural precursors and they were treated with metformin, there was an 
inhibition of the metformin-induced increase in neurogenesis (J. Wang et al., 2012).  Furthermore, 
the authors found metformin treatment in-vitro resulted in an increase in GFAP+ astrocytes, as 
well as A2B5+ oligodendrocyte precursors (J. Wang et al., 2012). Thus, metformin signals through 
aPKC to affect both neuro and gliogenesis.  
Downstream of aPKCζ, the authors discovered a role for the CREB binding protein 
(CBP), a histone acetyltransferase that has been shown to cause Rubinstein-Taybi syndrome 
(RTS), a genetic disorder that results in cognitive dysfunction. Knockdown of CBP in-vitro and in-
vivo results in reduced neurogenesis and gliogenesis and aPKCζ phosphorylation of CBP was 
found to be an essential event in its appropriate functioning (J. Wang et al., 2010).  When aPKCζ 
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was knocked down, the authors noted a loss of CBP phosphorylation, as well as a decrease in 
neurons and glia and an increase in Pax6+ radial precursors (J. Wang et al., 2010). Furthermore, 
CBP overexpression resulted in increased gliogenesis, and knockdown of aPKCζ, but not aPKCι, 
resulted in normal gliogenesis (J. Wang et al., 2010). Therefore, an mTOR/aPKC/CBP signaling 
pathway plays an important role in embryonic gliogenesis and neurogenesis.  
SVZ Niche, Polarity and Neural Stem Cell Proliferation and Differentiation 
It should be noted that the role of aPKC in neurogenesis has not completely been 
elucidated. While these studies point to aPKC playing an important role downstream of mTOR 
signaling, another study found no effect of aPKC knockout on neurogenesis in an mouse (Imai et 
al., 2006).  In this study, control brains expressed BrdU+ neuroepithelial cells in the middle layer 
of the ventricular zone, while aPKCι-/-;Nestin-Cre+ brains had BrdU+ neuroepithelial cells 
dispersed throughout the ventricular zone, indicating that interkenetic nuclear migration of 
neuroepithelial cells was altered by the loss of aPKCι. Interestingly, the authors found that the 
apical cellular process of these cells was detached from the ventricular surface, while basal 
processes remained attached (Imai et al., 2006).  Given the importance of polarity signaling in 
proper neural development (discussed below) and given the importance of aPKC in mTOR-
mediated regulation of neurogenesis (discussed above), the conclusion of the authors that 
regulation of neurogenesis is independent of aPKCι and/or adherens junctions warrants further 
study (Imai et al., 2006).  However, there are several factors which may account for their lack of 
response. For instance, the conditional nestin-cre mouse used in this study is expressed at E15; 
which may be too late to affect the appropriate progenitor type which relies on aPKC signaling 
and polarity signaling for proper differentiation. It has been shown that outer radial glia cells 
(oRG; nestin+,Sox2+, Pax6+, Tbr2-), shown to be present at E14.5 do not make contact with the 
ventricle, only contain a basal process, and do not undergo interkinetic nuclear migration during 
division (X. Wang, Tsai, LaMonica, & Kriegstein, 2011).  Radial glial cells, however, as well as 
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intermediate progenitor cells, have been shown to make apical contact with the ventricle 
(Mirzadeh, Merkle, Soriano-Navarro, Garcia-Verdugo, & Alvarez-Buylla, 2008). Furthermore, it 
has been shown that Tbr2+ intermediate progenitors in the E14.5 cortex do not express nestin 
(Englund et al., 2005); thus, it is possible that the use of a different conditional cre to target other 
neural progenitor cells may have a significant effect despite these results.  In addition, there may 
be significant compensatory mechanisms activated in the aPKCι-/-;Nestin-Cre+ mice, and this was 
not investigated.   
One important finding from this report which was not emphasized was a loss of the 
ependymal layer by p3 in the aPKCι-/-;Nestin-Cre+ mice and the eventual development of 
hydrocephalus leading to brain malformations and death (Imai et al., 2006). While the authors 
state the presence of a well maintained neuronal structure in the knockout mice, they do note the 
absence of an ependymal layer. The ependymal layer has been shown to be an important 
regulator of neurogenesis through its robust expression of Noggin, a strong antagonist of BMPs, 
which are expressed by neural stem cells (Lim et al., 2000). Ectopic expression of Noggin 
promoted neuronal differentiation of neural stem cells and the authors conclude that Noggin 
protein derived from the ependymal cells in vivo aids in creating a neurogenic environment in the 
adult SVZ (Lim et al., 2000). Therefore, the results of this study showing that aPKCι-/-;Nestin-Cre+  
mice did not have an effect on the proliferation or differentiation in the embryonic brain are 
surprising as many factors of the SVZ micro-environment, including the cytoarchitecture of the 
cells and the existence of ependymal cells has shown to be essential in appropriate embryonic 
development as well as adult neurogenesis.  
In the adult, the SVZ has been classified as a neurogenic niche due to its structure and 
microenvironment which contains signals to regulate stem cell behavior (Alvarez-Buylla & Lim, 
2004). The stem cell niche is made up of membrane bound molecules, such as adhesion junction 
proteins, extracellular matrix, and diffusible factors. These factors have been shown to be 
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instrumental in regulating the stemness of the cells, as transplantation studies have shown that 
the cells require this specialized niche in order to proliferate and differentiate normally (Gage, 
2002). In addition to this micro-environmental niche displaying polarity, the type-B cells 
themselves, like neuroepithelial cells, have a polarized cell body, with a contact maintained at the 
basal lamina and a process extending to the ventricular surface (Chapter 2). Adult type-B cells 
have been shown to contain an apical process allowing direct contact to the ventricle, through the 
ependymal layer (Mirzadeh et al., 2008). In addition, the cells were shown to extend a basal 
process which extends on to vasculature (Mirzadeh et al., 2008). Furthermore, earlier work 
showed that some B cells residing in the subventricular zone (SVZ) have part of their membrane 
contacting the ventricle and that upon stimulation of proliferation, the number of apical contacts at 
the ventricle increases (Fiona Doetsch, Caille, Lim, García-Verdugo, & Alvarez-Buylla, 1999). 
Studies have shown this organization to be instructive to the fate of B cells, as this polarity allows 
for the regulation of the tightly controlled process of interkinetic nuclear migration. For example, 
Shen, et al (2008) showed that infusion of GoH3, an a6 integrin-blocking antibody into the lateral 
ventricle of adult mice, which results in loss of B-cell adhesion to the blood vessels, led to a 
33.6% increase in proliferation of SVZ lineage cells (Shen et al., 2008).  
This microenvironmental polar structure of the SVZ interestingly mirrors the polarity of the 
embryonic stem cells, for which the role of polarity in neural stem cell proliferation and 
differentiation has been better examined.  Data has shown the importance of apical-basal polarity 
and aPKC/Par proteins for proliferation and differentiation in Caenorhabditis elegans and 
Drosophila melongaster. The evolutionarily conserved polarity genes were first discovered in 
studies of C. elegans and D. melanogaster. Work on early embryonic patterning in C. elegans 
identified the genes as responsible for the development of the anterior-posterior polarity axis.  
Genetic manipulation of these genes in the 1-cell embryo led to dramatic polarity defects and loss 
of the polarity axis (Bowerman & Shelton, 1999; Kemphues & Strome, 1997; Tabuse et al., 1998). 
C. elegans embryos which lack aPKC are embryonic lethal due to the effect on polarity (Tabuse 
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et al., 1998), which leads to defects in embryonic cell division. Similar phenotypes resulted from 
experiments with Par-3 (Tabuse et al., 1998) and with Par-6(Hung & Kemphues, 1999; Watts et 
al., 1996; Watts, Morton, Bestman, & Kemphues, 2000). 
It has previously been shown that the aPKC/Par3/Par6 complex is present during E12-
E14 stage at the apical surface of the mouse ventricular zone, and its expression is reduced in 
E16 (Costa, Wen, Lepier, Schroeder, & Götz, 2008). Along with the reduction of the polarity 
protein expression by E16, there is similarly a reduction in the pool of progenitors. Using shRNA, 
Costa et al. (2008) knocked-down expression of Par3 by in-utero injection at E12-E14 and found 
a lack of cell proliferation and an early progenitor cell cycle exit. This mirrors what is seen post-
E16, when Par3 expression is reduced and there is a considerable reduction in cell proliferation. 
Bultje, et al. (2009) provided evidence that Par-3 plays an important role for radial glia 
differentiation and proliferation during embryonic development (Bultje et al., 2009). In radial glial 
progenitors, Par-3 was found to be localized at the lateral membrane, specifically at the 
ventricular endfeet during interphase, but was delocalized as the cell cycle progressed. To disrupt 
the polarity of the glial progenitors, the authors used both removal of Par-3 and ectopic 
expression, which similarly led to a decrease in asymmetric divisions. Removal of Par-3, led to an 
increase in production of neurons; while the ectopic expression of Par-3, led to an increase in the 
production of radial glia progenitors (Bultje et al., 2009). More recently, Kim et al. (2010) found 
that disruption of the apical complex via Pals1, an evolutionarily conserved scaffold protein which 
can bind to the ternary complex, led to premature cell cycle exit and excessive neuron production 
(S. Kim et al., 2010). Similarly, Loulier, et al. (2009) examined the role of the NSC adhesion 
complex at the apical surface by disrupting the attachment of the apical process from the 
ventricular surface, using a B1 integrin antibody during important embryonic neurogenic periods 
(E12-E15) (Loulier et al., 2009). Interestingly, they found an increase in NSC proliferation and 
alteration in the cleavage planes, indicating an increase in asymmetric division (Loulier et al., 
2009).  In the developing chick embryo, Ghosh, et al. (2008) found aPKC to localize at the apical 
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membrane of proliferating neural stem cells, but not postmitotic cells. In addition, expression of 
myr-aPKC, a constitutive active construct, led to increased proliferation of the cells (Ghosh et al., 
2008b). Also in chick embryos, Das & Storey (2014) found aPKC localization to be restricted to 
an apical particle of Tuj1+ newborn neurons (Das & Storey, 2014).  The cell retracts this apical 
process, losing its polarity to mediate membrane detachment from the ventricular surface.  This 
process was also found to occur in Tuj1+ cells of the mouse spinal cord.  Cells which maintain 
their apical contact were found to express early neuronal markers, but not late neuronal markers 
or post-mitotic cell markers, indicating that cells with an aPKC containing apical protrusion are not 
post-mitotic, or have not exited the cell cycle (Das & Storey, 2014).  In addition, it has been 
previously shown that inheritance of polarity proteins determines asymmetric vs. symmetric 
division in neuroepithelial cells of E10-E12.5 mouse. In neuroepithelial cells that divided and 
inherited unequal distribution of the apical membrane, the daughter cell which inherited the apical 
membrane maintained its’ stem cell fate, while the daughter cell who did not receive the apical 
membrane became a neuron (Kosodo et al., 2004). Therefore, this overwhelming evidence points 
to the microenvironmental polar niche being instructive for the proliferation and differentiation of 
NSC in embryonic and adult SVZ.   
TNF-α and EGFR Signaling in Neural Stem Cell Proliferation and Differentiation 
Interestingly, microglia-derived-TNF-α and/or exogenous TNF-α has been shown to have 
an effect on NSC proliferation, although the evidence is contradictory (Cacci, Ajmone‐Cat, Anelli, 
Biagioni, & Minghetti, 2008; Iosif et al., 2006; Monje, Toda, & Palmer, 2003; Rubio-Araiz et al., 
2008; Widera, Mikenberg, Elvers, Kaltschmidt, & Kaltschmidt, 2006).  For instance, incubation of 
NSCs in conditioned media from acute activated microglia, which expressed increased TNF-α, 
among other cytokines such as IL-6, IL-1β and IL-1α, resulted in reduction of NSC survival, 
increased glial differentiation and prevention of neuronal differentiation (Cacci et al., 2008).  In 
addition, another study found that mice which lack TNFR1 or TNFR2 had increased proliferation 
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in the SGZ, indicating that signaling through TNFR negatively regulates NSC proliferation (Iosif et 
al., 2006). However, through upregulation of cyclin D1, TNF-α treated NSCs displayed a 
significant increase in NSC proliferation as evidenced by BrdU incorporation and increased 
neurosphere volume (Widera, Mikenberg, Elvers, et al., 2006).  Furthermore, this effect was 
attenuated by disrupting NF-κΒ activity through IKK-β knockdown and by use of the NF-κΒ super-
repressor IκΒα (Widera, Mikenberg, Elvers, et al., 2006; Widera, Mikenberg, Kaltschmidt, & 
Kaltschmidt, 2006).  The role of NF-κΒ in neural stem cell proliferation and differentiation remains 
to be elucidated, however, studies in human embryonic stem cells showing NF-κΒ activation in 
undifferentiated cells and down-regulation in differentiated cells points to a potential role for NF-
κΒ in stem-like maintenance (Armstrong et al., 2006; Dreesen & Brivanlou, 2007).  
Studies also suggest EGFR signaling is an important determinant in NSC proliferation 
and differentiation (Ferron et al., 2010; Y. Sun, Goderie, & Temple, 2005). For instance, infusion 
of EGF into the lateral ventricles results in a highly significant expansion of proliferation of NSC in 
the SVZ (Craig et al., 1996). As the cells divide asymmetrically, unequal inheritance of EGFR 
leads to a differential ability to proliferate and differentiate, as neural stem cells with higher EGFR 
levels form 2-fold more neurospheres than those with low EGFR levels (Ferron et al., 2010; Y. 
Sun et al., 2005).  In addition, it has been shown that both wtEGFR over-expression and 
EGFRvIII expression in postnatal NSCs leads to unrestricted proliferation and increased survival 
(Ayuso-Sacido et al., 2010). EGFR is frequently over-expressed in GBM and EGFRvIII is a 
common mutation which results in a truncated extracellular domain, creating a ligand-
independent constitutively active EGFR kinase. Complimentary to an increase in proliferation, 
postnatal NSCs with wtEGFR and EGFRVIII expression in subjected to differentiation conditions, 
fail to differentiate, as none of the cells express Tuj1 7 days post-differentiation, compared to 25% 
of control cells (Ayuso-Sacido et al., 2010). Therefore, EGFR is an important determinant in the 
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proliferation and differentiation of neural stem cells in addition to its role in oncogenic signaling 
presented in Chapter 3.  
EGFR Signaling and NF-κΒ 
It is important to note that although our studies in GBM (Chapter 3) examined 2 distinct 
signaling pathways both activating aPKC, recent studies have provided evidence of cross-talk 
between the intracellular EGFR signaling pathway and activation of NF-κΒ signaling in GBM 
(Pianetti, Arsura, Romieu-Mourez, Coffey, & Sonenshein, 2001; Tanaka et al., 2011; Wu, Abe, 
Inoue, Fujiki, & Kobayashi, 2004). For instance, in 2012, Bonavia et al (R. Bonavia et al., 2012)  
found that glioma cells expressing the constitutive active mutant EGFRVIII displayed increased 
angiogenesis and oncogenicity through activation of NF-κΒ, signaling through the PI3K/AKT 
pathway. Similarly, Wu et al (Wu et al., 2004) found that EGFRVIII expressing glioma cells were 
less oncogenic when NF-κΒ activity was blocked using IκΒαM, the NF-κΒ super-repressor. 
Interestingly, a report by Tanaka et al found that mTORC2 was stimulated downstream of 
EGFRVIII in glioma cells and that this led to NF-κΒ activation (Tanaka et al., 2011). Furthermore, 
they found that this mTORC2/NF-κΒ signaling pathway was responsible for glioma cell 
chemotherapy resistance (Tanaka et al., 2011).  
As described in Chapter 3, an analysis of human GBM samples led to the discovery of a 
frequent deletion of NFKBIA, the negative inhibitor of NF-κΒ (M. Bredel et al., 2011). Interestingly, 
this deletion is mutually exclusive with EGFR amplification as 52.5% of tumors had either 
amplification of EGFR or a deletion of NFKBIA, while only 5% had both. The reexpression of 
NFKBIA in NFKBIA-deleted-GBM led to reduced proliferation, migration, colony formation, as well 
as increased sensitivity to TMZ treatment, indicative of the tumor-suppressor activity of NFKBIA, 
as it acts to inhibit NF-κΒ activity. In GBM cells with amplification of EGFR, expression of NFKBIA 
reduced cell viability and decreased oncogenesis. However, in cells with a normal dose of EGFR, 
this effect was not apparent (M. Bredel et al., 2011).  
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Although not in glioma cells, Sun & Carpenter (1998) showed that EGF activates NF-κΒ 
in A-431 carcinoma cells. Like GBM cells, these cells over-express EGFR.  They found treatment 
with EGF led to a degradation of IΚΒα, allowing NF-κΒ to enter the nucleus (L. Sun & Carpenter, 
1998). In prostate cancer cells which express EGFR, Le Page et al. (2005) showed EGF induced 
phosphorylation of IΚΒα on serine 32/36, leading to IΚΒα degradation and NF-κΒ activation (Le 
Page, Koumakpayi, Lessard, Mes‐Masson, & Saad, 2005). Furthermore, the expression of a 
dominant negative IΚΒα Serine32/36 was able to block NF-κΒ activation downstream of EGFR, 
showing the direct association of EGFR and NF-κΒ activation.  
Similar to our work presented in Chapter 3, a recent study found EGF treatment of GBM 
cells to lead to up-regulation of vascular cell adhesion molecule-1 (VCAM-1) (Zheng, Yang, 
Aldape, He, & Lu, 2013).  However, the authors found this to be via a different signaling 
mechanism than we proposed. Their results showed VCAM-1 was up-regulated after EGF 
treatment in a PKCε and NF-κΒ dependent manner (Zheng et al., 2013).   Furthermore, the levels 
of EGFR activation in GBM samples was correlated with macrophage infiltration and EGF 
stimulation led to increased macrophage binding to GBM cells (Zheng et al., 2013).  This 
increased binding was inhibited when the cells were incubated in an EGFR inhibitor.  In addition, 
EGF-induced VCAM-1 up-regulation was inhibited in the presence of an NF-κΒ inhibitor or PKCε 
shRNA (Zheng et al., 2013), indicating that EGF is signaling through PKCε to activate NF-κΒ  
transcription of VCAM-1 in GBM cells.  VCAM-1 expression was found to be crucial for 
macrophage to GBM cell binding.  Similar to our results in chapter 3, this increased binding led to 
an increase in GBM cell invasion and VCAM-1 shRNA was able to block the increase in invasion 
(Zheng et al., 2013).  While this study elucidated one potential mechanism for EGF induced NF-
kB activation, other studies have discovered alternative signaling mechanisms as well.  
For instance, one study hypothesized the mechanism of EGFR induced NF-κΒ activation 
to be similar to TNFR induced NF-κΒ activation (Habib et al., 2001). Upon TNFR activation, an 
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adaptor protein, TRADD, associates with the receptor, which then recruits RIP and TRAF2. Co-
transfection of EGFR with TRADD or Fas-associated death domain protein (FADD; an adaptor 
protein which also associates with TNFR upon activation) failed to show any association in 293 
human embryonic kidney cells (HEK; these cells are used for their ease of transfection) (Habib et 
al., 2001). However, co-transfection of EGFR with RIP resulted in a physical association; and a 
kinase-inactive mutant of EGFR was unable to bind RIP. This association was seen in both HEK 
cells as well as MDA-MB-468 breast cancer cells (Habib et al., 2001). Therefore, EGFR is 
thought to recruit RIP in order to activate NF-κΒ.  In addition, EGFR was shown to associate with 
NF-κΒ inducing kinase (NIK) (Habib et al., 2001), a kinase which integrates signals downstream 
of TNFR and upstream of NF-κΒ.  In this study, the use of a PI3K inhibitor showed no effect on 
EGF-induced NF-κΒ activation although it blocked EGF induced AKT phosphorylation (Habib et 
al., 2001); indicating that this signaling pathway does not signal through AKT.  
However, other reports have shown that TNF-α signaling can activate AKT and lead to 
NF-κΒ activation. For instance, in EGFR+ breast cancer cells, the use an EGFR antibody blocked 
NF-κΒ activation, as well as a PI3K inhibitor, and Go6976, an NF-κΒ inhibitor, as evidenced by 
an NF-κΒ DNA binding assay (Biswas, Cruz, Gansberger, & Pardee, 2000). In GBM cells 
following EGF stimulation in-vitro, an increased association between Grb2-associated binder 1 
(Gab1) and SHP-2 (a tyrosine phosphatase with 2 SH2 domains) was identified (Kapoor, Zhan, 
Johnson, & O'Rourke, 2004).  This Gab1/SHP-2 complex was shown to regulate AKT activation 
as transfection of these proteins in GBM cells led to a threefold increase in AKT activity. 
Furthermore, treatment with EGF resulted in a change in NF-κΒ electromobility shift assay 
(EMSA), indicating NF-κΒ activation via DNA binding.  Active AKT transfection led to increased 
NF-κΒ activation via an NF-κΒ luciferase assay while mutant-inactive AKT transfection resulted in 
no change (Kapoor et al., 2004).  Co-transfection of the Gab1/SHP-2 complex led to a significant 
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increase in NF-κΒ activation and an EMSA showed an increase in NF-κΒ DNA binding (Kapoor et 
al., 2004). Thus, EGFR may directly lead to NF-κΒ activation, through various mechanisms.  
While these reports may contradict the results presented in Chapter 3, it does not 
preclude them. Multiple signaling pathways cooperate to promote oncogenesis.  Furthermore, we 
found that EGF treatment in GBM cells led to an increase in TNF-α ligand transcription and TNF-
α treatment led to an increase in EGF ligand transcription. Thus, there may be a feedback loop 
which is leading to coincidental activation of multiple signaling pathways within minutes of 
stimulation and receptor activation.  While we did not investigate the activation of PKCε, it is also 
possible that other PKC family members may be associated with these signaling cascades as 
various other PKCs have been implicated in GBM pathogenesis (do Carmo et al., 2013).  
The glioma stem cell hypothesis 
 Discovering the molecular mechanisms underlying neural stem cell proliferation (as in 
Chapter 2) and differentiation may provide insight into novel therapeutics for the treatment of 
GBM.  GBM tumors are extremely heterogeneous and contain many different cell types making 
them difficult to treat. Recently, the discovery of glioma stem cells (GSCs) has shifted the GBM 
research field into studying mechanisms which control GSC proliferation (Ignatova et al., 2002; 
Singh et al., 2004). Like neural stem cells, GSCs are also capable of proliferative self-renewal 
and multipotent differentiation into neurons, astrocytes and oligodendrocytes in vitro (Ignatova et 
al., 2002). While it requires 1 million glioma cells to initiate a tumor in mice, it was found that only 
100-1,000 glioma stem cells were required to form a tumor, providing evidence regarding their 
strong proliferation capacity in vivo (Ignatova et al., 2002; J. Lee et al., 2006). In addition, GSCs 
are resistant to radiation and chemotherapy, which has led to the hypothesis that GSCs remain 
undetected in the brain during treatment, and later return to establish a new tumor (Bao et al., 
2006; Jian Chen et al., 2012; X. Gao et al., 2013; G. Liu et al., 2006; J. Wang et al., 2012).  A 
recent study elegantly described the resistant nature of GSCs by the use of transgenic mice 
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which expressed GFP in adult SVZ NSCs and GSCs. After using a chemotherapy agent to arrest 
the initial growth of a GBM model in these transgenic mice, Chen et al. (Jian Chen et al., 2012) 
found that the tumor regrowth began with GFP+ stem cells. Furthermore, upon ablation of these 
GFP+ stem cells, the authors were able to show significantly reduced tumor growth, thus 
providing evidence for the virulent nature of these GSCs.  
 What are the signaling cascades which signal to the GSC to begin proliferation? Multiple 
signals have been identified as important regulators in this process. For instance, the platelet-
derived growth factor receptor (PDGFR) signaling pathway has also been implicated in GSC 
function. Interestingly, Kim et al. (Y. Kim et al., 2012) found that while PDGFRα is expressed on a 
subset of GBM cases, PDGFRβ is preferentially expressed by GSCs. The blockade of the 
PDGFRβ signaling cascade in GSCs led to reduced proliferation, oncogenicity and invasion of 
GBM mouse models in addition to increased survival. Downstream of PDGFRβ, the authors 
found that signaling was dependent upon the transcription factor STAT3 as constitutively active 
STAT3 rescued the inhibited PDGFRβ phenotype (Y. Kim et al., 2012).  
Given the importance of polarity signaling in stem cell regulation (described above & 
Chapter 2), the possibility exists that a loss of polarity may be one of the defining characteristics 
of neural stem cell oncogenic proliferation.  Quinones-Hinojosa & Chaichana (2007) described 
the similarities between NSCs and GSCs, in that they both undergo self-renewal and multiply 
(Quiñones-Hinojosa & Chaichana, 2007).  Therefore, it can be hypothesized that the polarity 
complex may regulate the proliferation and differentiation of GSCs. Aberrant function of the 
polarity signaling pathway may directly contribute to transformation of neural stem cell into glioma 
initiating cells. However, currently no data exists on this subject although it has been 
hypothesized that the regulation of asymmetric cell division may lead to GBM (Berger, Gay, 
Pelletier, Tropel, & Wion, 2004), indicating a potential important role for cellular polarity.  
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In line with this hypothesis, Lathia et al. (2011) found asymmetric distribution of CD133 in 
GSCs (Lathia et al., 2011).  CD133 (also known as prominin-1) has been used for the last decade 
as a GSC marker despite little evidence of its signaling function (Yan, Yang, & Rich, 2013). Using 
CD133+ GSCs isolated from GBM patients, Lathia et al. (2011) found that the majority of GSCs 
underwent symmetric division in order to expand the stem cell population. However, upon growth 
factor starvation, the cells switched to asymmetric division, indicating that growth factor signaling 
may be responsible for the expansion and survival of GSCs within the tumor (Lathia et al., 2011).  
CD133 was unequally distributed in GSCs and CD133 expression leads to increased survival.  
Therefore, cells which inherit CD133 through symmetrical divisions maintain the stem population 
and experience better survival and proliferation. However, asymmetric divisions may lead to an 
increase in differentiated cell types, increasing the cellular heterogeneity of the tumor. Recently 
Wei et al. (Wei et al., 2013) showed that CD133 signals through the PI3K/AKT signaling pathway 
in GSCs. Furthermore, they showed that silencing of CD133 inhibited the PI3K/AKT pathway and 
resulted in reduced GSC proliferation and oncogenicity (Wei et al., 2013). Currently a phase I 
clinical trial is underway to evaluate the efficacy of ICT-121, a vaccine which targets CD133 (Yan 
et al., 2013). 
The Eph RTKs have also been described as regulators of GSC tumor propagation (Day 
et al., 2013). While GBM tumors are made of extremely heterogeneous cell types, cells which 
display high EphA2 RTK expression correlated with tumor propagation capacity. The silencing of 
EphA2 in these cells led to reduced GSC proliferation and oncogenicity. Similar results were 
obtained by another group studying EphA3, however, it was found to signal through the mitogen-
activated protein kinase (MAPK) cascade, a strong regulator of cell growth and proliferation (Day 
et al., 2013).  
 The discovery of signaling pathways responsible for the regulation of GSC oncogenicity 
may lead to promising new therapeutic targeting. GBM patient prognosis remains abysmal and 
new therapies are desperately needed. If researchers can identify the signaling pathway which 
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may directly contribute to the transformation of NSCs into GSCs, we may be able to increase the 
current prognosis for this disease.  
Inhibitors in GBM Clinical Trials  
 New developments are on the horizon in the treatment of GBM. The search for inhibitors 
in GBM on the NIH Clinical Trials website reveals over 300 studies.  In addition to the 
aforementioned clinical trials underway, including CD133 inhibitor, EGFR and c-MET co-
inhibition, as well as the clinical trials investigating mTOR inhibition for GBM, there are other 
inhibitors of signaling molecules being tested. For instance, a phase I clinical trial investigating 
MK-1775, an inhibitor of wee1, a tyrosine kinase is currently recruiting subjects with GBM. Wee1 
is a tyrosine kinase that has been shown to impair the G2 DNA damage checkpoint, which may 
result in increased efficacy of TMZ or other chemotherapeutic agents. Expression of wee1 in 
GBM tumors was negatively correlated with survival and treatment of GBM cells in-vitro with a 
wee1 inhibitor resulted in increased sensitivity to TMZ (Mir et al., 2010). In-vivo, mice with GBM 
intracranial xenografts which were treated with radiation showed no increase in survival. 
However, mice whose xenografted GBM cells were knocked out for wee1 showed a significant 
increase in survival and those with wee1 knock out GBM cells and radiation treatment showed a 
very significant increase in survival. Similar results were obtained using a wee1 inhibitor (Mir et 
al., 2010).  The inhibition of the kinase wee1 in GBM patients may hopefully provide better 
response to chemotherapy and radiation, resulting in increased prognoses and survival.  
 A phase II clinical trial is currently underway investigating RO4929097, a gamma-
secretase/notch signaling inhibitor. Notch signaling has been shown to maintain the stem-like 
cells of the tumor, and promote chemoresistance (Capaccione & Pine, 2013). Using a gamma-
secretase/notch inhibitor, Chen et al (2010) treated GBM-derived neurospheres in-vitro and found 
a significant reduction in cell growth and proliferation (Jie Chen et al., 2010).  In another study, 
induced expression of active notch in GSCs led to increased tumor growth, while the use of 
gamma secretase/notch inhibitors reduced GSC neurosphere growth (X. Fan et al., 2010). 
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Furthermore, implantation of GSCs pre-treated with inhibitor failed to form tumors (X. Fan et al., 
2010).  The authors found this effect to be mediated via AKT signaling, as AKT phosphorylation 
was decreased in inhibitor treated cells (X. Fan et al., 2010).  
 Another phase II study is investigating the efficacy of Dovitinib (also known as receptor 
tyrosine kinase inhibitor TKI258), an inhibitor of FGFR3, which has been shown effective in other 
solid tumors (André et al., 2013; Huynh et al., 2012).  This inhibitor may also inhibit other RTKs 
such as VEGFR, FGFR1, PDGFRA (Angevin et al., 2013), and thus may result in a significant 
blockade in oncogenic signaling.  Furthermore, given the strong reliance on RTK signaling 
pathways in GBM, a general RTK inhibitor may prove more effective than singular RTK targeting. 
In patients with PTEN-/- GBM tumors, a phase I clinical trial is investigating the use of 
Buparlisib (BKM120), a PI3K pathway inhibitor, and INC280, a c-MET receptor tyrosine kinase 
inhibitor. The use of a PI3K inhibitor in patients without PTEN should yield better clinical outcome 
than the treatment with an EGFR inhibitor, as PTEN loss downstream of EGFR results in active 
PI3K despite EGFR inhibition.  c-MET signaling has been implicated in the propagation and 
survival of GSCs specifically (Joo et al., 2012; Y. Li et al., 2011; Rath et al., 2013), and inhibition 
of c-MET has been shown to disrupt GBM pathogenesis in-vitro and in-vivo (Joo et al., 2012).  
Therefore, targeting c-MET may allow for direct targeting of GSCs, and targeting PI3K may target 
both GSCs and differentiated astrocytic GBM cells, leading to significantly reduced oncogenesis 
and increased survival.  
In patients with EGFR amplification or EGFRVIII mutation, a phase II study is assessing 
the efficacy of dacomitinib, an irreversible pan-EGFR inhibitor. This inhibitor is effective in 
preventing the transautophophorylation, and thus activation, of EGFR, HER2, and HER4, 
resulting in abrogated downstream signaling. Recently tested in those with non-small cell lung 
cancer (NSCLC), the results were unfortunately disappointing as the inhibitor failed to show any 
improvement in survival when compared to erlotinib, the EGFR inhibitor. In patients with NSCLC 
who received no benefit from chemotherapy or erlotinib treatment, dacomitinib also provided no 
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benefit. In-vitro data was recently published with dacomitinib on primary GBM cells and while the 
inhibitor did decrease phosphorylation of EGFR, it failed to have an effect on cell viability.  
However, the use of a PI3K/mTOR inhibitor in addition to dacomitinib inhibited cell proliferation in 
GBM cells with both EGFR amplification and PI3K activation through PI3K mutation or PTEN loss 
(Zhu & Shah, 2014).  This study emphasizes the importance of targeting the appropriate patients 
with the appropriate treatments.  
Multiple studies are underway targeting multiple signaling pathways in GBM including 
many others not discussed here.  By identifying the type of mutations a patient has, we can 
directly target the signaling pathways leading to oncogenic progression.  For example, if a patient 
does not have an EGFR amplified tumor, treatment with an EGFR inhibitor may not be effective. 
However, if the same patient has an activating mutation in PI3K, the use of a PI3K inhibitor may 
provide efficacious results. In addition, the identification of the GBM classification (pro-neural, 
neural, mesenchymal, classical) would be advantageous as the identification of multiple aberrant 
signaling pathways associated with each classification has been discovered. The future of GBM 
treatment, therefore, lies in personalized medicine.   
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